id
stringlengths 1
5
| document_id
stringlengths 5
8
| passages
list | entities
list | events
sequence | coreferences
sequence | relations
sequence |
|---|---|---|---|---|---|---|
76400 | 3563413 | [
{
"id": "76401",
"type": "document",
"text": [
"Fasting and meal-stimulated plasma levels of neurotensin in obese patients after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio . The functional role of the jejunum and ileum with regard to peripheral plasma levels of intact neurotensin and NH2-terminal immunoreactivity of neurotensin was studied by using jejunoileal bypass as a model . Plasma levels were measured by radioimmunoassay before and after jejunoileal bypass randomized to different jejunoileal ratios . Seven patients were studied before bypass surgery and 28 were examined after end-to-side jejunoileal bypass with 50 cm intestine in continuity and a 3:1 or 1:3 ratio between the length of the jejunal and ileal segments . Fasting levels of intact neurotensin were unchanged by surgery , whereas levels of NH2-terminal immunoreactivity were higher in bypass patients with a long ileal segment ( 37.5 cm ) than in unoperated patients and in those with a short ileal segment ( 12.5 cm ) . Meal-stimulated levels of intact neurotensin were higher after 1:3 than 3:1 jejunoileal bypass . The levels of NH2-terminal immunoreactivity in patients with a short ileal segment and in controls were lower than in patients with a long ileal segment . The results show that postprandial levels of both intact neurotensin and NH2-terminal immunoreactivity are related to the length of the functioning ileum and that even a difference in length of 25 cm is reflected in the circulating levels of neurotensin ."
],
"offsets": [
[
0,
1466
]
]
}
] | [
{
"id": "76402",
"type": "Intervention_Surgical",
"text": [
"jejunoileal bypass"
],
"offsets": [
[
81,
99
]
],
"normalized": []
},
{
"id": "76403",
"type": "Intervention_Surgical",
"text": [
"end-to-side jejunoileal bypass with 50 cm intestine"
],
"offsets": [
[
551,
602
]
],
"normalized": []
},
{
"id": "76404",
"type": "Outcome_Physical",
"text": [
"Fasting levels of intact neurotensin"
],
"offsets": [
[
695,
731
]
],
"normalized": []
},
{
"id": "76405",
"type": "Outcome_Physical",
"text": [
"NH2-terminal immunoreactivity"
],
"offsets": [
[
247,
276
]
],
"normalized": []
},
{
"id": "76406",
"type": "Outcome_Physical",
"text": [
"Meal-stimulated levels of intact neurotensin"
],
"offsets": [
[
959,
1003
]
],
"normalized": []
},
{
"id": "76407",
"type": "Outcome_Physical",
"text": [
"levels of NH2-terminal immunoreactivity"
],
"offsets": [
[
768,
807
]
],
"normalized": []
},
{
"id": "76408",
"type": "Outcome_Physical",
"text": [
"postprandial levels of both intact neurotensin and NH2-terminal immunoreactivity"
],
"offsets": [
[
1233,
1313
]
],
"normalized": []
},
{
"id": "76409",
"type": "Participant_Condition",
"text": [
"obese patients after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio"
],
"offsets": [
[
60,
133
]
],
"normalized": []
},
{
"id": "76410",
"type": "Participant_Sample-size",
"text": [
"Seven patients"
],
"offsets": [
[
474,
488
]
],
"normalized": []
},
{
"id": "76411",
"type": "Participant_Condition",
"text": [
"bypass surgery"
],
"offsets": [
[
509,
523
]
],
"normalized": []
},
{
"id": "76412",
"type": "Participant_Sample-size",
"text": [
"28"
],
"offsets": [
[
528,
530
]
],
"normalized": []
},
{
"id": "76413",
"type": "Participant_Condition",
"text": [
"end-to-side jejunoileal bypass with 50 cm intestine in continuity and a 3:1 or 1:3 ratio between the length of the jejunal and ileal segments"
],
"offsets": [
[
551,
692
]
],
"normalized": []
}
] | [] | [] | [] |
76414 | 3586567 | [
{
"id": "76415",
"type": "document",
"text": [
"Antifibrinolytic therapy for prevention of hemorrhage during surgery of the thyroid gland . The amount of fibrinolytic activity in the thyroid gland equals that of the prostate . In order to examine the effect of the antifibrinolytic drug tranexemic acid on perioperative bleeding saline or tranexemic acid were given randomized double blind to 76 consecutive patients who came for scheduled thyroid surgery . No significant differences were found in perioperative bleeding between patients in the treatment group ( n = 39 ) and control group ( n = 37 ) ."
],
"offsets": [
[
0,
555
]
]
}
] | [
{
"id": "76416",
"type": "Intervention_Pharmacological",
"text": [
"Antifibrinolytic therapy"
],
"offsets": [
[
0,
24
]
],
"normalized": []
},
{
"id": "76417",
"type": "Intervention_Pharmacological",
"text": [
"antifibrinolytic drug tranexemic acid"
],
"offsets": [
[
217,
254
]
],
"normalized": []
},
{
"id": "76418",
"type": "Intervention_Pharmacological",
"text": [
"saline"
],
"offsets": [
[
281,
287
]
],
"normalized": []
},
{
"id": "76419",
"type": "Intervention_Pharmacological",
"text": [
"tranexemic acid"
],
"offsets": [
[
239,
254
]
],
"normalized": []
},
{
"id": "76420",
"type": "Outcome_Physical",
"text": [
"perioperative bleeding"
],
"offsets": [
[
258,
280
]
],
"normalized": []
},
{
"id": "76421",
"type": "Outcome_Physical",
"text": [
"perioperative bleeding"
],
"offsets": [
[
258,
280
]
],
"normalized": []
},
{
"id": "76422",
"type": "Participant_Sample-size",
"text": [
"76"
],
"offsets": [
[
345,
347
]
],
"normalized": []
},
{
"id": "76423",
"type": "Participant_Condition",
"text": [
"thyroid"
],
"offsets": [
[
76,
83
]
],
"normalized": []
}
] | [] | [] | [] |
76424 | 3594511 | [
{
"id": "76425",
"type": "document",
"text": [
"Effects of pindolol and clopamide on blood lipids in arterial hypertensive patients . The effects of clopamide , pindolol and its combination on plasma lipids in 49 hypertensive patients ( WHO I-II ) , divided into three parallel randomized groups , were studied over a 6 months period . Total cholesterol , triglycerides , HDL and LDL cholesterol fractions were determined twice during an initial 4-week washout phase , and after a 1- , 3- and 6-month active hypotensive drug phase . Patients were instructed to maintain their usual dietary habits . Daily drug doses were adjusted progressively to attain optimal hypotensive effects . In the clopamide monotherapy group , total cholesterol increased significantly ( p less than 0.05 ) ; triglycerides and LDL showed a tendency to increase while for HDL a tendency to decrease was observed . In the pindolol monotherapy group , a significant reduction of triglycerides ( p less than 0.01 ) and a significant increase of HDL cholesterol ( p less than 0.05 ) were recorded . No significant changes in total cholesterol or LDL fraction were observed . Combined pindolol-clopamide therapy decreased total triglycerides ( NS ) , increased HDL significantly ( p less than 0.05 ) and did not influence total cholesterol and LDL fraction . It is concluded that pindolol does not negatively influence blood lipids as the thiazide-type diuretic clopamide does , and that when both drugs are used together , the beta-blocker can probably counterbalance the diuretic-induced negative effects on blood lipids . Accordingly , it is suggested that pindolol could be a more favorable beta-blocker drug to be used on hypertensive subjects with metabolic coronary risk factors ."
],
"offsets": [
[
0,
1710
]
]
}
] | [
{
"id": "76426",
"type": "Intervention_Pharmacological",
"text": [
"pindolol"
],
"offsets": [
[
11,
19
]
],
"normalized": []
},
{
"id": "76427",
"type": "Intervention_Pharmacological",
"text": [
"clopamide"
],
"offsets": [
[
24,
33
]
],
"normalized": []
},
{
"id": "76428",
"type": "Intervention_Pharmacological",
"text": [
"clopamide"
],
"offsets": [
[
24,
33
]
],
"normalized": []
},
{
"id": "76429",
"type": "Intervention_Pharmacological",
"text": [
"pindolol"
],
"offsets": [
[
11,
19
]
],
"normalized": []
},
{
"id": "76430",
"type": "Intervention_Pharmacological",
"text": [
"combination on plasma lipids"
],
"offsets": [
[
130,
158
]
],
"normalized": []
},
{
"id": "76431",
"type": "Outcome_Physical",
"text": [
"blood lipids"
],
"offsets": [
[
37,
49
]
],
"normalized": []
},
{
"id": "76432",
"type": "Outcome_Physical",
"text": [
"Total cholesterol"
],
"offsets": [
[
288,
305
]
],
"normalized": []
},
{
"id": "76433",
"type": "Outcome_Physical",
"text": [
"triglycerides"
],
"offsets": [
[
308,
321
]
],
"normalized": []
},
{
"id": "76434",
"type": "Outcome_Physical",
"text": [
"HDL and LDL cholesterol fractions"
],
"offsets": [
[
324,
357
]
],
"normalized": []
},
{
"id": "76435",
"type": "Outcome_Physical",
"text": [
"total cholesterol"
],
"offsets": [
[
673,
690
]
],
"normalized": []
},
{
"id": "76436",
"type": "Outcome_Physical",
"text": [
"triglycerides"
],
"offsets": [
[
308,
321
]
],
"normalized": []
},
{
"id": "76437",
"type": "Outcome_Physical",
"text": [
"LDL"
],
"offsets": [
[
332,
335
]
],
"normalized": []
},
{
"id": "76438",
"type": "Outcome_Physical",
"text": [
"HDL"
],
"offsets": [
[
324,
327
]
],
"normalized": []
},
{
"id": "76439",
"type": "Outcome_Physical",
"text": [
"triglycerides"
],
"offsets": [
[
308,
321
]
],
"normalized": []
},
{
"id": "76440",
"type": "Outcome_Physical",
"text": [
"HDL cholesterol"
],
"offsets": [
[
970,
985
]
],
"normalized": []
},
{
"id": "76441",
"type": "Outcome_Physical",
"text": [
"total cholesterol or LDL fraction"
],
"offsets": [
[
1049,
1082
]
],
"normalized": []
},
{
"id": "76442",
"type": "Outcome_Physical",
"text": [
"total triglycerides ( NS )"
],
"offsets": [
[
1145,
1171
]
],
"normalized": []
},
{
"id": "76443",
"type": "Outcome_Physical",
"text": [
"HDL"
],
"offsets": [
[
324,
327
]
],
"normalized": []
},
{
"id": "76444",
"type": "Outcome_Physical",
"text": [
"total cholesterol and LDL fraction"
],
"offsets": [
[
1245,
1279
]
],
"normalized": []
},
{
"id": "76445",
"type": "Outcome_Physical",
"text": [
"blood lipids"
],
"offsets": [
[
37,
49
]
],
"normalized": []
},
{
"id": "76446",
"type": "Outcome_Physical",
"text": [
"blood lipids"
],
"offsets": [
[
37,
49
]
],
"normalized": []
},
{
"id": "76447",
"type": "Participant_Condition",
"text": [
"arterial hypertensive"
],
"offsets": [
[
53,
74
]
],
"normalized": []
},
{
"id": "76448",
"type": "Participant_Sample-size",
"text": [
"49"
],
"offsets": [
[
162,
164
]
],
"normalized": []
},
{
"id": "76449",
"type": "Participant_Condition",
"text": [
"hypertensive"
],
"offsets": [
[
62,
74
]
],
"normalized": []
},
{
"id": "76450",
"type": "Participant_Sample-size",
"text": [
"three"
],
"offsets": [
[
215,
220
]
],
"normalized": []
},
{
"id": "76451",
"type": "Participant_Condition",
"text": [
"hypertensive"
],
"offsets": [
[
62,
74
]
],
"normalized": []
},
{
"id": "76452",
"type": "Participant_Condition",
"text": [
"metabolic coronary risk"
],
"offsets": [
[
1677,
1700
]
],
"normalized": []
}
] | [] | [] | [] |
76453 | 3602307 | [
{
"id": "76454",
"type": "document",
"text": [
"The efficacy and safety of fenfluramine in autistic children : preliminary analysis of a double-blind study ."
],
"offsets": [
[
0,
109
]
]
}
] | [
{
"id": "76455",
"type": "Intervention_Pharmacological",
"text": [
"fenfluramine"
],
"offsets": [
[
27,
39
]
],
"normalized": []
},
{
"id": "76456",
"type": "Outcome_Other",
"text": [
"efficacy and safety"
],
"offsets": [
[
4,
23
]
],
"normalized": []
},
{
"id": "76457",
"type": "Participant_Condition",
"text": [
"autistic"
],
"offsets": [
[
43,
51
]
],
"normalized": []
},
{
"id": "76458",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
52,
60
]
],
"normalized": []
}
] | [] | [] | [] |
76459 | 3602327 | [
{
"id": "76460",
"type": "document",
"text": [
"The effects of amantadine vs. trihexyphenidyl on memory in elderly normal volunteers ."
],
"offsets": [
[
0,
86
]
]
}
] | [
{
"id": "76461",
"type": "Intervention_Pharmacological",
"text": [
"amantadine vs. trihexyphenidyl"
],
"offsets": [
[
15,
45
]
],
"normalized": []
},
{
"id": "76462",
"type": "Outcome_Mental",
"text": [
"memory"
],
"offsets": [
[
49,
55
]
],
"normalized": []
},
{
"id": "76463",
"type": "Participant_Age",
"text": [
"elderly"
],
"offsets": [
[
59,
66
]
],
"normalized": []
},
{
"id": "76464",
"type": "Participant_Age",
"text": [
"."
],
"offsets": [
[
28,
29
]
],
"normalized": []
}
] | [] | [] | [] |
76465 | 3608343 | [
{
"id": "76466",
"type": "document",
"text": [
"Circadian changes in the pharmacokinetics of oral ketoprofen . Several investigations which have taken treatment time into account have shown that the pharmacokinetic parameters , the therapeutic efficacy and even the toxicity of a large number of products may vary according to the administration schedule . The present study was carried out in order to evaluate any circadian changes in pharmacokinetic parameters of ketoprofen , a new non-steroidal anti-inflammatory drug ( NSAID ) . This randomised crossover study consisted of a single oral dose of ketoprofen 100mg administered to 8 healthy male volunteers , mean age 27.2 years , at 07.00 hours , 13.00 hours , 19.00 hours or 01.00 hours in 4 study periods during the first 3 months of the year . The order of administration was randomised , with each subject acting as his own control . A total of 14 blood and 4 urine samples were taken over a 12-hour period . The peak plasma concentration was twice as high after drug administration at 07.00 hours ( 13.4 +/- 1 mg/L ) than after other administration times ( 13.00 hours : 6.9 +/- 1 ; 19.00 hours : 7.2 +/- 0.7 ; 01.00 hours : 6.3 +/- 0.5 mg/L ) [ p less than 0.001 ] . The time to reach peak concentration was much longer after drug administration at 01.00 hours ( 135 +/- 16.7 min ) than at 07.00 ( 73.1 +/- 14.1 min ) , 13.00 ( 75 +/- 16.5 min ) or 19.00 hours ( 82.5 +/- 12.7 min ) [ p less than 0.05 ] . The lag time was significantly longer at 01.00 hours than at 13.00 hours ( p less than 0.01 ) . The absorption rate constant after treatment at 01.00 hours was less than at the other times of administration ( p less than 0.05 ) . The bodyweight-corrected area under the curve ( AUC0-12 ) was greater after 07.00 hours than after 13.00 ( p less than 0.01 ) or 19.00 hours ( p less than 0.05 ) and greater after 01.00 hours than after 13.00 hours ( p less than 0.05 ) . The elimination half-life was significantly longer after administration at 01.00 hours than after 19.00 hours ( p less than 0.05 ) , while the total clearance was lowest at 07.00 hours . Cosinor analysis demonstrated statistically significant circadian rhythms for all pharmacokinetic parameters described above . The amount of ketoprofen eliminated in the urine was delayed , and was significantly greater after the administration at 01.00 hours than 07.00 hours or 19.00 hours ( p less than 0.01 ) . The relationship between absorption , diffusion and/or elimination mechanisms of the drug are discussed ."
],
"offsets": [
[
0,
2494
]
]
}
] | [
{
"id": "76467",
"type": "Intervention_Pharmacological",
"text": [
"ketoprofen"
],
"offsets": [
[
50,
60
]
],
"normalized": []
},
{
"id": "76468",
"type": "Intervention_Pharmacological",
"text": [
"ketoprofen"
],
"offsets": [
[
50,
60
]
],
"normalized": []
},
{
"id": "76469",
"type": "Intervention_Pharmacological",
"text": [
"ketoprofen"
],
"offsets": [
[
50,
60
]
],
"normalized": []
},
{
"id": "76470",
"type": "Intervention_Pharmacological",
"text": [
"ketoprofen"
],
"offsets": [
[
50,
60
]
],
"normalized": []
},
{
"id": "76471",
"type": "Outcome_Physical",
"text": [
"pharmacokinetics"
],
"offsets": [
[
25,
41
]
],
"normalized": []
},
{
"id": "76472",
"type": "Outcome_Other",
"text": [
"therapeutic efficacy"
],
"offsets": [
[
184,
204
]
],
"normalized": []
},
{
"id": "76473",
"type": "Outcome_Adverse-effects",
"text": [
"toxicity"
],
"offsets": [
[
218,
226
]
],
"normalized": []
},
{
"id": "76474",
"type": "Outcome_Physical",
"text": [
"peak plasma concentration"
],
"offsets": [
[
924,
949
]
],
"normalized": []
},
{
"id": "76475",
"type": "Outcome_Physical",
"text": [
"time to reach peak concentration"
],
"offsets": [
[
1184,
1216
]
],
"normalized": []
},
{
"id": "76476",
"type": "Outcome_Other",
"text": [
"lag time"
],
"offsets": [
[
1423,
1431
]
],
"normalized": []
},
{
"id": "76477",
"type": "Outcome_Physical",
"text": [
"absorption rate"
],
"offsets": [
[
1519,
1534
]
],
"normalized": []
},
{
"id": "76478",
"type": "Outcome_Physical",
"text": [
"bodyweight-corrected area under the curve ( AUC0-12 )"
],
"offsets": [
[
1653,
1706
]
],
"normalized": []
},
{
"id": "76479",
"type": "Outcome_Physical",
"text": [
"elimination half-life"
],
"offsets": [
[
1891,
1912
]
],
"normalized": []
},
{
"id": "76480",
"type": "Outcome_Other",
"text": [
"total clearance"
],
"offsets": [
[
2030,
2045
]
],
"normalized": []
},
{
"id": "76481",
"type": "Outcome_Physical",
"text": [
"circadian rhythms"
],
"offsets": [
[
2130,
2147
]
],
"normalized": []
},
{
"id": "76482",
"type": "Participant_Sample-size",
"text": [
"8"
],
"offsets": [
[
587,
588
]
],
"normalized": []
},
{
"id": "76483",
"type": "Participant_Condition",
"text": [
"healthy"
],
"offsets": [
[
589,
596
]
],
"normalized": []
},
{
"id": "76484",
"type": "Participant_Sex",
"text": [
"male"
],
"offsets": [
[
597,
601
]
],
"normalized": []
},
{
"id": "76485",
"type": "Participant_Age",
"text": [
"27.2"
],
"offsets": [
[
624,
628
]
],
"normalized": []
}
] | [] | [] | [] |
76486 | 3617996 | [
{
"id": "76487",
"type": "document",
"text": [
"[ Intra-arterial chemotherapy in advanced ovarian cancers . 2 . Therapeutic results in relation to prognostic factors ] . 85 patients with advanced ovarian carcinomas were treated either intra-arterially with MTX and 5-FU , later systemically with the CMFV-combination ( therapy arm A ) or only systemically ( therapy arm B ) after randomization . The achieved rates of remission and survival time showed an obvious dependence on the histological type of tumor and on the degree of differentiation . Whereas the results of the treatment were nearly identical in both groups of treatment with badly differentiated carcinomas , a significant improvement could be achieved by the initial local treatment of well and moderately differentiated malignancies . More than one third of the cases of advanced tumors were operable by local chemotherapy . Thus the survival time could be extended . The intra-arterial chemotherapy represents an expensive , but effective method of treatment of advanced ovarian carcinomas ."
],
"offsets": [
[
0,
1011
]
]
}
] | [
{
"id": "76488",
"type": "Intervention_Pharmacological",
"text": [
"Intra-arterial chemotherapy"
],
"offsets": [
[
2,
29
]
],
"normalized": []
},
{
"id": "76489",
"type": "Intervention_Pharmacological",
"text": [
"intra-arterially with MTX"
],
"offsets": [
[
187,
212
]
],
"normalized": []
},
{
"id": "76490",
"type": "Intervention_Physical",
"text": [
"and"
],
"offsets": [
[
213,
216
]
],
"normalized": []
},
{
"id": "76491",
"type": "Intervention_Pharmacological",
"text": [
"5-FU"
],
"offsets": [
[
217,
221
]
],
"normalized": []
},
{
"id": "76492",
"type": "Intervention_Pharmacological",
"text": [
"systemically with the CMFV-combination"
],
"offsets": [
[
230,
268
]
],
"normalized": []
},
{
"id": "76493",
"type": "Intervention_Physical",
"text": [
"only systemically"
],
"offsets": [
[
290,
307
]
],
"normalized": []
},
{
"id": "76494",
"type": "Intervention_Pharmacological",
"text": [
"intra-arterial chemotherapy"
],
"offsets": [
[
891,
918
]
],
"normalized": []
},
{
"id": "76495",
"type": "Outcome_Mortality",
"text": [
"rates of remission and survival time"
],
"offsets": [
[
361,
397
]
],
"normalized": []
},
{
"id": "76496",
"type": "Outcome_Mortality",
"text": [
"survival time"
],
"offsets": [
[
384,
397
]
],
"normalized": []
},
{
"id": "76497",
"type": "Participant_Condition",
"text": [
"85 patients with advanced ovarian carcinomas"
],
"offsets": [
[
122,
166
]
],
"normalized": []
}
] | [] | [] | [] |
76498 | 3624669 | [
{
"id": "76499",
"type": "document",
"text": [
"Disopyramide-pyridostigmine interaction : selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect . This double-blind , randomized , placebo crossover study was used to evaluate the effects of a cholinesterase inhibitor -- slow-release pyridostigmine ( 180 mg orally every 12 hours ) -- on the anticholinergic and antiarrhythmic properties of disopyramide . Quantitative side effects questionnaire scores were used to guide disopyramide administration in 20 men with ventricular tachycardia . Disopyramide was given to each patient both with placebo and with active pyridostigmine . The maximal administered dose for each regimen was used in conjunction with corresponding questionnaire scores to calculate an index or estimate of the maximal tolerable dose of disopyramide . Additional evaluations performed at baseline and at each maximal administered dose regimen included tear and saliva quantitation , 24 hour electrocardiogram ( ECG ) , exercise testing and programmed ventricular stimulation . Results showed that the maximal administered dose of disopyramide was greater with active pyridostigmine than with placebo : 295 +/- 75 versus 245 +/- 100 mg every 6 hours ( p less than 0.05 ) . The calculated maximal tolerable dose was substantially greater in the presence of pyridostigmine : 355 +/- 90 versus 260 +/- 115 mg every 6 hours ( p less than 0.001 ) . Maximal side effects questionnaire scores also reflected decreased anticholinergic activity in the presence of pyridostigmine compared with placebo : 101.9 +/- 2.2 versus 104.6 +/- 2.8 , respectively ( p less than 0.005 ) . Baseline tear and saliva production was significantly reduced during disopyramide therapy , but was restored toward normal by the addition of pyridostigmine . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1819
]
]
}
] | [
{
"id": "76500",
"type": "Intervention_Pharmacological",
"text": [
"Disopyramide-pyridostigmine"
],
"offsets": [
[
0,
27
]
],
"normalized": []
},
{
"id": "76501",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
167,
174
]
],
"normalized": []
},
{
"id": "76502",
"type": "Intervention_Pharmacological",
"text": [
"cholinesterase inhibitor -- slow-release pyridostigmine"
],
"offsets": [
[
229,
284
]
],
"normalized": []
},
{
"id": "76503",
"type": "Intervention_Pharmacological",
"text": [
"disopyramide"
],
"offsets": [
[
377,
389
]
],
"normalized": []
},
{
"id": "76504",
"type": "Intervention_Pharmacological",
"text": [
"disopyramide"
],
"offsets": [
[
377,
389
]
],
"normalized": []
},
{
"id": "76505",
"type": "Intervention_Pharmacological",
"text": [
"Disopyramide"
],
"offsets": [
[
0,
12
]
],
"normalized": []
},
{
"id": "76506",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
167,
174
]
],
"normalized": []
},
{
"id": "76507",
"type": "Intervention_Pharmacological",
"text": [
"pyridostigmine"
],
"offsets": [
[
13,
27
]
],
"normalized": []
},
{
"id": "76508",
"type": "Intervention_Pharmacological",
"text": [
"disopyramide"
],
"offsets": [
[
377,
389
]
],
"normalized": []
},
{
"id": "76509",
"type": "Intervention_Pharmacological",
"text": [
"disopyramide"
],
"offsets": [
[
377,
389
]
],
"normalized": []
},
{
"id": "76510",
"type": "Intervention_Pharmacological",
"text": [
"pyridostigmine"
],
"offsets": [
[
13,
27
]
],
"normalized": []
},
{
"id": "76511",
"type": "Intervention_Pharmacological",
"text": [
"pyridostigmine"
],
"offsets": [
[
13,
27
]
],
"normalized": []
},
{
"id": "76512",
"type": "Intervention_Pharmacological",
"text": [
"pyridostigmine"
],
"offsets": [
[
13,
27
]
],
"normalized": []
},
{
"id": "76513",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
167,
174
]
],
"normalized": []
},
{
"id": "76514",
"type": "Outcome_Physical",
"text": [
"anticholinergic and antiarrhythmic properties"
],
"offsets": [
[
328,
373
]
],
"normalized": []
},
{
"id": "76515",
"type": "Outcome_Other",
"text": [
"maximal tolerable dose"
],
"offsets": [
[
769,
791
]
],
"normalized": []
},
{
"id": "76516",
"type": "Outcome_Physical",
"text": [
"tear and saliva quantitation , 24 hour electrocardiogram ( ECG ) , exercise testing and programmed ventricular stimulation ."
],
"offsets": [
[
910,
1034
]
],
"normalized": []
},
{
"id": "76517",
"type": "Outcome_Other",
"text": [
"maximal tolerable dose"
],
"offsets": [
[
769,
791
]
],
"normalized": []
},
{
"id": "76518",
"type": "Outcome_Adverse-effects",
"text": [
"Maximal side effects questionnaire scores"
],
"offsets": [
[
1401,
1442
]
],
"normalized": []
},
{
"id": "76519",
"type": "Outcome_Physical",
"text": [
"anticholinergic activity"
],
"offsets": [
[
1468,
1492
]
],
"normalized": []
},
{
"id": "76520",
"type": "Participant_Sample-size",
"text": [
"20"
],
"offsets": [
[
489,
491
]
],
"normalized": []
},
{
"id": "76521",
"type": "Participant_Sex",
"text": [
"men"
],
"offsets": [
[
492,
495
]
],
"normalized": []
},
{
"id": "76522",
"type": "Participant_Condition",
"text": [
"ventricular tachycardia"
],
"offsets": [
[
501,
524
]
],
"normalized": []
},
{
"id": "76523",
"type": "Participant_Condition",
"text": [
"placebo"
],
"offsets": [
[
167,
174
]
],
"normalized": []
},
{
"id": "76524",
"type": "Participant_Condition",
"text": [
"active pyridostigmine ."
],
"offsets": [
[
593,
616
]
],
"normalized": []
}
] | [] | [] | [] |
76525 | 3630589 | [
{
"id": "76526",
"type": "document",
"text": [
"Gastric contents and pH after oral premedication . Forty women , aged 26-40 years , were investigated with regard to gastric contents and pH before general anaesthesia . The patients were divided into two groups ( 20 in each ) . Group 100 received 0.3 mg kg-1 diazepam orally with 100 ml of water 2 h before surgery . Group 50 received 0.3 mg kg-1 diazepam with 50 ml of water 2 h before surgery . The amount of gastric content was significantly greater in Group 100 than in Group 50 ( P less than 0.05 ) . There was no statistical difference in pH values between the groups . The number of patients with both gastric pH less than 2.5 and gastric volume greater than 25 ml was significantly higher in Group 100 compared to Group 50 ( P less than 0.05 ) . We can not recommend the use of oral premedication using these amounts of water , considering the increased risk of aspiration of gastric contents ."
],
"offsets": [
[
0,
903
]
]
}
] | [
{
"id": "76527",
"type": "Intervention_Physical",
"text": [
"premedication"
],
"offsets": [
[
35,
48
]
],
"normalized": []
},
{
"id": "76528",
"type": "Intervention_Physical",
"text": [
"anaesthesia"
],
"offsets": [
[
156,
167
]
],
"normalized": []
},
{
"id": "76529",
"type": "Intervention_Pharmacological",
"text": [
"diazepam"
],
"offsets": [
[
260,
268
]
],
"normalized": []
},
{
"id": "76530",
"type": "Intervention_Pharmacological",
"text": [
"water"
],
"offsets": [
[
291,
296
]
],
"normalized": []
},
{
"id": "76531",
"type": "Intervention_Pharmacological",
"text": [
"diazepam with"
],
"offsets": [
[
348,
361
]
],
"normalized": []
},
{
"id": "76532",
"type": "Intervention_Pharmacological",
"text": [
"water"
],
"offsets": [
[
291,
296
]
],
"normalized": []
},
{
"id": "76533",
"type": "Intervention_Pharmacological",
"text": [
"premedication"
],
"offsets": [
[
35,
48
]
],
"normalized": []
},
{
"id": "76534",
"type": "Outcome_Physical",
"text": [
"Gastric contents"
],
"offsets": [
[
0,
16
]
],
"normalized": []
},
{
"id": "76535",
"type": "Outcome_Physical",
"text": [
"amount of gastric content"
],
"offsets": [
[
402,
427
]
],
"normalized": []
},
{
"id": "76536",
"type": "Outcome_Physical",
"text": [
"pH values"
],
"offsets": [
[
546,
555
]
],
"normalized": []
},
{
"id": "76537",
"type": "Outcome_Physical",
"text": [
"gastric pH"
],
"offsets": [
[
610,
620
]
],
"normalized": []
},
{
"id": "76538",
"type": "Outcome_Physical",
"text": [
"gastric volume"
],
"offsets": [
[
639,
653
]
],
"normalized": []
},
{
"id": "76539",
"type": "Participant_Age",
"text": [
"Forty women , aged 26-40 years"
],
"offsets": [
[
51,
81
]
],
"normalized": []
}
] | [] | [] | [] |
76540 | 3653128 | [
{
"id": "76541",
"type": "document",
"text": [
"Deleterious effects of low-dose oestrogen therapy on coronary status in patients with prostatic cancer . The effects of oestrogen therapy and of orchidectomy on coronary status , as reflected by exercise ECG-testing before and after one year of treatment , were assessed in a randomized study of patients ( N = 100 ) with prostatic cancer . Oestrogen was given as polyestradiol phosphate 80 mg i.m . per month in combination with 150 micrograms ethinylestradiol p.o . per day . There were no significant inter-group differences in conventional risk factors or in pre-treatment exercise test results . Twelve months after the start of therapy the oestrogen group showed a significantly greater depression of the ST-segment during maximal exercise in leads CH2 ( P less than 0.0005 ) and CH5 ( P less than 0.01 ) compared with the pre-treatment depression . Twenty-five per cent ( N = 13 ) of the patients in the oestrogen group suffered cardiovascular complications during the year of therapy , whereas no such complications were observed in the orchidectomy group . However , even the patients in the oestrogen group who had not suffered cardiovascular complications had significantly greater depressions of the ST-segment during exercise both in lead CH2 ( P less than 0.0005 ) and in CH5 ( P less than 0.05 ) . There was no significant change in the ST-segment level in the orchidectomy group twelve months after surgery . In summary , we found evidence of an induction of myocardial ischaemia during treatment with exogenous oestrogens at low dosage in patients with prostatic cancer . This deleterious effect of oestrogen on the coronary status argues against oestrogen therapy , since oestrogen has not been shown to be more beneficial than orchidectomy against prostatic carcinoma ."
],
"offsets": [
[
0,
1788
]
]
}
] | [
{
"id": "76542",
"type": "Intervention_Pharmacological",
"text": [
"low-dose oestrogen therapy"
],
"offsets": [
[
23,
49
]
],
"normalized": []
},
{
"id": "76543",
"type": "Intervention_Pharmacological",
"text": [
"oestrogen therapy"
],
"offsets": [
[
32,
49
]
],
"normalized": []
},
{
"id": "76544",
"type": "Intervention_Surgical",
"text": [
"orchidectomy"
],
"offsets": [
[
145,
157
]
],
"normalized": []
},
{
"id": "76545",
"type": "Intervention_Pharmacological",
"text": [
"Oestrogen"
],
"offsets": [
[
341,
350
]
],
"normalized": []
},
{
"id": "76546",
"type": "Intervention_Pharmacological",
"text": [
"polyestradiol phosphate"
],
"offsets": [
[
364,
387
]
],
"normalized": []
},
{
"id": "76547",
"type": "Intervention_Pharmacological",
"text": [
"150 micrograms ethinylestradiol"
],
"offsets": [
[
430,
461
]
],
"normalized": []
},
{
"id": "76548",
"type": "Intervention_Pharmacological",
"text": [
"exogenous oestrogens"
],
"offsets": [
[
1518,
1538
]
],
"normalized": []
},
{
"id": "76549",
"type": "Intervention_Pharmacological",
"text": [
"oestrogen"
],
"offsets": [
[
32,
41
]
],
"normalized": []
},
{
"id": "76550",
"type": "Intervention_Pharmacological",
"text": [
"oestrogen"
],
"offsets": [
[
32,
41
]
],
"normalized": []
},
{
"id": "76551",
"type": "Outcome_Adverse-effects",
"text": [
"cardiovascular complications"
],
"offsets": [
[
936,
964
]
],
"normalized": []
},
{
"id": "76552",
"type": "Outcome_Adverse-effects",
"text": [
"cardiovascular complications"
],
"offsets": [
[
936,
964
]
],
"normalized": []
},
{
"id": "76553",
"type": "Outcome_Physical",
"text": [
"depressions of the ST-segment"
],
"offsets": [
[
1193,
1222
]
],
"normalized": []
},
{
"id": "76554",
"type": "Outcome_Physical",
"text": [
"ST-segment level"
],
"offsets": [
[
1352,
1368
]
],
"normalized": []
},
{
"id": "76555",
"type": "Outcome_Physical",
"text": [
"myocardial ischaemia"
],
"offsets": [
[
1475,
1495
]
],
"normalized": []
},
{
"id": "76556",
"type": "Participant_Condition",
"text": [
"patients with prostatic cancer ."
],
"offsets": [
[
72,
104
]
],
"normalized": []
},
{
"id": "76557",
"type": "Participant_Sample-size",
"text": [
"N = 100"
],
"offsets": [
[
307,
314
]
],
"normalized": []
},
{
"id": "76558",
"type": "Participant_Condition",
"text": [
"prostatic cancer"
],
"offsets": [
[
86,
102
]
],
"normalized": []
}
] | [] | [] | [] |
76559 | 3673207 | [
{
"id": "76560",
"type": "document",
"text": [
"Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine : serological and clinical responses in man . Clinical reactions and neutralizing antibody responses to six pre-exposure regimens of purified chick embryo cell culture rabies vaccine ( PCECV ) and human diploid cell strain rabies vaccine ( HDCSV ) were studied in 177 volunteers . Antibody kinetics , height of the response and persistence of antibody over two years were virtually identical after PCECV and HDCSV . An antibody response was detected in all subjects on day 14 when the highest titres were found after two intramuscular ( i.m . ) 1.0 ml doses of a schedule of immunization on days 0 , 7 and 21 . In comparison , a schedule of immunization on days 0 , 28 and 56 ultimately evoked the highest titres 21 days after the final injection , but antibody persisted equally well over two years with either schedule . Neutralizing antibody titres were lower after intradermal ( i.d . ) vaccination with 0.1 ml compared to 1.0 ml i.m . on days 0 , 7 and 21 , but when given on days 0 , 28 and 56 the responses were comparable . Three subjects with a personal or family history of atopy developed urticarial lesions after PCECV . Both vaccines were otherwise well tolerated ."
],
"offsets": [
[
0,
1285
]
]
}
] | [
{
"id": "76561",
"type": "Intervention_Pharmacological",
"text": [
"purified chick embryo cell culture rabies vaccine"
],
"offsets": [
[
26,
75
]
],
"normalized": []
},
{
"id": "76562",
"type": "Intervention_Pharmacological",
"text": [
"human diploid cell vaccine"
],
"offsets": [
[
80,
106
]
],
"normalized": []
},
{
"id": "76563",
"type": "Intervention_Pharmacological",
"text": [
"purified chick embryo cell culture rabies vaccine ( PCECV )"
],
"offsets": [
[
240,
299
]
],
"normalized": []
},
{
"id": "76564",
"type": "Intervention_Pharmacological",
"text": [
"human diploid cell strain rabies vaccine ( HDCSV )"
],
"offsets": [
[
304,
354
]
],
"normalized": []
},
{
"id": "76565",
"type": "Intervention_Pharmacological",
"text": [
"PCECV"
],
"offsets": [
[
292,
297
]
],
"normalized": []
},
{
"id": "76566",
"type": "Intervention_Pharmacological",
"text": [
"HDCSV"
],
"offsets": [
[
347,
352
]
],
"normalized": []
},
{
"id": "76567",
"type": "Intervention_Pharmacological",
"text": [
"PCECV"
],
"offsets": [
[
292,
297
]
],
"normalized": []
},
{
"id": "76568",
"type": "Outcome_Other",
"text": [
"response"
],
"offsets": [
[
134,
142
]
],
"normalized": []
},
{
"id": "76569",
"type": "Outcome_Other",
"text": [
"persistence of antibody over two years"
],
"offsets": [
[
435,
473
]
],
"normalized": []
},
{
"id": "76570",
"type": "Outcome_Mental",
"text": [
"antibody response"
],
"offsets": [
[
189,
206
]
],
"normalized": []
},
{
"id": "76571",
"type": "Outcome_Other",
"text": [
"titres 21 days after the final injection"
],
"offsets": [
[
813,
853
]
],
"normalized": []
},
{
"id": "76572",
"type": "Outcome_Other",
"text": [
"Neutralizing"
],
"offsets": [
[
930,
942
]
],
"normalized": []
},
{
"id": "76573",
"type": "Outcome_Physical",
"text": [
"antibody titres"
],
"offsets": [
[
943,
958
]
],
"normalized": []
},
{
"id": "76574",
"type": "Outcome_Physical",
"text": [
"urticarial lesions"
],
"offsets": [
[
1207,
1225
]
],
"normalized": []
},
{
"id": "76575",
"type": "Participant_Sex",
"text": [
"man"
],
"offsets": [
[
82,
85
]
],
"normalized": []
},
{
"id": "76576",
"type": "Participant_Sample-size",
"text": [
"177"
],
"offsets": [
[
371,
374
]
],
"normalized": []
}
] | [] | [] | [] |
76577 | 3675403 | [
{
"id": "76578",
"type": "document",
"text": [
"A randomised comparison of three drainage systems following cholecystectomy . The efficacy of low pressure , high pressure and passive drainage systems have been compared after cholecystectomy . Symptoms of pain , discomfort and nausea were compared using linear analogue scales and spirometry was used to examine pre-operative and postoperative respiratory function . The low pressure suction drain removed an intraperitoneal marker , gentamicin , more effectively than the high pressure suction drain , but not more effectively than the passive drain . There were no differences in postoperative respiratory function nor in the amount of pain or discomfort between the groups . The passive drain group reported less nausea than the suction drain groups . If a negative pressure drainage system is to be used , a low pressure suction drain should be used in preference to a high pressure system ."
],
"offsets": [
[
0,
897
]
]
}
] | [
{
"id": "76579",
"type": "Intervention_Surgical",
"text": [
"low pressure , high pressure and passive drainage systems"
],
"offsets": [
[
94,
151
]
],
"normalized": []
},
{
"id": "76580",
"type": "Intervention_Surgical",
"text": [
"low pressure suction drain"
],
"offsets": [
[
373,
399
]
],
"normalized": []
},
{
"id": "76581",
"type": "Intervention_Surgical",
"text": [
"high pressure suction drain"
],
"offsets": [
[
475,
502
]
],
"normalized": []
},
{
"id": "76582",
"type": "Intervention_Surgical",
"text": [
"passive drain"
],
"offsets": [
[
127,
140
]
],
"normalized": []
},
{
"id": "76583",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
82,
90
]
],
"normalized": []
},
{
"id": "76584",
"type": "Outcome_Pain",
"text": [
"Symptoms of pain"
],
"offsets": [
[
195,
211
]
],
"normalized": []
},
{
"id": "76585",
"type": "Outcome_Physical",
"text": [
","
],
"offsets": [
[
107,
108
]
],
"normalized": []
},
{
"id": "76586",
"type": "Outcome_Adverse-effects",
"text": [
"discomfort and nausea"
],
"offsets": [
[
214,
235
]
],
"normalized": []
},
{
"id": "76587",
"type": "Outcome_Physical",
"text": [
"respiratory function ."
],
"offsets": [
[
346,
368
]
],
"normalized": []
},
{
"id": "76588",
"type": "Outcome_Physical",
"text": [
"intraperitoneal marker , gentamicin"
],
"offsets": [
[
411,
446
]
],
"normalized": []
},
{
"id": "76589",
"type": "Outcome_Physical",
"text": [
"postoperative respiratory function"
],
"offsets": [
[
332,
366
]
],
"normalized": []
},
{
"id": "76590",
"type": "Outcome_Pain",
"text": [
"amount of pain or discomfort"
],
"offsets": [
[
630,
658
]
],
"normalized": []
},
{
"id": "76591",
"type": "Outcome_Physical",
"text": [
"nausea"
],
"offsets": [
[
229,
235
]
],
"normalized": []
},
{
"id": "76592",
"type": "Participant_Condition",
"text": [
"following cholecystectomy ."
],
"offsets": [
[
50,
77
]
],
"normalized": []
},
{
"id": "76593",
"type": "Participant_Condition",
"text": [
"after cholecystectomy ."
],
"offsets": [
[
171,
194
]
],
"normalized": []
}
] | [] | [] | [] |
76594 | 3690941 | [
{
"id": "76595",
"type": "document",
"text": [
"The additive analgesic efficacy of acetaminophen , 1000 mg , and codeine , 60 mg , in dental pain . In a double-blind , randomized , single-dose trial the analgesic contribution of acetaminophen , 1000 mg , and codeine , 60 mg , was determined . The study was a 2 X 2 factorial experiment in which 120 patients suffering from pain as a result of oral surgery rated their pain intensity and pain relief for up to 5 hours after a single dose of one of : 1000 mg acetaminophen , 60 mg codeine , 1000 mg acetaminophen plus 60 mg codeine , or placebo . The factorial analysis showed that both 1000 mg acetaminophen and 60 mg codeine made a statistically significant ( P less than 0.05 ) contribution to the analgesic effectiveness of the combination on all measures of efficacy ( sum of pain intensity differences , largest pain intensity difference , total pain relief , largest pain relief , and time to remedication ) . The incidence of adverse effects did not appear to differ among the treatments , including placebo ."
],
"offsets": [
[
0,
1018
]
]
}
] | [
{
"id": "76596",
"type": "Intervention_Pharmacological",
"text": [
"acetaminophen"
],
"offsets": [
[
35,
48
]
],
"normalized": []
},
{
"id": "76597",
"type": "Intervention_Pharmacological",
"text": [
"codeine"
],
"offsets": [
[
65,
72
]
],
"normalized": []
},
{
"id": "76598",
"type": "Intervention_Pharmacological",
"text": [
"acetaminophen , 1000 mg"
],
"offsets": [
[
35,
58
]
],
"normalized": []
},
{
"id": "76599",
"type": "Intervention_Pharmacological",
"text": [
"codeine , 60 mg"
],
"offsets": [
[
65,
80
]
],
"normalized": []
},
{
"id": "76600",
"type": "Intervention_Pharmacological",
"text": [
"acetaminophen"
],
"offsets": [
[
35,
48
]
],
"normalized": []
},
{
"id": "76601",
"type": "Intervention_Pharmacological",
"text": [
"acetaminophen plus 60 mg codeine"
],
"offsets": [
[
500,
532
]
],
"normalized": []
},
{
"id": "76602",
"type": "Intervention_Control",
"text": [
"placebo ."
],
"offsets": [
[
538,
547
]
],
"normalized": []
},
{
"id": "76603",
"type": "Intervention_Pharmacological",
"text": [
"acetaminophen"
],
"offsets": [
[
35,
48
]
],
"normalized": []
},
{
"id": "76604",
"type": "Intervention_Pharmacological",
"text": [
"codeine"
],
"offsets": [
[
65,
72
]
],
"normalized": []
},
{
"id": "76605",
"type": "Outcome_Pain",
"text": [
"pain intensity"
],
"offsets": [
[
371,
385
]
],
"normalized": []
},
{
"id": "76606",
"type": "Outcome_Pain",
"text": [
"pain relief"
],
"offsets": [
[
390,
401
]
],
"normalized": []
},
{
"id": "76607",
"type": "Outcome_Other",
"text": [
"analgesic effectiveness"
],
"offsets": [
[
702,
725
]
],
"normalized": []
},
{
"id": "76608",
"type": "Outcome_Pain",
"text": [
"of the combination on all measures of efficacy"
],
"offsets": [
[
726,
772
]
],
"normalized": []
},
{
"id": "76609",
"type": "Outcome_Pain",
"text": [
"sum of pain intensity differences"
],
"offsets": [
[
775,
808
]
],
"normalized": []
},
{
"id": "76610",
"type": "Outcome_Pain",
"text": [
"largest pain intensity difference"
],
"offsets": [
[
811,
844
]
],
"normalized": []
},
{
"id": "76611",
"type": "Outcome_Pain",
"text": [
"total pain relief"
],
"offsets": [
[
847,
864
]
],
"normalized": []
},
{
"id": "76612",
"type": "Outcome_Pain",
"text": [
"largest pain relief"
],
"offsets": [
[
867,
886
]
],
"normalized": []
},
{
"id": "76613",
"type": "Outcome_Pain",
"text": [
"time to remedication"
],
"offsets": [
[
893,
913
]
],
"normalized": []
},
{
"id": "76614",
"type": "Outcome_Adverse-effects",
"text": [
"incidence of adverse effects"
],
"offsets": [
[
922,
950
]
],
"normalized": []
},
{
"id": "76615",
"type": "Participant_Condition",
"text": [
"dental pain"
],
"offsets": [
[
86,
97
]
],
"normalized": []
},
{
"id": "76616",
"type": "Participant_Sample-size",
"text": [
"120"
],
"offsets": [
[
298,
301
]
],
"normalized": []
}
] | [] | [] | [] |
76617 | 3704665 | [
{
"id": "76618",
"type": "document",
"text": [
"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols . The PVSG was organized in 1967 to establish effective diagnostic criteria for polycythemia vera , to study the natural history of the disease and to define the optimal treatment . Although polycythemia vera and the other myeloproliferative diseases are relatively uncommon , the PVSG was able to accumulate well over 1,000 patients with these various disorders and to study them according to a total of 15 different protocols . PVSG-01 , a long-term randomized controlled study of phlebotomy alone compared with the myelosuppressive agents , 32P or chlorambucil supplemented by phlebotomy , continues to receive follow-up data on 93 % of surviving patients 18 years after initiation of the study . During its lifetime , PVSG has developed a widely accepted and highly effective set of criteria for the specific diagnosis of polycythemia vera as well as useful criteria for the diagnosis of essential thrombocythemia . It has gathered an enormous volume of data on the natural history of the myeloproliferative diseases and in particular on the nature of the prevalent complications , such as thrombotic events and hematologic and nonhematologic malignancies . With respect to the final question , the optimal treatment for polycythemia vera , it is apparent that the expectation of a single optimal therapy that would apply to all patients at all ages and stages of the disease was naive . Nevertheless considerable progress has been made . Moreover , the group has defined more precisely than ever before the nature of the complications of the disease and the association of the risks of specific complications with specific forms of therapy . It thus has made it possible to pose the next series of therapeutic questions that must be addressed in this disorder with a greater degree of sophistication than was previously possible ."
],
"offsets": [
[
0,
1933
]
]
}
] | [
{
"id": "76619",
"type": "Intervention_Control",
"text": [
"phlebotomy alone"
],
"offsets": [
[
581,
597
]
],
"normalized": []
},
{
"id": "76620",
"type": "Intervention_Pharmacological",
"text": [
"myelosuppressive agents"
],
"offsets": [
[
616,
639
]
],
"normalized": []
},
{
"id": "76621",
"type": "Intervention_Pharmacological",
"text": [
"32P"
],
"offsets": [
[
642,
645
]
],
"normalized": []
},
{
"id": "76622",
"type": "Intervention_Pharmacological",
"text": [
"chlorambucil"
],
"offsets": [
[
649,
661
]
],
"normalized": []
},
{
"id": "76623",
"type": "Intervention_Physical",
"text": [
"phlebotomy"
],
"offsets": [
[
581,
591
]
],
"normalized": []
},
{
"id": "76624",
"type": "Outcome_Physical",
"text": [
"recommendations"
],
"offsets": [
[
12,
27
]
],
"normalized": []
},
{
"id": "76625",
"type": "Outcome_Physical",
"text": [
"nature of the complications"
],
"offsets": [
[
1610,
1637
]
],
"normalized": []
},
{
"id": "76626",
"type": "Outcome_Physical",
"text": [
"risks of"
],
"offsets": [
[
1680,
1688
]
],
"normalized": []
},
{
"id": "76627",
"type": "Outcome_Adverse-effects",
"text": [
"specific complications"
],
"offsets": [
[
1689,
1711
]
],
"normalized": []
},
{
"id": "76628",
"type": "Participant_Condition",
"text": [
"polycythemia vera"
],
"offsets": [
[
31,
48
]
],
"normalized": []
},
{
"id": "76629",
"type": "Participant_Condition",
"text": [
"myeloproliferative diseases"
],
"offsets": [
[
321,
348
]
],
"normalized": []
},
{
"id": "76630",
"type": "Participant_Sample-size",
"text": [
"well over 1,000"
],
"offsets": [
[
407,
422
]
],
"normalized": []
}
] | [] | [] | [] |
76631 | 3710012 | [
{
"id": "76632",
"type": "document",
"text": [
"Acute reduction of arterial blood pressure reduces urinary albumin excretion in type 1 ( insulin-dependent ) diabetic patients with incipient nephropathy . The effect of an acute reduction in arterial blood pressure upon kidney function was studied in 12 patients with Type 1 ( insulin-dependent ) diabetes and incipient nephropathy ( persistent microalbuminuria ) . Renal function was assessed by measurement of the glomerular filtration rate ( single bolus 51Cr-EDTA technique ) and by the urinary albumin excretion rate ( radioimmunoassay ) . The study was performed twice within 2 weeks , with the patients receiving a slow intravenous injection of either clonidine ( 225 micrograms ) or saline ( 154 mmol/l ) in random order . Clonidine reduced arterial blood pressure from 125/79 +/- 13/8 to 104/68 +/- 9/7 mmHg ( p less than 0.01 ) , urinary albumin excretion rate from 68 ( 31-369 ) to 46 ( 6-200 ) micrograms/min ( median and range ) ( p less than 0.01 ) , and fractional clearance of albumin in all patients ( median 29 % ) ( p less than 0.01 ) . Glomerular filtration rate was 110 +/- 11 before and 106 +/- 13 ml/min/1.73 m2 after clonidine injection . The blood glucose concentration was 15 +/- 4 mmol/l before and 14 +/- 5 mmol/l after clonidine injection . In agreement with findings in animal studies , our results suggest that microalbuminuria is to a large extent pressure-dependent , probably because of glomerular hypertension , and that autoregulation of glomerular filtration rate is normal in most patients with incipient diabetic nephropathy ."
],
"offsets": [
[
0,
1566
]
]
}
] | [
{
"id": "76633",
"type": "Intervention_Pharmacological",
"text": [
"clonidine"
],
"offsets": [
[
660,
669
]
],
"normalized": []
},
{
"id": "76634",
"type": "Intervention_Pharmacological",
"text": [
"saline"
],
"offsets": [
[
692,
698
]
],
"normalized": []
},
{
"id": "76635",
"type": "Intervention_Pharmacological",
"text": [
"Clonidine"
],
"offsets": [
[
732,
741
]
],
"normalized": []
},
{
"id": "76636",
"type": "Intervention_Pharmacological",
"text": [
"clonidine"
],
"offsets": [
[
660,
669
]
],
"normalized": []
},
{
"id": "76637",
"type": "Intervention_Pharmacological",
"text": [
"clonidine"
],
"offsets": [
[
660,
669
]
],
"normalized": []
},
{
"id": "76638",
"type": "Outcome_Physical",
"text": [
"urinary albumin excretion"
],
"offsets": [
[
51,
76
]
],
"normalized": []
},
{
"id": "76639",
"type": "Outcome_Physical",
"text": [
"kidney function"
],
"offsets": [
[
221,
236
]
],
"normalized": []
},
{
"id": "76640",
"type": "Outcome_Physical",
"text": [
"Renal function"
],
"offsets": [
[
367,
381
]
],
"normalized": []
},
{
"id": "76641",
"type": "Outcome_Physical",
"text": [
"glomerular filtration rate"
],
"offsets": [
[
417,
443
]
],
"normalized": []
},
{
"id": "76642",
"type": "Outcome_Physical",
"text": [
"urinary albumin excretion rate ( radioimmunoassay ) ."
],
"offsets": [
[
492,
545
]
],
"normalized": []
},
{
"id": "76643",
"type": "Outcome_Physical",
"text": [
"arterial blood pressure"
],
"offsets": [
[
19,
42
]
],
"normalized": []
},
{
"id": "76644",
"type": "Outcome_Physical",
"text": [
"urinary albumin excretion rate"
],
"offsets": [
[
492,
522
]
],
"normalized": []
},
{
"id": "76645",
"type": "Outcome_Physical",
"text": [
"fractional clearance of albumin"
],
"offsets": [
[
970,
1001
]
],
"normalized": []
},
{
"id": "76646",
"type": "Outcome_Physical",
"text": [
"Glomerular filtration rate"
],
"offsets": [
[
1057,
1083
]
],
"normalized": []
},
{
"id": "76647",
"type": "Outcome_Physical",
"text": [
"blood glucose concentration"
],
"offsets": [
[
1168,
1195
]
],
"normalized": []
},
{
"id": "76648",
"type": "Outcome_Physical",
"text": [
"glomerular filtration rate"
],
"offsets": [
[
417,
443
]
],
"normalized": []
},
{
"id": "76649",
"type": "Participant_Condition",
"text": [
"type 1 ( insulin-dependent ) diabetic patients with incipient nephropathy ."
],
"offsets": [
[
80,
155
]
],
"normalized": []
},
{
"id": "76650",
"type": "Participant_Condition",
"text": [
"12 patients with Type 1 ( insulin-dependent ) diabetes and incipient nephropathy ( persistent microalbuminuria ) ."
],
"offsets": [
[
252,
366
]
],
"normalized": []
}
] | [] | [] | [] |
76651 | 3715614 | [
{
"id": "76652",
"type": "document",
"text": [
"[ Randomized cooperative studies of the surgical treatment of cancer of the thyroid gland ] ."
],
"offsets": [
[
0,
93
]
]
}
] | [
{
"id": "76653",
"type": "Intervention_Physical",
"text": [
"surgical treatment"
],
"offsets": [
[
40,
58
]
],
"normalized": []
},
{
"id": "76654",
"type": "Participant_Condition",
"text": [
"cancer of the thyroid gland ]"
],
"offsets": [
[
62,
91
]
],
"normalized": []
}
] | [] | [] | [] |
76655 | 371644 | [
{
"id": "76656",
"type": "document",
"text": [
"Management of unstable angina at rest by verapamil . A double-blind cross-over study in coronary care unit . A therapeutic trial with verapamil , a calcium-antagonist drug , was performed in 12 patients admitted to our coronary care unit because of frequent daily attacks of angina at rest attributed to coronary vasospasm . After a 48-hour run-in period , oral verapamil 480 mg/day and placebo were administered alternately during 4 randomised 48-hour periods . Transient ischaemic attacks with ST segment elevation or depression , with or without pain , were documented by continuous electrocardiographic monitoring . The number of attacks during the run-in and 2 placebo periods were 128 , 123 , and 130 , respectively , and 31 and 23 during the 2 treatment periods ( P less than 0.006 and P less than 0.003 ) . This drug therefore appears to be effective in the management of patients with frequent attacks of angina at rest ."
],
"offsets": [
[
0,
930
]
]
}
] | [
{
"id": "76657",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
41,
50
]
],
"normalized": []
},
{
"id": "76658",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
41,
50
]
],
"normalized": []
},
{
"id": "76659",
"type": "Intervention_Pharmacological",
"text": [
"calcium-antagonist drug"
],
"offsets": [
[
148,
171
]
],
"normalized": []
},
{
"id": "76660",
"type": "Intervention_Pharmacological",
"text": [
"oral verapamil 480 mg/day"
],
"offsets": [
[
357,
382
]
],
"normalized": []
},
{
"id": "76661",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
387,
394
]
],
"normalized": []
},
{
"id": "76662",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
387,
394
]
],
"normalized": []
},
{
"id": "76663",
"type": "Outcome_Physical",
"text": [
"Transient ischaemic attacks with ST segment elevation or depression , with or without pain"
],
"offsets": [
[
463,
553
]
],
"normalized": []
},
{
"id": "76664",
"type": "Outcome_Other",
"text": [
"continuous electrocardiographic monitoring"
],
"offsets": [
[
575,
617
]
],
"normalized": []
},
{
"id": "76665",
"type": "Outcome_Physical",
"text": [
"number of attacks"
],
"offsets": [
[
624,
641
]
],
"normalized": []
},
{
"id": "76666",
"type": "Outcome_Physical",
"text": [
"attacks of angina at rest"
],
"offsets": [
[
264,
289
]
],
"normalized": []
},
{
"id": "76667",
"type": "Participant_Condition",
"text": [
"unstable angina"
],
"offsets": [
[
14,
29
]
],
"normalized": []
},
{
"id": "76668",
"type": "Participant_Sample-size",
"text": [
"12 patients"
],
"offsets": [
[
191,
202
]
],
"normalized": []
},
{
"id": "76669",
"type": "Participant_Condition",
"text": [
"angina"
],
"offsets": [
[
23,
29
]
],
"normalized": []
},
{
"id": "76670",
"type": "Participant_Condition",
"text": [
"coronary vasospasm"
],
"offsets": [
[
304,
322
]
],
"normalized": []
},
{
"id": "76671",
"type": "Participant_Condition",
"text": [
"angina"
],
"offsets": [
[
23,
29
]
],
"normalized": []
}
] | [] | [] | [] |
76672 | 3732715 | [
{
"id": "76673",
"type": "document",
"text": [
"[ Opposing effects of propranolol and diltiazem on the angina threshold during an exercise test in patients with syndrome X ] . Patients with angina pectoris , exercise induced myocardial ischemia , normal coronary arteries and no evidence of epicardial spasm , i.e . patients with syndrome x , have been suggested to haven inadequate increase in coronary blood flow during tachycardia , possibly due to a functional disorder of small coronary vessels . To evaluate the best medical management of this syndrome we studied 13 patients who showed the above set of findings . Patients were given propranolol ( 160 mg daily ) , diltiazem ( 360 mg daily ) and placebo for 2 weeks , using a randomized single blind protocol . Upright bicycle ergometer testing was performed at the end of each period of treatment . Compared to placebo , diltiazem significantly ( p less than 0.001 ) prolonged exercise duration ( x +/- SD : 365 +/- 86 vs 303 +/- 89 sec ) and time to onset of angina ( 358 +/- 88 vs 276 +/- 90 sec ) . Angina appeared in 7 patients with diltiazem vs 13 patients with placebo and occurred at a higher rate pressure product ( 26.3 +/- 3.5 vs 24.1 +/- 2.8 X 10 ( -3 ) ; p less than 0.02 ) . Conversely , following propranolol exercise duration and time to onset of angina were unchanged and angina appeared in all patients at a lower rate pressure product ( 18.3 +/- 2.9 vs 24.4 +/- 3.6 X 10 ( -3 ) ; p less than 0.001 ) . The most likely explanations for these findings are : propranolol counteracts beta 2-adrenergic receptors , thus further reducing coronary reserve . This may lower the anginal threshold ; Diltiazem reduces smooth muscle tone in small coronary vessels . This may result in increased coronary reserve and exercise duration ."
],
"offsets": [
[
0,
1752
]
]
}
] | [
{
"id": "76674",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
22,
33
]
],
"normalized": []
},
{
"id": "76675",
"type": "Intervention_Pharmacological",
"text": [
"diltiazem"
],
"offsets": [
[
38,
47
]
],
"normalized": []
},
{
"id": "76676",
"type": "Intervention_Pharmacological",
"text": [
"diltiazem"
],
"offsets": [
[
38,
47
]
],
"normalized": []
},
{
"id": "76677",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
655,
662
]
],
"normalized": []
},
{
"id": "76678",
"type": "Intervention_Physical",
"text": [
"Upright bicycle ergometer testing"
],
"offsets": [
[
720,
753
]
],
"normalized": []
},
{
"id": "76679",
"type": "Intervention_Pharmacological",
"text": [
"diltiazem"
],
"offsets": [
[
38,
47
]
],
"normalized": []
},
{
"id": "76680",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
655,
662
]
],
"normalized": []
},
{
"id": "76681",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
22,
33
]
],
"normalized": []
},
{
"id": "76682",
"type": "Intervention_Pharmacological",
"text": [
"Diltiazem"
],
"offsets": [
[
1618,
1627
]
],
"normalized": []
},
{
"id": "76683",
"type": "Outcome_Physical",
"text": [
"angina threshold"
],
"offsets": [
[
55,
71
]
],
"normalized": []
},
{
"id": "76684",
"type": "Outcome_Physical",
"text": [
"coronary blood flow during tachycardia"
],
"offsets": [
[
347,
385
]
],
"normalized": []
},
{
"id": "76685",
"type": "Outcome_Physical",
"text": [
"exercise duration"
],
"offsets": [
[
887,
904
]
],
"normalized": []
},
{
"id": "76686",
"type": "Outcome_Physical",
"text": [
"time to onset of angina"
],
"offsets": [
[
953,
976
]
],
"normalized": []
},
{
"id": "76687",
"type": "Outcome_Physical",
"text": [
"Angina"
],
"offsets": [
[
1012,
1018
]
],
"normalized": []
},
{
"id": "76688",
"type": "Outcome_Physical",
"text": [
"pressure product"
],
"offsets": [
[
1115,
1131
]
],
"normalized": []
},
{
"id": "76689",
"type": "Outcome_Physical",
"text": [
"exercise duration and time to onset of angina"
],
"offsets": [
[
1233,
1278
]
],
"normalized": []
},
{
"id": "76690",
"type": "Outcome_Physical",
"text": [
"angina"
],
"offsets": [
[
55,
61
]
],
"normalized": []
},
{
"id": "76691",
"type": "Outcome_Physical",
"text": [
"pressure product"
],
"offsets": [
[
1115,
1131
]
],
"normalized": []
},
{
"id": "76692",
"type": "Outcome_Physical",
"text": [
"coronary reserve ."
],
"offsets": [
[
1560,
1578
]
],
"normalized": []
},
{
"id": "76693",
"type": "Outcome_Physical",
"text": [
"anginal threshold ;"
],
"offsets": [
[
1598,
1617
]
],
"normalized": []
},
{
"id": "76694",
"type": "Outcome_Physical",
"text": [
"smooth muscle tone"
],
"offsets": [
[
1636,
1654
]
],
"normalized": []
},
{
"id": "76695",
"type": "Outcome_Physical",
"text": [
"coronary reserve and exercise duration ."
],
"offsets": [
[
1712,
1752
]
],
"normalized": []
},
{
"id": "76696",
"type": "Participant_Condition",
"text": [
"patients with syndrome X ]"
],
"offsets": [
[
99,
125
]
],
"normalized": []
},
{
"id": "76697",
"type": "Participant_Condition",
"text": [
"Patients with angina pectoris , exercise induced myocardial ischemia"
],
"offsets": [
[
128,
196
]
],
"normalized": []
},
{
"id": "76698",
"type": "Participant_Condition",
"text": [
"normal coronary arteries and no evidence of epicardial spasm"
],
"offsets": [
[
199,
259
]
],
"normalized": []
},
{
"id": "76699",
"type": "Participant_Condition",
"text": [
"patients with syndrome x"
],
"offsets": [
[
268,
292
]
],
"normalized": []
},
{
"id": "76700",
"type": "Participant_Sample-size",
"text": [
"13 patients"
],
"offsets": [
[
522,
533
]
],
"normalized": []
}
] | [] | [] | [] |
76701 | 3739807 | [
{
"id": "76702",
"type": "document",
"text": [
"Abstinence or controlled drinking in clinical practice : indications at initial assessment . Previous research has suggested two leading hypotheses concerning which excessive drinkers can re-establish control : one based upon level of dependence , the other upon the client 's personal persuasion . Using initial assessment data from 46 clients of a clinical psychology alcohol problems service ( 30 men , 16 women ) , an attempt was made to operationalize the concepts of dependence and personal persuasion using a variety of indicators of each . Although SADQ scores and Rand definite alcoholism were in general agreement , there were a number of borderline instances and cases of disagreement , and neither was in good agreement with estimates of problem duration , nor with reports of recent or earlier attainment of abstinence or control . Indicators of personal persuasion were more consistent . Those with dependence indicators for abstinence tended to prefer abstinence as a goal , but there were many departures from this pattern particularly for women . It is concluded that in clinical practice it will be very difficult to make a clear cut recommendation about treatment goal at initial assessment except in a few cases ."
],
"offsets": [
[
0,
1233
]
]
}
] | [
{
"id": "76703",
"type": "Intervention_Educational",
"text": [
"Abstinence"
],
"offsets": [
[
0,
10
]
],
"normalized": []
},
{
"id": "76704",
"type": "Intervention_Educational",
"text": [
"controlled drinking"
],
"offsets": [
[
14,
33
]
],
"normalized": []
},
{
"id": "76705",
"type": "Intervention_Educational",
"text": [
"abstinence"
],
"offsets": [
[
821,
831
]
],
"normalized": []
},
{
"id": "76706",
"type": "Intervention_Educational",
"text": [
"control"
],
"offsets": [
[
14,
21
]
],
"normalized": []
},
{
"id": "76707",
"type": "Outcome_Mental",
"text": [
"SADQ scores"
],
"offsets": [
[
557,
568
]
],
"normalized": []
},
{
"id": "76708",
"type": "Outcome_Mental",
"text": [
"Rand definite alcoholism"
],
"offsets": [
[
573,
597
]
],
"normalized": []
},
{
"id": "76709",
"type": "Outcome_Mental",
"text": [
"personal persuasion"
],
"offsets": [
[
277,
296
]
],
"normalized": []
},
{
"id": "76710",
"type": "Outcome_Mental",
"text": [
"indicators for abstinence"
],
"offsets": [
[
924,
949
]
],
"normalized": []
},
{
"id": "76711",
"type": "Participant_Condition",
"text": [
"Abstinence or controlled drinking"
],
"offsets": [
[
0,
33
]
],
"normalized": []
},
{
"id": "76712",
"type": "Participant_Condition",
"text": [
"excessive drinkers"
],
"offsets": [
[
165,
183
]
],
"normalized": []
},
{
"id": "76713",
"type": "Participant_Sample-size",
"text": [
"46"
],
"offsets": [
[
334,
336
]
],
"normalized": []
},
{
"id": "76714",
"type": "Participant_Sample-size",
"text": [
"30"
],
"offsets": [
[
397,
399
]
],
"normalized": []
},
{
"id": "76715",
"type": "Participant_Sex",
"text": [
"men"
],
"offsets": [
[
86,
89
]
],
"normalized": []
},
{
"id": "76716",
"type": "Participant_Sample-size",
"text": [
"16"
],
"offsets": [
[
406,
408
]
],
"normalized": []
},
{
"id": "76717",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
409,
414
]
],
"normalized": []
}
] | [] | [] | [] |
76718 | 3741313 | [
{
"id": "76719",
"type": "document",
"text": [
"High general anger : correlates and treatment ."
],
"offsets": [
[
0,
47
]
]
}
] | [
{
"id": "76720",
"type": "Intervention_Educational",
"text": [
"correlates"
],
"offsets": [
[
21,
31
]
],
"normalized": []
},
{
"id": "76721",
"type": "Intervention_Physical",
"text": [
"treatment ."
],
"offsets": [
[
36,
47
]
],
"normalized": []
},
{
"id": "76722",
"type": "Outcome_Mental",
"text": [
"anger :"
],
"offsets": [
[
13,
20
]
],
"normalized": []
},
{
"id": "76723",
"type": "Participant_Condition",
"text": [
"High general anger"
],
"offsets": [
[
0,
18
]
],
"normalized": []
}
] | [] | [] | [] |
76724 | 3745846 | [
{
"id": "76725",
"type": "document",
"text": [
"Domperidone , metoclopramide , and placebo . All give symptomatic improvement in gastroesophageal reflux . A double-blind crossover study was conducted of two gastric prokinetic drugs in 23 patients with gastroesophageal reflux . Patients were divided into two groups on the basis of a dual-isotope mixed-meal study of their gastric emptying ( GE ) . Group I had normal GE and group II delayed GE . Nine gastrointestinal symptoms were assessed for frequency and severity before treatment . The trial had three 1-month treatment periods using metoclopramide 10 mg q.i.d. , domperidone 20 mg q.i.d. , or placebo on a random basis . Symptoms were reassessed at the end of each month . Taken as a whole , the group showed a significant symptomatic response in all three treatment periods ( p less than 0.0001 ) , but patients with delayed or normal GE did not differ significantly in their symptomatic response . Eleven patients complained of side effects with metoclopramide and three stopped therapy before the 1-month course was completed . Two patients described side effects with domperidone , including one woman with galactorrhea after 36 h of treatment . Three patients on placebo also complained of important side effects . We conclude that a significant placebo effect is present in the treatment of gastroesophageal reflux . No significant difference was demonstrated in symptomatic improvement between placebo , domperidone , and metoclopramide in this study ."
],
"offsets": [
[
0,
1468
]
]
}
] | [
{
"id": "76726",
"type": "Intervention_Pharmacological",
"text": [
"gastric prokinetic drugs"
],
"offsets": [
[
159,
183
]
],
"normalized": []
},
{
"id": "76727",
"type": "Intervention_Pharmacological",
"text": [
"domperidone"
],
"offsets": [
[
572,
583
]
],
"normalized": []
},
{
"id": "76728",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
35,
42
]
],
"normalized": []
},
{
"id": "76729",
"type": "Intervention_Pharmacological",
"text": [
"metoclopramide"
],
"offsets": [
[
14,
28
]
],
"normalized": []
},
{
"id": "76730",
"type": "Outcome_Physical",
"text": [
"symptomatic response"
],
"offsets": [
[
732,
752
]
],
"normalized": []
},
{
"id": "76731",
"type": "Outcome_Adverse-effects",
"text": [
"side effects"
],
"offsets": [
[
939,
951
]
],
"normalized": []
},
{
"id": "76732",
"type": "Outcome_Adverse-effects",
"text": [
"galactorrhea"
],
"offsets": [
[
1120,
1132
]
],
"normalized": []
},
{
"id": "76733",
"type": "Outcome_Adverse-effects",
"text": [
"important side effects"
],
"offsets": [
[
1204,
1226
]
],
"normalized": []
},
{
"id": "76734",
"type": "Outcome_Other",
"text": [
"symptomatic improvement"
],
"offsets": [
[
54,
77
]
],
"normalized": []
},
{
"id": "76735",
"type": "Participant_Sample-size",
"text": [
"23 patients"
],
"offsets": [
[
187,
198
]
],
"normalized": []
},
{
"id": "76736",
"type": "Participant_Condition",
"text": [
"gastroesophageal reflux"
],
"offsets": [
[
81,
104
]
],
"normalized": []
}
] | [] | [] | [] |
76737 | 375690 | [
{
"id": "76738",
"type": "document",
"text": [
"Zinc supplementation in alcoholic cirrhosis . A double-blind clinical trial . A double-blind clinical trial with zinc sulfate , 0.2 g three times daily , and a placebo was performed in 30 patients with biopsy-proven alcoholic liver cirrhosis . The disease was in a stable phase , and none of the patients showed evidence of a decompensated liver function . Parameters of liver function , taste acuity , dark adaptation and of zinc and vitamin A metabolism were followed for six weeks . In the zinc-treated group of 16 patients , serum zinc rose from a normal mean value of 13.3 to 17.4 mumol/l , whereas the mean serum vitamin A level remained practically unaltered within the normal range , 1.89 at the entry and 1.83 mumol/l at the end of the study . Plasma prothrombin and serum alkaline phosphatase levels of the zinc group increased and serum bilirubin and serum carotene decreased significantly . The dark adaptation did not change , but the taste function was significantly improved during zinc treatment . The results indicate that zinc supplementation causes alleviation of certain abnormalities of cirrhotics , which deserves further attention ."
],
"offsets": [
[
0,
1155
]
]
}
] | [
{
"id": "76739",
"type": "Intervention_Pharmacological",
"text": [
"Zinc supplementation"
],
"offsets": [
[
0,
20
]
],
"normalized": []
},
{
"id": "76740",
"type": "Intervention_Pharmacological",
"text": [
"zinc sulfate"
],
"offsets": [
[
113,
125
]
],
"normalized": []
},
{
"id": "76741",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
160,
167
]
],
"normalized": []
},
{
"id": "76742",
"type": "Intervention_Pharmacological",
"text": [
"zinc"
],
"offsets": [
[
113,
117
]
],
"normalized": []
},
{
"id": "76743",
"type": "Intervention_Pharmacological",
"text": [
"vitamin A metabolism"
],
"offsets": [
[
435,
455
]
],
"normalized": []
},
{
"id": "76744",
"type": "Intervention_Pharmacological",
"text": [
"zinc supplementation"
],
"offsets": [
[
1040,
1060
]
],
"normalized": []
},
{
"id": "76745",
"type": "Outcome_Physical",
"text": [
"Parameters of liver function , taste acuity , dark adaptation and of zinc and vitamin A metabolism"
],
"offsets": [
[
357,
455
]
],
"normalized": []
},
{
"id": "76746",
"type": "Outcome_Physical",
"text": [
"serum zinc"
],
"offsets": [
[
529,
539
]
],
"normalized": []
},
{
"id": "76747",
"type": "Outcome_Physical",
"text": [
"mean serum vitamin A level"
],
"offsets": [
[
608,
634
]
],
"normalized": []
},
{
"id": "76748",
"type": "Outcome_Physical",
"text": [
"Plasma prothrombin and serum alkaline phosphatase levels"
],
"offsets": [
[
753,
809
]
],
"normalized": []
},
{
"id": "76749",
"type": "Outcome_Physical",
"text": [
"serum bilirubin and serum carotene"
],
"offsets": [
[
842,
876
]
],
"normalized": []
},
{
"id": "76750",
"type": "Outcome_Physical",
"text": [
"dark adaptation"
],
"offsets": [
[
403,
418
]
],
"normalized": []
},
{
"id": "76751",
"type": "Outcome_Physical",
"text": [
"taste function"
],
"offsets": [
[
948,
962
]
],
"normalized": []
},
{
"id": "76752",
"type": "Participant_Condition",
"text": [
"alcoholic cirrhosis"
],
"offsets": [
[
24,
43
]
],
"normalized": []
},
{
"id": "76753",
"type": "Participant_Sample-size",
"text": [
"30 patients"
],
"offsets": [
[
185,
196
]
],
"normalized": []
},
{
"id": "76754",
"type": "Participant_Condition",
"text": [
"with biopsy-proven alcoholic liver cirrhosis ."
],
"offsets": [
[
197,
243
]
],
"normalized": []
}
] | [] | [] | [] |
76755 | 3803417 | [
{
"id": "76756",
"type": "document",
"text": [
"Acipimox in the treatment of patients with hyperlipidaemia : a double blind trial . Fifty-two patients with Fredrickson Type IIb or Type IV hyperlipidaemia , in whom diet had not achieved satisfactory lipid levels , completed a double blind randomised study of acipimox versus placebo . The patients were given acipimox , 250 mg three times daily or placebo for a three month period , and plasma lipids and glucose were monitored . The patients receiving acipimox showed a fall in the mean concentration of plasma triglyceride compared to placebo ( 0.74 mmol/l ) and this was most marked in patients whose initial plasma triglyceride levels were greater than 3 mmol/l ( 1.0 mmol/l , confidence limits 0.18 , 1.82 ) . Acipimox was well tolerated , and could be a useful addition to the drugs available for the treatment of patients with hypertriglyceridaemia ."
],
"offsets": [
[
0,
859
]
]
}
] | [
{
"id": "76757",
"type": "Intervention_Pharmacological",
"text": [
"Acipimox"
],
"offsets": [
[
0,
8
]
],
"normalized": []
},
{
"id": "76758",
"type": "Intervention_Pharmacological",
"text": [
"acipimox"
],
"offsets": [
[
261,
269
]
],
"normalized": []
},
{
"id": "76759",
"type": "Intervention_Control",
"text": [
"placebo ."
],
"offsets": [
[
277,
286
]
],
"normalized": []
},
{
"id": "76760",
"type": "Intervention_Pharmacological",
"text": [
"acipimox"
],
"offsets": [
[
261,
269
]
],
"normalized": []
},
{
"id": "76761",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
277,
284
]
],
"normalized": []
},
{
"id": "76762",
"type": "Outcome_Physical",
"text": [
"plasma lipids and glucose"
],
"offsets": [
[
389,
414
]
],
"normalized": []
},
{
"id": "76763",
"type": "Outcome_Physical",
"text": [
"plasma triglyceride"
],
"offsets": [
[
507,
526
]
],
"normalized": []
},
{
"id": "76764",
"type": "Outcome_Physical",
"text": [
"plasma triglyceride levels"
],
"offsets": [
[
614,
640
]
],
"normalized": []
},
{
"id": "76765",
"type": "Outcome_Other",
"text": [
"tolerated"
],
"offsets": [
[
735,
744
]
],
"normalized": []
},
{
"id": "76766",
"type": "Participant_Condition",
"text": [
"hyperlipidaemia"
],
"offsets": [
[
43,
58
]
],
"normalized": []
},
{
"id": "76767",
"type": "Participant_Sample-size",
"text": [
"Fifty-two"
],
"offsets": [
[
84,
93
]
],
"normalized": []
},
{
"id": "76768",
"type": "Participant_Condition",
"text": [
"Fredrickson Type IIb or Type IV hyperlipidaemia"
],
"offsets": [
[
108,
155
]
],
"normalized": []
},
{
"id": "76769",
"type": "Participant_Condition",
"text": [
"hypertriglyceridaemia"
],
"offsets": [
[
836,
857
]
],
"normalized": []
}
] | [] | [] | [] |
76770 | 380614 | [
{
"id": "76771",
"type": "document",
"text": [
"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents . 1 . Twenty-two maturity-onset type diabetics treated with oral hypoglycaemic agents entered a single-blind crossover study using placebo ( periods A and C , 2 months each ) and clofibrate ( 2 g/day ; period B ; 2 months ) . 2 . In thirteen patients , under reasonably good control , clofibrate did not reduce fasting or post-prandial blood glucose , nor 24 h glycosuria ; no improvement was noted in the M-value , an index of diabetes control . 3 . In contrast , in nine patients , with poor diabetes control , clofibrate reduced 24 h glycosuria and significantly improved the M-value . 4 . In all patients , clofibrate therapy was associated with a significant 19-23 % reduction in plasma fibrinogen . 5 . It is suggested that addition of clofibrate may be useful in maturity-onset diabetics not adequately controlled by diet combined with oral hypoglycaemic agents ."
],
"offsets": [
[
0,
953
]
]
}
] | [
{
"id": "76772",
"type": "Intervention_Pharmacological",
"text": [
"Clofibrate"
],
"offsets": [
[
0,
10
]
],
"normalized": []
},
{
"id": "76773",
"type": "Intervention_Pharmacological",
"text": [
"oral hypoglycaemic agents"
],
"offsets": [
[
57,
82
]
],
"normalized": []
},
{
"id": "76774",
"type": "Intervention_Pharmacological",
"text": [
"oral hypoglycaemic agents"
],
"offsets": [
[
57,
82
]
],
"normalized": []
},
{
"id": "76775",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
214,
221
]
],
"normalized": []
},
{
"id": "76776",
"type": "Intervention_Pharmacological",
"text": [
"clofibrate"
],
"offsets": [
[
262,
272
]
],
"normalized": []
},
{
"id": "76777",
"type": "Intervention_Pharmacological",
"text": [
"clofibrate"
],
"offsets": [
[
262,
272
]
],
"normalized": []
},
{
"id": "76778",
"type": "Intervention_Pharmacological",
"text": [
"clofibrate"
],
"offsets": [
[
262,
272
]
],
"normalized": []
},
{
"id": "76779",
"type": "Intervention_Physical",
"text": [
"clofibrate therapy"
],
"offsets": [
[
694,
712
]
],
"normalized": []
},
{
"id": "76780",
"type": "Intervention_Pharmacological",
"text": [
"clofibrate"
],
"offsets": [
[
262,
272
]
],
"normalized": []
},
{
"id": "76781",
"type": "Intervention_Pharmacological",
"text": [
"oral hypoglycaemic agents"
],
"offsets": [
[
57,
82
]
],
"normalized": []
},
{
"id": "76782",
"type": "Outcome_Other",
"text": [
"diabetes control"
],
"offsets": [
[
15,
31
]
],
"normalized": []
},
{
"id": "76783",
"type": "Outcome_Physical",
"text": [
"fasting or post-prandial blood glucose"
],
"offsets": [
[
394,
432
]
],
"normalized": []
},
{
"id": "76784",
"type": "Outcome_Physical",
"text": [
"24 h glycosuria"
],
"offsets": [
[
439,
454
]
],
"normalized": []
},
{
"id": "76785",
"type": "Outcome_Physical",
"text": [
"M-value"
],
"offsets": [
[
489,
496
]
],
"normalized": []
},
{
"id": "76786",
"type": "Outcome_Physical",
"text": [
"index of"
],
"offsets": [
[
502,
510
]
],
"normalized": []
},
{
"id": "76787",
"type": "Outcome_Other",
"text": [
"diabetes control"
],
"offsets": [
[
15,
31
]
],
"normalized": []
},
{
"id": "76788",
"type": "Outcome_Physical",
"text": [
"diabetes control"
],
"offsets": [
[
15,
31
]
],
"normalized": []
},
{
"id": "76789",
"type": "Outcome_Physical",
"text": [
"24 h glycosuria"
],
"offsets": [
[
439,
454
]
],
"normalized": []
},
{
"id": "76790",
"type": "Outcome_Physical",
"text": [
"M-value"
],
"offsets": [
[
489,
496
]
],
"normalized": []
},
{
"id": "76791",
"type": "Outcome_Physical",
"text": [
"plasma fibrinogen"
],
"offsets": [
[
768,
785
]
],
"normalized": []
},
{
"id": "76792",
"type": "Participant_Condition",
"text": [
"patients treated with oral hypoglycaemic agents"
],
"offsets": [
[
35,
82
]
],
"normalized": []
},
{
"id": "76793",
"type": "Participant_Sample-size",
"text": [
"Twenty-two"
],
"offsets": [
[
89,
99
]
],
"normalized": []
},
{
"id": "76794",
"type": "Participant_Condition",
"text": [
"type diabetics treated with oral hypoglycaemic agents"
],
"offsets": [
[
115,
168
]
],
"normalized": []
},
{
"id": "76795",
"type": "Participant_Sample-size",
"text": [
"thirteen"
],
"offsets": [
[
316,
324
]
],
"normalized": []
}
] | [] | [] | [] |
76796 | 3812946 | [
{
"id": "76797",
"type": "document",
"text": [
"Intravenous regional anaesthesia below the knee . A cross-over study with prilocaine in volunteers . The quality of anaesthesia provided by three dosages of prilocaine , 40 ml 0.5 % , 20 ml 1 % , or 40 ml 1 % , administered in random order , for intravenous regional anaesthesia of the lower extremity below the knee was compared in six volunteers . Limited sensory blockade was achieved in the groups with 40 ml 0.5 % and 20 ml 1 % during the 30-minute test period . One subject was not fully anaesthetised with any of the dosages used . Recovery was rapid ( mean 12-13 minutes ) in these two groups . In two subjects given 40 ml of 1 % , complete recovery took 90 minutes . At 30 minutes , the degree of flexion remaining in the great toe ( control 100 % ) was 4 % in the groups who received 40 ml of 0.5 % and 1 % , but 34 % in those who received 20 ml of 1 % respectively . Full motor recovery was achieved in 8-9 minutes . Five of six volunteers who received the 400-mg dose experienced subjective signs of central nervous system side effects when the cuff was released . In this group , the mean plasma level of prilocaine at 2 minutes was 1.22 micrograms/ml , maximum 2.12 micrograms/ml . In a radiological examination , no leak of contrast medium under the tourniquet cuff ( 300 mmHg ) was detected . The development of anaesthesia was fastest following the largest dose , but the large number of central side effects makes that dosage less suitable for clinical work ."
],
"offsets": [
[
0,
1477
]
]
}
] | [
{
"id": "76798",
"type": "Intervention_Pharmacological",
"text": [
"Intravenous regional anaesthesia"
],
"offsets": [
[
0,
32
]
],
"normalized": []
},
{
"id": "76799",
"type": "Intervention_Pharmacological",
"text": [
"prilocaine"
],
"offsets": [
[
74,
84
]
],
"normalized": []
},
{
"id": "76800",
"type": "Intervention_Pharmacological",
"text": [
"prilocaine"
],
"offsets": [
[
74,
84
]
],
"normalized": []
},
{
"id": "76801",
"type": "Intervention_Pharmacological",
"text": [
"prilocaine"
],
"offsets": [
[
74,
84
]
],
"normalized": []
},
{
"id": "76802",
"type": "Outcome_Physical",
"text": [
"Recovery was rapid"
],
"offsets": [
[
539,
557
]
],
"normalized": []
},
{
"id": "76803",
"type": "Outcome_Physical",
"text": [
"complete recovery"
],
"offsets": [
[
640,
657
]
],
"normalized": []
},
{
"id": "76804",
"type": "Outcome_Physical",
"text": [
"degree of flexion remaining in the great toe"
],
"offsets": [
[
696,
740
]
],
"normalized": []
},
{
"id": "76805",
"type": "Outcome_Physical",
"text": [
"Full motor recovery"
],
"offsets": [
[
878,
897
]
],
"normalized": []
},
{
"id": "76806",
"type": "Outcome_Adverse-effects",
"text": [
"subjective signs of central nervous system side effects"
],
"offsets": [
[
992,
1047
]
],
"normalized": []
},
{
"id": "76807",
"type": "Outcome_Physical",
"text": [
"mean plasma level"
],
"offsets": [
[
1097,
1114
]
],
"normalized": []
},
{
"id": "76808",
"type": "Outcome_Physical",
"text": [
"no leak of contrast medium under the tourniquet cuff ( 300 mmHg )"
],
"offsets": [
[
1228,
1293
]
],
"normalized": []
},
{
"id": "76809",
"type": "Outcome_Other",
"text": [
"fastest"
],
"offsets": [
[
1344,
1351
]
],
"normalized": []
},
{
"id": "76810",
"type": "Outcome_Adverse-effects",
"text": [
"large number of central side effects"
],
"offsets": [
[
1389,
1425
]
],
"normalized": []
},
{
"id": "76811",
"type": "Outcome_Physical",
"text": [
"less suitable for clinical work"
],
"offsets": [
[
1444,
1475
]
],
"normalized": []
},
{
"id": "76812",
"type": "Participant_Sample-size",
"text": [
"six"
],
"offsets": [
[
333,
336
]
],
"normalized": []
}
] | [] | [] | [] |
76813 | 3816105 | [
{
"id": "76814",
"type": "document",
"text": [
"Evaluation of three dosage-prediction methods for initial in-hospital stabilization of warfarin therapy . Three dosage-prediction methods for initial in-hospital stabilization of warfarin therapy were evaluated . Adult inpatients who had received warfarin sodium 10 mg daily for less than three days were eligible for the study . After receiving their third warfarin dose , patients were randomly assigned to have their warfarin dosages adjusted using one of three dosage-prediction methods : by analog computer ( n = 31 ) , linear regression ( n = 22 ) , or empiric dosing by the physician ( n = 34 ) . A prothrombin time ( PT ) ratio ( patient PT divided by control PT ) between 1.3 and 2.5 was considered to be in the therapeutic range . For patients who achieved a stable PT ratio ( defined as a PT ratio between 1.3 and 2.5 that varied by less than 0.05 on two consecutive days or by less than 0.1 on three consecutive days without a dosage change ) before discharge , the number of days ( time to stabilization ) from administration of the first warfarin dose to achievement of the warfarin dosage that produced a stable PT ratio ( stabilization dosage ) was compared . A total of 54 patients met the study criteria for a stable PT ratio before hospital discharge ( analog computer , n = 20 ; linear regression , n = 15 ; empiric dosing , n = 19 ) . The mean times to stabilization were 6.8 days in the analog-computer group , 7.3 days in the linear-regression group , and 8.4 days in the empiric-dosing group ; these times were not significantly different . All 20 stabilized patients in the analog-computer group achieved a stable PT ratio by the fourth dosage prediction . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1717
]
]
}
] | [
{
"id": "76815",
"type": "Intervention_Pharmacological",
"text": [
"three dosage-prediction"
],
"offsets": [
[
14,
37
]
],
"normalized": []
},
{
"id": "76816",
"type": "Intervention_Pharmacological",
"text": [
"Three dosage-prediction methods"
],
"offsets": [
[
106,
137
]
],
"normalized": []
},
{
"id": "76817",
"type": "Intervention_Pharmacological",
"text": [
"warfarin therapy"
],
"offsets": [
[
87,
103
]
],
"normalized": []
},
{
"id": "76818",
"type": "Intervention_Pharmacological",
"text": [
"warfarin sodium 10 mg daily"
],
"offsets": [
[
247,
274
]
],
"normalized": []
},
{
"id": "76819",
"type": "Intervention_Pharmacological",
"text": [
"warfarin"
],
"offsets": [
[
87,
95
]
],
"normalized": []
},
{
"id": "76820",
"type": "Intervention_Pharmacological",
"text": [
"warfarin"
],
"offsets": [
[
87,
95
]
],
"normalized": []
},
{
"id": "76821",
"type": "Intervention_Physical",
"text": [
"analog computer"
],
"offsets": [
[
496,
511
]
],
"normalized": []
},
{
"id": "76822",
"type": "Intervention_Physical",
"text": [
"linear regression"
],
"offsets": [
[
525,
542
]
],
"normalized": []
},
{
"id": "76823",
"type": "Intervention_Physical",
"text": [
"empiric dosing by the physician"
],
"offsets": [
[
559,
590
]
],
"normalized": []
},
{
"id": "76824",
"type": "Outcome_Physical",
"text": [
"prothrombin time ( PT ) ratio"
],
"offsets": [
[
606,
635
]
],
"normalized": []
},
{
"id": "76825",
"type": "Outcome_Physical",
"text": [
"stable PT ratio"
],
"offsets": [
[
769,
784
]
],
"normalized": []
},
{
"id": "76826",
"type": "Outcome_Other",
"text": [
"number of days ( time to stabilization )"
],
"offsets": [
[
978,
1018
]
],
"normalized": []
},
{
"id": "76827",
"type": "Outcome_Physical",
"text": [
"stable PT ratio"
],
"offsets": [
[
769,
784
]
],
"normalized": []
},
{
"id": "76828",
"type": "Outcome_Other",
"text": [
"stabilization dosage )"
],
"offsets": [
[
1138,
1160
]
],
"normalized": []
},
{
"id": "76829",
"type": "Outcome_Other",
"text": [
"stable PT ratio"
],
"offsets": [
[
769,
784
]
],
"normalized": []
},
{
"id": "76830",
"type": "Outcome_Physical",
"text": [
"mean times to stabilization"
],
"offsets": [
[
1360,
1387
]
],
"normalized": []
},
{
"id": "76831",
"type": "Participant_Condition",
"text": [
"Adult inpatients who had received warfarin sodium 10 mg daily for less than three days were eligible for the study ."
],
"offsets": [
[
213,
329
]
],
"normalized": []
}
] | [] | [] | [] |
76832 | 3818024 | [
{
"id": "76833",
"type": "document",
"text": [
"Beta-adrenoceptor blockade and cardiovascular response to the cold pressor test . Seven healthy subjects immersed a hand in random order in either warm water or in cold water at 5 degrees C for 2 min , after taking orally a single dose of 120 mg of propranolol or a placebo in a double blind fashion . The cold stress resulted in a significant increase in blood pressure and the rate pressure product without a change in heart rate . Beta-adrenoceptor blockade did not affect the pressor response the cold . The changes induced by the cold stress in the cardiovascular variables in the placebo and propranolol experiments were not statistically different . The highest rate pressure product during the cold pressor test was about 109 units . This was well below the pain threshold value of about 200 found during exercise in patients with ischaemic heart disease . In the recovery phase , the cardiovascular variables reverted to pre-immersion values within 1 min inspite of continued low hand skin temperature ."
],
"offsets": [
[
0,
1012
]
]
}
] | [
{
"id": "76834",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
249,
260
]
],
"normalized": []
},
{
"id": "76835",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
266,
273
]
],
"normalized": []
},
{
"id": "76836",
"type": "Outcome_Physical",
"text": [
"cardiovascular response"
],
"offsets": [
[
31,
54
]
],
"normalized": []
},
{
"id": "76837",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
356,
370
]
],
"normalized": []
},
{
"id": "76838",
"type": "Outcome_Physical",
"text": [
"rate pressure product"
],
"offsets": [
[
379,
400
]
],
"normalized": []
},
{
"id": "76839",
"type": "Outcome_Physical",
"text": [
"heart rate ."
],
"offsets": [
[
421,
433
]
],
"normalized": []
},
{
"id": "76840",
"type": "Outcome_Physical",
"text": [
"pressor response the cold ."
],
"offsets": [
[
480,
507
]
],
"normalized": []
},
{
"id": "76841",
"type": "Outcome_Physical",
"text": [
"cardiovascular variables"
],
"offsets": [
[
554,
578
]
],
"normalized": []
},
{
"id": "76842",
"type": "Outcome_Physical",
"text": [
"rate pressure product"
],
"offsets": [
[
379,
400
]
],
"normalized": []
},
{
"id": "76843",
"type": "Outcome_Physical",
"text": [
"pain threshold"
],
"offsets": [
[
766,
780
]
],
"normalized": []
},
{
"id": "76844",
"type": "Outcome_Physical",
"text": [
"cardiovascular variables"
],
"offsets": [
[
554,
578
]
],
"normalized": []
}
] | [] | [] | [] |
76845 | 3825543 | [
{
"id": "76846",
"type": "document",
"text": [
"Parietal cell density in duodenal ulcer patients after short-term treatment with cimetidine and antacids . In a prospective study , 20 patients with endoscopically proven duodenal ulcers were randomised to be treated with cimetidine 1 g daily or with antacids 350 mmol daily . The duration of treatment was 30 days , but this was extended to three months in 3 patients in the cimetidine group and 4 patients in the antacid group . A morphological study of biopsies taken via a gastroscope from the corpus mucosa showed no change in mucosal height , parietal cell density per unit volume or changes in cellular infiltration after 30 and 90 days treatment in the two groups . Neither H-2 receptor blockers nor antacids alter mucosal height or parietal cell density . Treatment was not found to induce gastritic changes in the mucosa ."
],
"offsets": [
[
0,
832
]
]
}
] | [
{
"id": "76847",
"type": "Intervention_Pharmacological",
"text": [
"cimetidine"
],
"offsets": [
[
81,
91
]
],
"normalized": []
},
{
"id": "76848",
"type": "Intervention_Pharmacological",
"text": [
"antacids"
],
"offsets": [
[
96,
104
]
],
"normalized": []
},
{
"id": "76849",
"type": "Intervention_Pharmacological",
"text": [
"cimetidine"
],
"offsets": [
[
81,
91
]
],
"normalized": []
},
{
"id": "76850",
"type": "Intervention_Pharmacological",
"text": [
"antacids"
],
"offsets": [
[
96,
104
]
],
"normalized": []
},
{
"id": "76851",
"type": "Intervention_Pharmacological",
"text": [
"cimetidine"
],
"offsets": [
[
81,
91
]
],
"normalized": []
},
{
"id": "76852",
"type": "Intervention_Pharmacological",
"text": [
"antacid"
],
"offsets": [
[
96,
103
]
],
"normalized": []
},
{
"id": "76853",
"type": "Intervention_Pharmacological",
"text": [
"H-2 receptor blockers"
],
"offsets": [
[
682,
703
]
],
"normalized": []
},
{
"id": "76854",
"type": "Intervention_Pharmacological",
"text": [
"antacids"
],
"offsets": [
[
96,
104
]
],
"normalized": []
},
{
"id": "76855",
"type": "Outcome_Physical",
"text": [
"Parietal cell density"
],
"offsets": [
[
0,
21
]
],
"normalized": []
},
{
"id": "76856",
"type": "Outcome_Physical",
"text": [
"mucosal height"
],
"offsets": [
[
532,
546
]
],
"normalized": []
},
{
"id": "76857",
"type": "Outcome_Physical",
"text": [
"parietal cell density per unit volume"
],
"offsets": [
[
549,
586
]
],
"normalized": []
},
{
"id": "76858",
"type": "Outcome_Physical",
"text": [
"changes in cellular infiltration"
],
"offsets": [
[
590,
622
]
],
"normalized": []
},
{
"id": "76859",
"type": "Outcome_Physical",
"text": [
"mucosal height"
],
"offsets": [
[
532,
546
]
],
"normalized": []
},
{
"id": "76860",
"type": "Outcome_Physical",
"text": [
"parietal cell density"
],
"offsets": [
[
549,
570
]
],
"normalized": []
},
{
"id": "76861",
"type": "Outcome_Physical",
"text": [
"gastritic changes"
],
"offsets": [
[
799,
816
]
],
"normalized": []
},
{
"id": "76862",
"type": "Participant_Condition",
"text": [
"duodenal ulcer"
],
"offsets": [
[
25,
39
]
],
"normalized": []
},
{
"id": "76863",
"type": "Participant_Condition",
"text": [
"endoscopically proven duodenal ulcers"
],
"offsets": [
[
149,
186
]
],
"normalized": []
}
] | [] | [] | [] |
76864 | 3830804 | [
{
"id": "76865",
"type": "document",
"text": [
"[ Results of a cooperative prospective study of treatment of primary digestive localizations of non-Hodgkin 's lymphoma ] . We report the results of chemotherapy treatment in 82 patients presenting with primary digestive lymphoma and included in a study conducted between October 1977 and October 1985 . There were 31 gastric lymphoma , 18 small intestinal lymphomas , and 19 with multiple involvement : 63 patients had had a surgical staging with total tumor resection in 15 cases . Nineteen patients with limited disease ( ID and IID ) were randomly assigned to either a 3-week chemotherapy regimen associated with whole abdominal radiotherapy or chemotherapy for 3 years . Twenty-seven stage IIID and thirty-six stage IV were treated with chemotherapy alone for 3 years . Low grade lymphomas ( 16 patients ) received a cyclophosphamide , vincristine , prednisone association . Intermediate ( 56 patients ) and high grade ( 10 patients ) lymphomas received cyclophosphamide , vincristine , adriamycin , prednisone . The overall complete remission obtained was 63 p. 100 ( 51 patients ) with 17 patients in relapse within 6 to 40 months . Overall survival was 46 p. 100 at 5 years . Survival was dependent on abdominal extension , histologic grade according to the new working formulation used for lymph-node lymphomas , initial localization ( gastric lymphomas have the best survival ) and achievement of complete remission . Chemotherapy is an effective treatment for primary digestive lymphomas . The role of surgery in the management of lymphomas has to be defined by further studies ."
],
"offsets": [
[
0,
1590
]
]
}
] | [
{
"id": "76866",
"type": "Intervention_Pharmacological",
"text": [
"chemotherapy treatment"
],
"offsets": [
[
149,
171
]
],
"normalized": []
},
{
"id": "76867",
"type": "Intervention_Physical",
"text": [
"chemotherapy"
],
"offsets": [
[
149,
161
]
],
"normalized": []
},
{
"id": "76868",
"type": "Intervention_Physical",
"text": [
"whole abdominal radiotherapy"
],
"offsets": [
[
617,
645
]
],
"normalized": []
},
{
"id": "76869",
"type": "Intervention_Physical",
"text": [
"chemotherapy"
],
"offsets": [
[
149,
161
]
],
"normalized": []
},
{
"id": "76870",
"type": "Intervention_Physical",
"text": [
"chemotherapy"
],
"offsets": [
[
149,
161
]
],
"normalized": []
},
{
"id": "76871",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide"
],
"offsets": [
[
822,
838
]
],
"normalized": []
},
{
"id": "76872",
"type": "Intervention_Pharmacological",
"text": [
"vincristine"
],
"offsets": [
[
841,
852
]
],
"normalized": []
},
{
"id": "76873",
"type": "Intervention_Pharmacological",
"text": [
"prednisone association"
],
"offsets": [
[
855,
877
]
],
"normalized": []
},
{
"id": "76874",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide"
],
"offsets": [
[
822,
838
]
],
"normalized": []
},
{
"id": "76875",
"type": "Intervention_Pharmacological",
"text": [
"vincristine"
],
"offsets": [
[
841,
852
]
],
"normalized": []
},
{
"id": "76876",
"type": "Intervention_Pharmacological",
"text": [
"adriamycin"
],
"offsets": [
[
992,
1002
]
],
"normalized": []
},
{
"id": "76877",
"type": "Intervention_Pharmacological",
"text": [
"prednisone"
],
"offsets": [
[
855,
865
]
],
"normalized": []
},
{
"id": "76878",
"type": "Intervention_Physical",
"text": [
"Chemotherapy"
],
"offsets": [
[
1428,
1440
]
],
"normalized": []
},
{
"id": "76879",
"type": "Outcome_Physical",
"text": [
"overall complete remission"
],
"offsets": [
[
1022,
1048
]
],
"normalized": []
},
{
"id": "76880",
"type": "Outcome_Physical",
"text": [
"relapse"
],
"offsets": [
[
1108,
1115
]
],
"normalized": []
},
{
"id": "76881",
"type": "Outcome_Mortality",
"text": [
"Overall survival"
],
"offsets": [
[
1140,
1156
]
],
"normalized": []
},
{
"id": "76882",
"type": "Outcome_Mortality",
"text": [
"Survival"
],
"offsets": [
[
1184,
1192
]
],
"normalized": []
},
{
"id": "76883",
"type": "Outcome_Physical",
"text": [
"abdominal extension , histologic grade according to the new working formulation used for lymph-node lymphomas , initial localization"
],
"offsets": [
[
1210,
1342
]
],
"normalized": []
},
{
"id": "76884",
"type": "Outcome_Physical",
"text": [
"complete remission"
],
"offsets": [
[
1030,
1048
]
],
"normalized": []
},
{
"id": "76885",
"type": "Outcome_Other",
"text": [
"treatment"
],
"offsets": [
[
48,
57
]
],
"normalized": []
},
{
"id": "76886",
"type": "Participant_Condition",
"text": [
"non-Hodgkin 's lymphoma ]"
],
"offsets": [
[
96,
121
]
],
"normalized": []
},
{
"id": "76887",
"type": "Participant_Sample-size",
"text": [
"82"
],
"offsets": [
[
175,
177
]
],
"normalized": []
},
{
"id": "76888",
"type": "Participant_Condition",
"text": [
"primary digestive lymphoma"
],
"offsets": [
[
203,
229
]
],
"normalized": []
},
{
"id": "76889",
"type": "Participant_Sample-size",
"text": [
"31"
],
"offsets": [
[
315,
317
]
],
"normalized": []
},
{
"id": "76890",
"type": "Participant_Condition",
"text": [
"gastric lymphoma"
],
"offsets": [
[
318,
334
]
],
"normalized": []
},
{
"id": "76891",
"type": "Participant_Sample-size",
"text": [
"18"
],
"offsets": [
[
337,
339
]
],
"normalized": []
},
{
"id": "76892",
"type": "Participant_Condition",
"text": [
"small intestinal lymphomas"
],
"offsets": [
[
340,
366
]
],
"normalized": []
},
{
"id": "76893",
"type": "Participant_Sample-size",
"text": [
"19"
],
"offsets": [
[
280,
282
]
],
"normalized": []
},
{
"id": "76894",
"type": "Participant_Condition",
"text": [
"multiple involvement"
],
"offsets": [
[
381,
401
]
],
"normalized": []
},
{
"id": "76895",
"type": "Participant_Sample-size",
"text": [
"Nineteen"
],
"offsets": [
[
484,
492
]
],
"normalized": []
},
{
"id": "76896",
"type": "Participant_Condition",
"text": [
"limited disease ( ID and IID )"
],
"offsets": [
[
507,
537
]
],
"normalized": []
},
{
"id": "76897",
"type": "Participant_Sample-size",
"text": [
"Twenty-seven"
],
"offsets": [
[
676,
688
]
],
"normalized": []
},
{
"id": "76898",
"type": "Participant_Condition",
"text": [
"stage IIID"
],
"offsets": [
[
689,
699
]
],
"normalized": []
},
{
"id": "76899",
"type": "Participant_Sample-size",
"text": [
"thirty-six"
],
"offsets": [
[
704,
714
]
],
"normalized": []
},
{
"id": "76900",
"type": "Participant_Condition",
"text": [
"stage IV"
],
"offsets": [
[
715,
723
]
],
"normalized": []
}
] | [] | [] | [] |
76901 | 3839157 | [
{
"id": "76902",
"type": "document",
"text": [
"The Eastern Cooperative Oncology Group experience with cyclophosphamide , adriamycin , and 5-fluorouracil ( CAF ) in patients with metastatic breast cancer . Data on 162 women ( 90 premenopausal and 72 postmenopausal ) with metastatic breast cancer randomized to receive cyclophosphamide , Adriamycin ( doxorubicin ) and 5-fluorouracil ( CAF ) on two Eastern Cooperative Oncology Group ( ECOG ) protocols were analyzed . Twenty-three percent had complete remission ; 39 % had partial remission ; 28 % had no change ; and 3 % had disease progression . Of those patients in whom receptors were known , response rates were 65 % for estrogen ( ER ) -receptor positive and 70 % for ER-negative patients . The median duration of response was 11.4 months . The median survival time from the start of CAF was 20.2 months . The response rate , time to treatment failure ( TTF ) , and median survival time were superior in the premenopausal women . These differences ceased , however , to be statistically significant in logistic models . Factors significantly associated with longer TTF and longer survival were as follows : one or two organs with metastases ( TTF , P less than 0.0001 ; survival , P less than 0.0001 ) ; dominant site other than soft tissue ( TTF , P less than 0.0001 ; survival , P = 0.05 ) ; and an initial good performance status ( TTF , P = 0.007 ; survival , P = 0.02 ) . Patients with ER-positive disease had a significantly longer median survival time ( P = 0.003 ) ."
],
"offsets": [
[
0,
1483
]
]
}
] | [
{
"id": "76903",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide , adriamycin , and 5-fluorouracil ( CAF )"
],
"offsets": [
[
55,
113
]
],
"normalized": []
},
{
"id": "76904",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide , Adriamycin ( doxorubicin ) and 5-fluorouracil ( CAF )"
],
"offsets": [
[
271,
343
]
],
"normalized": []
},
{
"id": "76905",
"type": "Outcome_Other",
"text": [
"median duration"
],
"offsets": [
[
704,
719
]
],
"normalized": []
},
{
"id": "76906",
"type": "Outcome_Mortality",
"text": [
"median survival time"
],
"offsets": [
[
754,
774
]
],
"normalized": []
},
{
"id": "76907",
"type": "Outcome_Physical",
"text": [
"response rate"
],
"offsets": [
[
600,
613
]
],
"normalized": []
},
{
"id": "76908",
"type": "Outcome_Other",
"text": [
"time to treatment failure ( TTF )"
],
"offsets": [
[
835,
868
]
],
"normalized": []
},
{
"id": "76909",
"type": "Outcome_Mortality",
"text": [
"median survival time"
],
"offsets": [
[
754,
774
]
],
"normalized": []
},
{
"id": "76910",
"type": "Outcome_Other",
"text": [
"TTF"
],
"offsets": [
[
863,
866
]
],
"normalized": []
},
{
"id": "76911",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
761,
769
]
],
"normalized": []
},
{
"id": "76912",
"type": "Outcome_Mortality",
"text": [
"longer median survival time"
],
"offsets": [
[
1440,
1467
]
],
"normalized": []
},
{
"id": "76913",
"type": "Participant_Condition",
"text": [
"metastatic breast cancer"
],
"offsets": [
[
131,
155
]
],
"normalized": []
},
{
"id": "76914",
"type": "Participant_Sample-size",
"text": [
"162"
],
"offsets": [
[
166,
169
]
],
"normalized": []
},
{
"id": "76915",
"type": "Participant_Sample-size",
"text": [
"90"
],
"offsets": [
[
178,
180
]
],
"normalized": []
},
{
"id": "76916",
"type": "Participant_Condition",
"text": [
"premenopausal"
],
"offsets": [
[
181,
194
]
],
"normalized": []
},
{
"id": "76917",
"type": "Participant_Sample-size",
"text": [
"72"
],
"offsets": [
[
199,
201
]
],
"normalized": []
},
{
"id": "76918",
"type": "Participant_Condition",
"text": [
"postmenopausal"
],
"offsets": [
[
202,
216
]
],
"normalized": []
},
{
"id": "76919",
"type": "Participant_Condition",
"text": [
"metastatic breast cancer"
],
"offsets": [
[
131,
155
]
],
"normalized": []
}
] | [] | [] | [] |
76920 | 384024 | [
{
"id": "76921",
"type": "document",
"text": [
"Butorphanol and meperidine compared in patients with acute ureteral colic . Pain relief was evaluated in 81 patients with acute ureteral colic and the confirmed presence of a calculus . A randomized double-blind comparison of intramuscular 2 and 4 mg. butorphanol and 80 mg. meperidine was used . Pain intensity and pain relief were evaluated at half hour and hourly intervals for 4 hours . A 2 mg. dose of butorphanol was found to be analgesically equivalent to 80 mg. meperidine , while a 4 mg. dose of butorphanol was found to be more effective than 80 mg. meperidine and 2 mg. butorphanol . Each patient received up to 2 doses of analgesic medication when necessary . There was no significant difference in the incidence of side effects among treatments . One patient had visual hallucinations after a 2 mg. dose of butorphanol , possibly owing to its antagonistic activity to significant narcotic experience given previously at another hospital . There was no other evidence of toxicity with butorphanol . It was found to be a safe , effective and wall tolerated drug for the treatment of ureteral colic and is recommended in place of narcotics ."
],
"offsets": [
[
0,
1151
]
]
}
] | [
{
"id": "76922",
"type": "Intervention_Pharmacological",
"text": [
"Butorphanol"
],
"offsets": [
[
0,
11
]
],
"normalized": []
},
{
"id": "76923",
"type": "Intervention_Pharmacological",
"text": [
"meperidine"
],
"offsets": [
[
16,
26
]
],
"normalized": []
},
{
"id": "76924",
"type": "Intervention_Pharmacological",
"text": [
"butorphanol"
],
"offsets": [
[
252,
263
]
],
"normalized": []
},
{
"id": "76925",
"type": "Intervention_Pharmacological",
"text": [
"meperidine"
],
"offsets": [
[
16,
26
]
],
"normalized": []
},
{
"id": "76926",
"type": "Intervention_Pharmacological",
"text": [
"butorphanol"
],
"offsets": [
[
252,
263
]
],
"normalized": []
},
{
"id": "76927",
"type": "Intervention_Pharmacological",
"text": [
"meperidine"
],
"offsets": [
[
16,
26
]
],
"normalized": []
},
{
"id": "76928",
"type": "Intervention_Pharmacological",
"text": [
"butorphanol"
],
"offsets": [
[
252,
263
]
],
"normalized": []
},
{
"id": "76929",
"type": "Intervention_Pharmacological",
"text": [
"meperidine"
],
"offsets": [
[
16,
26
]
],
"normalized": []
},
{
"id": "76930",
"type": "Intervention_Pharmacological",
"text": [
"butorphanol"
],
"offsets": [
[
252,
263
]
],
"normalized": []
},
{
"id": "76931",
"type": "Intervention_Pharmacological",
"text": [
"butorphanol"
],
"offsets": [
[
252,
263
]
],
"normalized": []
},
{
"id": "76932",
"type": "Intervention_Pharmacological",
"text": [
"butorphanol"
],
"offsets": [
[
252,
263
]
],
"normalized": []
},
{
"id": "76933",
"type": "Outcome_Pain",
"text": [
"Pain intensity"
],
"offsets": [
[
297,
311
]
],
"normalized": []
},
{
"id": "76934",
"type": "Outcome_Pain",
"text": [
"pain relief"
],
"offsets": [
[
316,
327
]
],
"normalized": []
},
{
"id": "76935",
"type": "Outcome_Adverse-effects",
"text": [
"incidence of side effects"
],
"offsets": [
[
715,
740
]
],
"normalized": []
},
{
"id": "76936",
"type": "Outcome_Physical",
"text": [
"visual hallucinations"
],
"offsets": [
[
776,
797
]
],
"normalized": []
},
{
"id": "76937",
"type": "Outcome_Other",
"text": [
"toxicity"
],
"offsets": [
[
983,
991
]
],
"normalized": []
},
{
"id": "76938",
"type": "Outcome_Other",
"text": [
"safe , effective and wall tolerated"
],
"offsets": [
[
1032,
1067
]
],
"normalized": []
},
{
"id": "76939",
"type": "Participant_Condition",
"text": [
"acute ureteral colic"
],
"offsets": [
[
53,
73
]
],
"normalized": []
},
{
"id": "76940",
"type": "Participant_Sample-size",
"text": [
"81"
],
"offsets": [
[
105,
107
]
],
"normalized": []
},
{
"id": "76941",
"type": "Participant_Condition",
"text": [
"acute ureteral colic"
],
"offsets": [
[
53,
73
]
],
"normalized": []
}
] | [] | [] | [] |
76942 | 384574 | [
{
"id": "76943",
"type": "document",
"text": [
"Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer : A Central Oncology Group study . In a controlled , prospectively randomized trial , 74 patients with hepatic metastases from colorectal cancer were randomized to either intra-arterial hepatic artery infusion with 5-fluorouracil ( 5-FU ) or systemic chemotherapy with 5-FU . In 61 acceptable patients , there was no significant difference in terms of response rate , time to progression , duration of the response , and survival rate . Though the response rate for the intra-arterial infusion arm was slightly higher than for the systemic arm , the difference was not significant , and the intra-arterial infusion arm was associated with a greater incidence of nausea , vomiting , diarrhea , in addition to complications of femoral-arterial thrombosis , bleeding , and infection at the catheter site not seen in patients treated by systemic chemotherapy . Patients with an objective response to chemotherapy on either treatment arm survived twice as long as the nonresponders . Long-term survival in one patient , 77 months , can occasionally be achieved in patients with hepatic metastases ."
],
"offsets": [
[
0,
1275
]
]
}
] | [
{
"id": "76944",
"type": "Intervention_Pharmacological",
"text": [
"hepatic artery infusion with 5-fluorouracil"
],
"offsets": [
[
45,
88
]
],
"normalized": []
},
{
"id": "76945",
"type": "Intervention_Pharmacological",
"text": [
"intravenous 5-fluorouracil"
],
"offsets": [
[
96,
122
]
],
"normalized": []
},
{
"id": "76946",
"type": "Intervention_Pharmacological",
"text": [
"intra-arterial hepatic artery infusion with 5-fluorouracil ( 5-FU )"
],
"offsets": [
[
353,
420
]
],
"normalized": []
},
{
"id": "76947",
"type": "Intervention_Pharmacological",
"text": [
"systemic chemotherapy with 5-FU"
],
"offsets": [
[
424,
455
]
],
"normalized": []
},
{
"id": "76948",
"type": "Intervention_Physical",
"text": [
"systemic chemotherapy"
],
"offsets": [
[
424,
445
]
],
"normalized": []
},
{
"id": "76949",
"type": "Intervention_Pharmacological",
"text": [
"."
],
"offsets": [
[
215,
216
]
],
"normalized": []
},
{
"id": "76950",
"type": "Outcome_Other",
"text": [
"response rate"
],
"offsets": [
[
534,
547
]
],
"normalized": []
},
{
"id": "76951",
"type": "Outcome_Other",
"text": [
"time to progression"
],
"offsets": [
[
550,
569
]
],
"normalized": []
},
{
"id": "76952",
"type": "Outcome_Other",
"text": [
"duration of the response"
],
"offsets": [
[
572,
596
]
],
"normalized": []
},
{
"id": "76953",
"type": "Outcome_Mortality",
"text": [
"survival rate"
],
"offsets": [
[
603,
616
]
],
"normalized": []
},
{
"id": "76954",
"type": "Outcome_Other",
"text": [
"response rate"
],
"offsets": [
[
534,
547
]
],
"normalized": []
},
{
"id": "76955",
"type": "Outcome_Adverse-effects",
"text": [
"nausea"
],
"offsets": [
[
844,
850
]
],
"normalized": []
},
{
"id": "76956",
"type": "Outcome_Adverse-effects",
"text": [
"vomiting"
],
"offsets": [
[
853,
861
]
],
"normalized": []
},
{
"id": "76957",
"type": "Outcome_Adverse-effects",
"text": [
"diarrhea"
],
"offsets": [
[
864,
872
]
],
"normalized": []
},
{
"id": "76958",
"type": "Outcome_Adverse-effects",
"text": [
"femoral-arterial thrombosis"
],
"offsets": [
[
907,
934
]
],
"normalized": []
},
{
"id": "76959",
"type": "Outcome_Adverse-effects",
"text": [
"bleeding"
],
"offsets": [
[
937,
945
]
],
"normalized": []
},
{
"id": "76960",
"type": "Outcome_Adverse-effects",
"text": [
"infection at the catheter site"
],
"offsets": [
[
952,
982
]
],
"normalized": []
},
{
"id": "76961",
"type": "Outcome_Mortality",
"text": [
"survived"
],
"offsets": [
[
1115,
1123
]
],
"normalized": []
},
{
"id": "76962",
"type": "Outcome_Mortality",
"text": [
"Long-term survival"
],
"offsets": [
[
1161,
1179
]
],
"normalized": []
},
{
"id": "76963",
"type": "Participant_Condition",
"text": [
"hepatic metastases"
],
"offsets": [
[
140,
158
]
],
"normalized": []
},
{
"id": "76964",
"type": "Participant_Condition",
"text": [
"colorectal cancer"
],
"offsets": [
[
164,
181
]
],
"normalized": []
},
{
"id": "76965",
"type": "Participant_Sample-size",
"text": [
"74"
],
"offsets": [
[
268,
270
]
],
"normalized": []
},
{
"id": "76966",
"type": "Participant_Condition",
"text": [
"hepatic metastases"
],
"offsets": [
[
140,
158
]
],
"normalized": []
},
{
"id": "76967",
"type": "Participant_Condition",
"text": [
"colorectal cancer"
],
"offsets": [
[
164,
181
]
],
"normalized": []
}
] | [] | [] | [] |
76968 | 3859359 | [
{
"id": "76969",
"type": "document",
"text": [
"Comparison of maintenance treatment regimens for first central nervous system relapse in children with acute lymphocytic leukemia . A Pediatric Oncology Group study . Eighty-seven children with central nervous system ( CNS ) leukemia were randomized to receive either induction intrathecal chemotherapy ( ITC ) and cranial irradiation ( CRT ) plus maintenance ITC , or induction ITC and craniospinal irradiation ( CSpRT ) with no maintenance ITC . ITC consisted of six weekly injections of methotrexate , hydrocortisone , and arabinosylcytosine . Also , intensification of systemic induction and maintenance chemotherapy was given . CRT + ITC was given as CRT , 2400 rad in 12 fractions followed by ITC maintenance bimonthly for 2 years . Craniospinal irradiation consisted of CRT + 1400 rad in ten fractions to the spine . Randomization was stratified according to whether CNS leukemia occurred at initial diagnosis of acute lymphocytic leukemia ( ALL ) ( Stratum I , 15 patients ) , during first bone marrow ( BM ) remission ( Stratum II , 49 patients ) , simultaneous with first BM relapse ( Stratum III , 12 patients ) , or during second BM remission ( Stratum IV , 11 patients ) . The median follow-up for patients who remain at risk is 15 + months . Eight children ( seven on CRT + ITC , one on CSpRT ) developed presumed therapy related encephalopathy . In Stratum II , 16 of 29 ( 55 % ) patients receiving CRT + ITC experienced adverse events : 3 deaths during continuous complete remission ( CCR ) and 13 relapses ( 2 CNS , 1 CNS + BM , 1 BM + testes , and 2 testes ) as compared with only 5 relapses in 20 ( 25 % ) patients on CSpRT ( 1 CNS , 1 CNS + BM , 1 BM , and 2 testes ) . The children on both regimens were comparable for sex , race , age at initial ALL diagnosis , time from ALL diagnosis to first episode of CNS leukemia , systemic therapy both before and after CNS relapse , and number of blasts in the spinal fluid at diagnosis of CNS leukemia . The conclusion is that children with isolated CNS leukemia can achieve prolonged survival with aggressive therapy , and that CSpRT is possibly less toxic and more likely than is CRT + ITC to prevent subsequent BM and testicular relapse ( P less than 0.02 ) , but not subsequent CNS relapse ( P = 0.7 ) . A possible systemic therapy effect of spinal irradiation is postulated to explain the superiority of CSpRT ."
],
"offsets": [
[
0,
2380
]
]
}
] | [
{
"id": "76970",
"type": "Intervention_Physical",
"text": [
"induction intrathecal chemotherapy"
],
"offsets": [
[
268,
302
]
],
"normalized": []
},
{
"id": "76971",
"type": "Intervention_Pharmacological",
"text": [
"( ITC )"
],
"offsets": [
[
303,
310
]
],
"normalized": []
},
{
"id": "76972",
"type": "Intervention_Physical",
"text": [
"cranial irradiation ( CRT )"
],
"offsets": [
[
315,
342
]
],
"normalized": []
},
{
"id": "76973",
"type": "Intervention_Pharmacological",
"text": [
"plus"
],
"offsets": [
[
343,
347
]
],
"normalized": []
},
{
"id": "76974",
"type": "Intervention_Physical",
"text": [
"maintenance ITC"
],
"offsets": [
[
348,
363
]
],
"normalized": []
},
{
"id": "76975",
"type": "Intervention_Physical",
"text": [
"induction ITC"
],
"offsets": [
[
369,
382
]
],
"normalized": []
},
{
"id": "76976",
"type": "Intervention_Pharmacological",
"text": [
"and craniospinal irradiation ( CSpRT ) with no maintenance ITC"
],
"offsets": [
[
383,
445
]
],
"normalized": []
},
{
"id": "76977",
"type": "Intervention_Pharmacological",
"text": [
"methotrexate"
],
"offsets": [
[
490,
502
]
],
"normalized": []
},
{
"id": "76978",
"type": "Intervention_Pharmacological",
"text": [
"hydrocortisone"
],
"offsets": [
[
505,
519
]
],
"normalized": []
},
{
"id": "76979",
"type": "Intervention_Pharmacological",
"text": [
"arabinosylcytosine"
],
"offsets": [
[
526,
544
]
],
"normalized": []
},
{
"id": "76980",
"type": "Intervention_Physical",
"text": [
"intensification of systemic induction"
],
"offsets": [
[
554,
591
]
],
"normalized": []
},
{
"id": "76981",
"type": "Intervention_Physical",
"text": [
"maintenance chemotherapy"
],
"offsets": [
[
596,
620
]
],
"normalized": []
},
{
"id": "76982",
"type": "Intervention_Physical",
"text": [
"CRT"
],
"offsets": [
[
337,
340
]
],
"normalized": []
},
{
"id": "76983",
"type": "Intervention_Pharmacological",
"text": [
"+"
],
"offsets": [
[
637,
638
]
],
"normalized": []
},
{
"id": "76984",
"type": "Intervention_Physical",
"text": [
"ITC"
],
"offsets": [
[
305,
308
]
],
"normalized": []
},
{
"id": "76985",
"type": "Intervention_Physical",
"text": [
"CRT"
],
"offsets": [
[
337,
340
]
],
"normalized": []
},
{
"id": "76986",
"type": "Intervention_Physical",
"text": [
"ITC"
],
"offsets": [
[
305,
308
]
],
"normalized": []
},
{
"id": "76987",
"type": "Intervention_Physical",
"text": [
"Craniospinal irradiation consisted of CRT"
],
"offsets": [
[
739,
780
]
],
"normalized": []
},
{
"id": "76988",
"type": "Intervention_Physical",
"text": [
"CSpRT"
],
"offsets": [
[
414,
419
]
],
"normalized": []
},
{
"id": "76989",
"type": "Outcome_Physical",
"text": [
"presumed therapy related encephalopathy ."
],
"offsets": [
[
1319,
1360
]
],
"normalized": []
},
{
"id": "76990",
"type": "Outcome_Physical",
"text": [
"adverse events :"
],
"offsets": [
[
1436,
1452
]
],
"normalized": []
},
{
"id": "76991",
"type": "Outcome_Physical",
"text": [
"deaths during continuous complete remission ( CCR )"
],
"offsets": [
[
1455,
1506
]
],
"normalized": []
},
{
"id": "76992",
"type": "Outcome_Physical",
"text": [
"relapses"
],
"offsets": [
[
1514,
1522
]
],
"normalized": []
},
{
"id": "76993",
"type": "Outcome_Physical",
"text": [
"relapses"
],
"offsets": [
[
1514,
1522
]
],
"normalized": []
},
{
"id": "76994",
"type": "Outcome_Physical",
"text": [
"time from ALL diagnosis to first episode of CNS leukemia , systemic therapy both before and after CNS relapse , and number of blasts in the spinal fluid at diagnosis of CNS leukemia ."
],
"offsets": [
[
1784,
1967
]
],
"normalized": []
},
{
"id": "76995",
"type": "Outcome_Mental",
"text": [
"prolonged survival with aggressive therapy"
],
"offsets": [
[
2039,
2081
]
],
"normalized": []
},
{
"id": "76996",
"type": "Outcome_Physical",
"text": [
"CSpRT is possibly less toxic"
],
"offsets": [
[
2093,
2121
]
],
"normalized": []
},
{
"id": "76997",
"type": "Outcome_Physical",
"text": [
"subsequent BM and testicular relapse"
],
"offsets": [
[
2167,
2203
]
],
"normalized": []
},
{
"id": "76998",
"type": "Outcome_Physical",
"text": [
"CNS relapse"
],
"offsets": [
[
1882,
1893
]
],
"normalized": []
},
{
"id": "76999",
"type": "Outcome_Physical",
"text": [
"spinal irradiation"
],
"offsets": [
[
393,
411
]
],
"normalized": []
},
{
"id": "77000",
"type": "Outcome_Physical",
"text": [
"superiority of CSpRT ."
],
"offsets": [
[
2358,
2380
]
],
"normalized": []
},
{
"id": "77001",
"type": "Participant_Condition",
"text": [
"central nervous system relapse"
],
"offsets": [
[
55,
85
]
],
"normalized": []
},
{
"id": "77002",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
89,
97
]
],
"normalized": []
},
{
"id": "77003",
"type": "Participant_Condition",
"text": [
"acute lymphocytic leukemia"
],
"offsets": [
[
103,
129
]
],
"normalized": []
},
{
"id": "77004",
"type": "Participant_Sample-size",
"text": [
"Eighty-seven"
],
"offsets": [
[
167,
179
]
],
"normalized": []
},
{
"id": "77005",
"type": "Participant_Condition",
"text": [
"central nervous system ( CNS ) leukemia"
],
"offsets": [
[
194,
233
]
],
"normalized": []
}
] | [] | [] | [] |
77006 | 387204 | [
{
"id": "77007",
"type": "document",
"text": [
"5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer : a Southwest Oncology Group Study . A randomized trial was conducted by the Southwest Oncology Group ( SWOG ) in advanced carcinoma of the stomach and pancreas . Patients were assigned to receive monthly 5-fluorouracil 96-hour continuous infusions with either bolus mitomycin-C or oral methyl-CCNU . Mitomycin-C and methyl-CCNU were administered every eight weeks . The 5 FU-mitomycin combination produced a 14 % and 22 % response rate in disseminated stomach and pancreatic carcinoma , respectively . The combination of infusion 5 FU and methyl-CCNU achieved responses in 9 % and 5 % of stomach and pancreatic tumors , respectively . There was no significant difference in survival between limbs for either tumor . Median survival in gastric carcinoma on the 5 FU-mitomycin regimen was 25 weeks vs. 18 weeks on the 5 FU-METHYL-CCNU arm . In pancreatic carcinoma median survival on the mitomycin limb was 19 weeks as compared to 17 weeks on the methyl-CCNU program . Leukopenia was greater for the first course on the mitomycin limb . Regression analysis demonstrated that performance status was the most important pretreatment characteristic for predicting survival in both tumors . Neither 5 FU infusion combination appears to significantly alter the dismal prognosis of advanced upper gastrointestinal neoplasms ."
],
"offsets": [
[
0,
1442
]
]
}
] | [
{
"id": "77008",
"type": "Intervention_Pharmacological",
"text": [
"mitomycin-C vs. 5 FU infusion with methyl-CCNU"
],
"offsets": [
[
19,
65
]
],
"normalized": []
},
{
"id": "77009",
"type": "Intervention_Physical",
"text": [
"5-fluorouracil 96-hour continuous infusions"
],
"offsets": [
[
330,
373
]
],
"normalized": []
},
{
"id": "77010",
"type": "Intervention_Pharmacological",
"text": [
"bolus mitomycin-C or oral methyl-CCNU"
],
"offsets": [
[
386,
423
]
],
"normalized": []
},
{
"id": "77011",
"type": "Intervention_Pharmacological",
"text": [
"Mitomycin-C and methyl-CCNU"
],
"offsets": [
[
426,
453
]
],
"normalized": []
},
{
"id": "77012",
"type": "Intervention_Pharmacological",
"text": [
"5 FU-mitomycin combination"
],
"offsets": [
[
496,
522
]
],
"normalized": []
},
{
"id": "77013",
"type": "Intervention_Pharmacological",
"text": [
"combination of infusion 5 FU and methyl-CCNU"
],
"offsets": [
[
632,
676
]
],
"normalized": []
},
{
"id": "77014",
"type": "Intervention_Pharmacological",
"text": [
"5 FU-mitomycin"
],
"offsets": [
[
496,
510
]
],
"normalized": []
},
{
"id": "77015",
"type": "Intervention_Pharmacological",
"text": [
"5 FU-METHYL-CCNU"
],
"offsets": [
[
942,
958
]
],
"normalized": []
},
{
"id": "77016",
"type": "Intervention_Pharmacological",
"text": [
"methyl-CCNU"
],
"offsets": [
[
54,
65
]
],
"normalized": []
},
{
"id": "77017",
"type": "Intervention_Pharmacological",
"text": [
"mitomycin"
],
"offsets": [
[
19,
28
]
],
"normalized": []
},
{
"id": "77018",
"type": "Intervention_Pharmacological",
"text": [
"5 FU infusion"
],
"offsets": [
[
0,
13
]
],
"normalized": []
},
{
"id": "77019",
"type": "Outcome_Physical",
"text": [
"response rate"
],
"offsets": [
[
548,
561
]
],
"normalized": []
},
{
"id": "77020",
"type": "Outcome_Physical",
"text": [
"responses"
],
"offsets": [
[
686,
695
]
],
"normalized": []
},
{
"id": "77021",
"type": "Outcome_Mortality",
"text": [
"difference in survival"
],
"offsets": [
[
786,
808
]
],
"normalized": []
},
{
"id": "77022",
"type": "Outcome_Mortality",
"text": [
"Median survival"
],
"offsets": [
[
842,
857
]
],
"normalized": []
},
{
"id": "77023",
"type": "Outcome_Mortality",
"text": [
"pancreatic carcinoma median survival"
],
"offsets": [
[
968,
1004
]
],
"normalized": []
},
{
"id": "77024",
"type": "Outcome_Physical",
"text": [
"Leukopenia"
],
"offsets": [
[
1093,
1103
]
],
"normalized": []
},
{
"id": "77025",
"type": "Outcome_Physical",
"text": [
"performance status"
],
"offsets": [
[
1199,
1217
]
],
"normalized": []
},
{
"id": "77026",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
800,
808
]
],
"normalized": []
}
] | [] | [] | [] |
77027 | 3877292 | [
{
"id": "77028",
"type": "document",
"text": [
"Intraocular pressure changes with propofol ( 'Diprivan ' ) : comparison with thiopentone . The effects of propofol , a new non-barbiturate intravenous anaesthetic agent , on intraocular pressure ( IOP ) were assessed and compared with those of thiopentone . IOP was measured using an applanation tonometer for 5 min following administration of induction doses of propofol or thiopentone and inhalation of 66 % nitrous oxide in oxygen . Both agents produced a significant fall in IOP for the period of study , by a maximum of 53 % with propofol and 40 % with thiopentone . Apnoea occurred with similar frequency in the two groups . Use of propofol was associated with a significant fall in arterial pressure and pain on injection in 5 out of 20 patients ."
],
"offsets": [
[
0,
754
]
]
}
] | [
{
"id": "77029",
"type": "Intervention_Pharmacological",
"text": [
"propofol"
],
"offsets": [
[
34,
42
]
],
"normalized": []
},
{
"id": "77030",
"type": "Intervention_Pharmacological",
"text": [
"thiopentone"
],
"offsets": [
[
77,
88
]
],
"normalized": []
},
{
"id": "77031",
"type": "Intervention_Pharmacological",
"text": [
"propofol"
],
"offsets": [
[
34,
42
]
],
"normalized": []
},
{
"id": "77032",
"type": "Intervention_Pharmacological",
"text": [
"thiopentone"
],
"offsets": [
[
77,
88
]
],
"normalized": []
},
{
"id": "77033",
"type": "Intervention_Pharmacological",
"text": [
"propofol"
],
"offsets": [
[
34,
42
]
],
"normalized": []
},
{
"id": "77034",
"type": "Intervention_Pharmacological",
"text": [
"thiopentone"
],
"offsets": [
[
77,
88
]
],
"normalized": []
},
{
"id": "77035",
"type": "Intervention_Pharmacological",
"text": [
"nitrous oxide in oxygen"
],
"offsets": [
[
410,
433
]
],
"normalized": []
},
{
"id": "77036",
"type": "Outcome_Physical",
"text": [
"intraocular pressure"
],
"offsets": [
[
174,
194
]
],
"normalized": []
},
{
"id": "77037",
"type": "Outcome_Physical",
"text": [
"IOP"
],
"offsets": [
[
197,
200
]
],
"normalized": []
},
{
"id": "77038",
"type": "Outcome_Physical",
"text": [
"IOP"
],
"offsets": [
[
197,
200
]
],
"normalized": []
},
{
"id": "77039",
"type": "Outcome_Adverse-effects",
"text": [
"Apnoea"
],
"offsets": [
[
572,
578
]
],
"normalized": []
},
{
"id": "77040",
"type": "Outcome_Physical",
"text": [
"arterial pressure"
],
"offsets": [
[
689,
706
]
],
"normalized": []
},
{
"id": "77041",
"type": "Outcome_Pain",
"text": [
"pain on injection"
],
"offsets": [
[
711,
728
]
],
"normalized": []
},
{
"id": "77042",
"type": "Participant_Sample-size",
"text": [
"20 patients"
],
"offsets": [
[
741,
752
]
],
"normalized": []
}
] | [] | [] | [] |
77043 | 3881176 | [
{
"id": "77044",
"type": "document",
"text": [
"Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population ."
],
"offsets": [
[
0,
1254
]
]
}
] | [
{
"id": "77045",
"type": "Intervention_Physical",
"text": [
"chemotherapy"
],
"offsets": [
[
32,
44
]
],
"normalized": []
},
{
"id": "77046",
"type": "Intervention_Pharmacological",
"text": [
"doxorubicin"
],
"offsets": [
[
238,
249
]
],
"normalized": []
},
{
"id": "77047",
"type": "Intervention_Pharmacological",
"text": [
"lomustine"
],
"offsets": [
[
254,
263
]
],
"normalized": []
},
{
"id": "77048",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide and 5-FU ( CF )"
],
"offsets": [
[
276,
308
]
],
"normalized": []
},
{
"id": "77049",
"type": "Intervention_Pharmacological",
"text": [
"CF"
],
"offsets": [
[
304,
306
]
],
"normalized": []
},
{
"id": "77050",
"type": "Intervention_Pharmacological",
"text": [
"DC"
],
"offsets": [
[
266,
268
]
],
"normalized": []
},
{
"id": "77051",
"type": "Intervention_Pharmacological",
"text": [
"CF"
],
"offsets": [
[
304,
306
]
],
"normalized": []
},
{
"id": "77052",
"type": "Intervention_Pharmacological",
"text": [
"DC"
],
"offsets": [
[
266,
268
]
],
"normalized": []
},
{
"id": "77053",
"type": "Outcome_Other",
"text": [
"tolerated"
],
"offsets": [
[
480,
489
]
],
"normalized": []
},
{
"id": "77054",
"type": "Outcome_Physical",
"text": [
"levels of myelosuppression"
],
"offsets": [
[
506,
532
]
],
"normalized": []
},
{
"id": "77055",
"type": "Outcome_Other",
"text": [
"objective partial response rate"
],
"offsets": [
[
539,
570
]
],
"normalized": []
},
{
"id": "77056",
"type": "Outcome_Physical",
"text": [
"Objective stabilization"
],
"offsets": [
[
604,
627
]
],
"normalized": []
},
{
"id": "77057",
"type": "Outcome_Other",
"text": [
"subjective response rate ( partial plus complete )"
],
"offsets": [
[
742,
792
]
],
"normalized": []
},
{
"id": "77058",
"type": "Outcome_Other",
"text": [
"response rates"
],
"offsets": [
[
920,
934
]
],
"normalized": []
},
{
"id": "77059",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
947,
955
]
],
"normalized": []
},
{
"id": "77060",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
947,
955
]
],
"normalized": []
},
{
"id": "77061",
"type": "Outcome_Other",
"text": [
"tolerated"
],
"offsets": [
[
480,
489
]
],
"normalized": []
}
] | [] | [] | [] |
77062 | 3882217 | [
{
"id": "77063",
"type": "document",
"text": [
"A randomized , prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck , breast , and trunk . Since 1977 , 31 patients were entered in a randomized , prospective study testing the efficacy of adjuvant chemotherapy after aggressive local treatment of high-grade sarcomas of the head , neck , breast , and trunk ( excluding retroperitoneal sarcomas ) . All patients had complete resection of gross tumor and underwent postoperative radiotherapy ( 6000-6300 rads over 7-8 weeks ) . Seventeen patients received adjuvant chemotherapy consisting of doxorubicin ( less than or equal to 550 mg/m2 ) , cyclophosphamide ( less than or equal to 5500 mg/m2 ) , and methotrexate ( less than or equal to 1000 mg/kg ) . Three-year actuarial disease-free survival in the chemotherapy arm was 77 % , compared to 49 % in the no-chemotherapy arm ( P = 0.075 ) . Three-year overall actuarial survivals in the two treatment arms , however , were 68 % and 58 % , respectively ( P = 0.38 ) . Considering only patients with tumors of the trunk ( 22 patients ) , 3-year actuarial disease-free survival in the chemotherapy arm was 92 % , compared to 47 % in the no-chemotherapy arm ( P = 0.006 ) . Actuarial 3-year overall survival in the chemotherapy arm was 82 % , compared to 61 % in the no-chemotherapy arm ( P = 0.18 ) . An additional 26 patients were treated in an identical fashion , but were not part of the randomized trial because of contraindications to chemotherapy , refusal to enter the randomized trial , or because they were treated before 1977 in a trial in which all patients received chemotherapy . Considering the entire group of 57 patients , follow-up ranged from 10 to 86 months ( median , 35 months ) . Local control was achieved in 46 patients ( 81 % ) ; 3-year actuarial disease-free and overall survivals were 67 % and 77 % , respectively . A tendency toward improved disease-free survival was apparent among patients treated with chemotherapy ( P = 0.018 ) , but there was no statistically significant improvement in overall actuarial survival ( P = 0.46 ) . The subgroup of patients with sarcomas of the trunk ( 39 patients ) demonstrated the greatest benefit from chemotherapy , with regard to disease-free survival ( P less than or equal to 0.001 ) . The most significant toxicity associated with chemotherapy was doxorubicin-induced cardiomyopathy , which resulted in clinically apparent congestive heart failure in five patients . Thus , the use of chemotherapy when combined with aggressive local measures appears to improve disease-free survival , but additional patients and longer follow-up are necessary to determine if improved overall survival will result ."
],
"offsets": [
[
0,
2715
]
]
}
] | [
{
"id": "77064",
"type": "Intervention_Pharmacological",
"text": [
"adjuvant chemotherapy"
],
"offsets": [
[
36,
57
]
],
"normalized": []
},
{
"id": "77065",
"type": "Intervention_Pharmacological",
"text": [
"adjuvant chemotherapy"
],
"offsets": [
[
36,
57
]
],
"normalized": []
},
{
"id": "77066",
"type": "Intervention_Surgical",
"text": [
"resection of gross tumor"
],
"offsets": [
[
421,
445
]
],
"normalized": []
},
{
"id": "77067",
"type": "Intervention_Physical",
"text": [
"postoperative radiotherapy"
],
"offsets": [
[
460,
486
]
],
"normalized": []
},
{
"id": "77068",
"type": "Intervention_Pharmacological",
"text": [
"adjuvant chemotherapy consisting of doxorubicin ( less than or equal to 550 mg/m2 )"
],
"offsets": [
[
551,
634
]
],
"normalized": []
},
{
"id": "77069",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide ( less than or equal to 5500 mg/m2 )"
],
"offsets": [
[
637,
690
]
],
"normalized": []
},
{
"id": "77070",
"type": "Intervention_Pharmacological",
"text": [
"methotrexate ( less than or equal to 1000 mg/kg"
],
"offsets": [
[
697,
744
]
],
"normalized": []
},
{
"id": "77071",
"type": "Intervention_Pharmacological",
"text": [
"chemotherapy"
],
"offsets": [
[
45,
57
]
],
"normalized": []
},
{
"id": "77072",
"type": "Intervention_Control",
"text": [
"no-chemotherapy"
],
"offsets": [
[
851,
866
]
],
"normalized": []
},
{
"id": "77073",
"type": "Intervention_Pharmacological",
"text": [
"chemotherapy"
],
"offsets": [
[
45,
57
]
],
"normalized": []
},
{
"id": "77074",
"type": "Intervention_Pharmacological",
"text": [
"chemotherapy"
],
"offsets": [
[
45,
57
]
],
"normalized": []
},
{
"id": "77075",
"type": "Intervention_Pharmacological",
"text": [
"doxorubicin-induced"
],
"offsets": [
[
2363,
2382
]
],
"normalized": []
},
{
"id": "77076",
"type": "Intervention_Pharmacological",
"text": [
"chemotherapy"
],
"offsets": [
[
45,
57
]
],
"normalized": []
},
{
"id": "77077",
"type": "Outcome_Mortality",
"text": [
"actuarial disease-free survival"
],
"offsets": [
[
760,
791
]
],
"normalized": []
},
{
"id": "77078",
"type": "Outcome_Mortality",
"text": [
"overall actuarial survivals"
],
"offsets": [
[
898,
925
]
],
"normalized": []
},
{
"id": "77079",
"type": "Outcome_Other",
"text": [
"Local control"
],
"offsets": [
[
1745,
1758
]
],
"normalized": []
},
{
"id": "77080",
"type": "Outcome_Mortality",
"text": [
"actuarial disease-free and overall survivals"
],
"offsets": [
[
1805,
1849
]
],
"normalized": []
},
{
"id": "77081",
"type": "Outcome_Mortality",
"text": [
"disease-free survival"
],
"offsets": [
[
770,
791
]
],
"normalized": []
},
{
"id": "77082",
"type": "Outcome_Mortality",
"text": [
"overall actuarial survival"
],
"offsets": [
[
898,
924
]
],
"normalized": []
},
{
"id": "77083",
"type": "Outcome_Mortality",
"text": [
"disease-free survival"
],
"offsets": [
[
770,
791
]
],
"normalized": []
},
{
"id": "77084",
"type": "Outcome_Physical",
"text": [
"toxicity"
],
"offsets": [
[
2321,
2329
]
],
"normalized": []
},
{
"id": "77085",
"type": "Outcome_Adverse-effects",
"text": [
"doxorubicin-induced cardiomyopathy"
],
"offsets": [
[
2363,
2397
]
],
"normalized": []
},
{
"id": "77086",
"type": "Outcome_Physical",
"text": [
"congestive heart failure"
],
"offsets": [
[
2438,
2462
]
],
"normalized": []
},
{
"id": "77087",
"type": "Outcome_Mortality",
"text": [
"disease-free survival"
],
"offsets": [
[
770,
791
]
],
"normalized": []
},
{
"id": "77088",
"type": "Outcome_Mortality",
"text": [
"overall survival"
],
"offsets": [
[
1233,
1249
]
],
"normalized": []
},
{
"id": "77089",
"type": "Participant_Age",
"text": [
"adults"
],
"offsets": [
[
61,
67
]
],
"normalized": []
},
{
"id": "77090",
"type": "Participant_Condition",
"text": [
"with soft tissue sarcomas of the head and neck , breast , and trunk ."
],
"offsets": [
[
68,
137
]
],
"normalized": []
},
{
"id": "77091",
"type": "Participant_Sample-size",
"text": [
"57"
],
"offsets": [
[
1668,
1670
]
],
"normalized": []
},
{
"id": "77092",
"type": "Participant_Sample-size",
"text": [
"subgroup of patients with sarcomas of the trunk ( 39 patients )"
],
"offsets": [
[
2109,
2172
]
],
"normalized": []
}
] | [] | [] | [] |
77093 | 3884411 | [
{
"id": "77094",
"type": "document",
"text": [
"The treatment of senile dementia associated with cerebrovascular insufficiency : a comparative study of buflomedil and dihydrogenated ergot alkaloids . Seventy-six patients took part in a randomized , comparative study of the efficacy of buflomedil hydrochloride and dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency . Efficacy was assessed by the patients ' performance in four psychometric tests . The results showed that a trend in favour of the buflomedil group in three of the tests became statistically significant in the fourth . Both drugs appeared to be safe , causing no marked adverse reactions . In conclusion , buflomedil is as effective or more effective than dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency and could prove a valuable addition to long-term therapy if further studies support the trend shown in this study ."
],
"offsets": [
[
0,
965
]
]
}
] | [
{
"id": "77095",
"type": "Intervention_Pharmacological",
"text": [
"buflomedil"
],
"offsets": [
[
104,
114
]
],
"normalized": []
},
{
"id": "77096",
"type": "Intervention_Pharmacological",
"text": [
"dihydrogenated ergot alkaloids"
],
"offsets": [
[
119,
149
]
],
"normalized": []
},
{
"id": "77097",
"type": "Intervention_Pharmacological",
"text": [
"buflomedil hydrochloride"
],
"offsets": [
[
238,
262
]
],
"normalized": []
},
{
"id": "77098",
"type": "Intervention_Pharmacological",
"text": [
"dihydrogenated ergot alkaloids"
],
"offsets": [
[
119,
149
]
],
"normalized": []
},
{
"id": "77099",
"type": "Outcome_Physical",
"text": [
"senile dementia"
],
"offsets": [
[
17,
32
]
],
"normalized": []
},
{
"id": "77100",
"type": "Outcome_Physical",
"text": [
"senile dementia"
],
"offsets": [
[
17,
32
]
],
"normalized": []
},
{
"id": "77101",
"type": "Outcome_Other",
"text": [
"Efficacy"
],
"offsets": [
[
382,
390
]
],
"normalized": []
},
{
"id": "77102",
"type": "Outcome_Mental",
"text": [
"psychometric tests"
],
"offsets": [
[
442,
460
]
],
"normalized": []
},
{
"id": "77103",
"type": "Outcome_Other",
"text": [
"safe"
],
"offsets": [
[
626,
630
]
],
"normalized": []
},
{
"id": "77104",
"type": "Outcome_Adverse-effects",
"text": [
"adverse reactions"
],
"offsets": [
[
651,
668
]
],
"normalized": []
},
{
"id": "77105",
"type": "Outcome_Physical",
"text": [
"senile dementia"
],
"offsets": [
[
17,
32
]
],
"normalized": []
},
{
"id": "77106",
"type": "Participant_Condition",
"text": [
"dihydrogenated"
],
"offsets": [
[
119,
133
]
],
"normalized": []
}
] | [] | [] | [] |
77107 | 3885290 | [
{
"id": "77108",
"type": "document",
"text": [
"Neuroleptic-related dyskinesias in autistic children : a prospective study ."
],
"offsets": [
[
0,
76
]
]
}
] | [
{
"id": "77109",
"type": "Intervention_Pharmacological",
"text": [
"Neuroleptic-related dyskinesias"
],
"offsets": [
[
0,
31
]
],
"normalized": []
},
{
"id": "77110",
"type": "Participant_Condition",
"text": [
"autistic"
],
"offsets": [
[
35,
43
]
],
"normalized": []
}
] | [] | [] | [] |
77111 | 3885865 | [
{
"id": "77112",
"type": "document",
"text": [
"[ Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis ] . The effect of high-dose metoclopramide ( 2 mg/kg , 4 times every 2 hours ) on the emesis of patients treated with CDDP ( 80 mg/m2 ) was examined by randomized control trial . The above metoclopramide regimen significantly suppressed the frequency of vomiting on the day of CDDP administration . The duration of nausea and anorexia after CDDP treatment was also shortened by high-dose metoclopramide administration ."
],
"offsets": [
[
0,
515
]
]
}
] | [
{
"id": "77113",
"type": "Intervention_Pharmacological",
"text": [
"metoclopramide"
],
"offsets": [
[
40,
54
]
],
"normalized": []
},
{
"id": "77114",
"type": "Intervention_Pharmacological",
"text": [
"high-dose metoclopramide ( 2 mg/kg"
],
"offsets": [
[
114,
148
]
],
"normalized": []
},
{
"id": "77115",
"type": "Intervention_Pharmacological",
"text": [
"metoclopramide"
],
"offsets": [
[
40,
54
]
],
"normalized": []
},
{
"id": "77116",
"type": "Intervention_Pharmacological",
"text": [
"metoclopramide"
],
"offsets": [
[
40,
54
]
],
"normalized": []
},
{
"id": "77117",
"type": "Outcome_Physical",
"text": [
"CDDP-induced emesis ]"
],
"offsets": [
[
76,
97
]
],
"normalized": []
},
{
"id": "77118",
"type": "Outcome_Physical",
"text": [
"emesis"
],
"offsets": [
[
89,
95
]
],
"normalized": []
},
{
"id": "77119",
"type": "Outcome_Physical",
"text": [
"suppressed the frequency of vomiting"
],
"offsets": [
[
322,
358
]
],
"normalized": []
},
{
"id": "77120",
"type": "Outcome_Physical",
"text": [
"nausea and anorexia"
],
"offsets": [
[
411,
430
]
],
"normalized": []
}
] | [] | [] | [] |
77121 | 3886510 | [
{
"id": "77122",
"type": "document",
"text": [
"[ Clinical trials with pirprofen and naproxen in patients with gonarthrosis and coxarthrosis ] ."
],
"offsets": [
[
0,
96
]
]
}
] | [
{
"id": "77123",
"type": "Intervention_Pharmacological",
"text": [
"pirprofen"
],
"offsets": [
[
23,
32
]
],
"normalized": []
},
{
"id": "77124",
"type": "Intervention_Pharmacological",
"text": [
"naproxen"
],
"offsets": [
[
37,
45
]
],
"normalized": []
},
{
"id": "77125",
"type": "Outcome_Physical",
"text": [
"gonarthrosis and coxarthrosis"
],
"offsets": [
[
63,
92
]
],
"normalized": []
},
{
"id": "77126",
"type": "Participant_Condition",
"text": [
"patients with gonarthrosis and coxarthrosis"
],
"offsets": [
[
49,
92
]
],
"normalized": []
}
] | [] | [] | [] |
77127 | 3890395 | [
{
"id": "77128",
"type": "document",
"text": [
"Interference on metabolism induced by muzolimine and chlorthalidone in type II hypertensive diabetics . There is a very high prevalence of hypertension in diabetic subjects , which makes it necessary to use an antihypertensive drug with the least possible metabolic interference . For example , in the early phase of hypertension , diuretics usually worsen the metabolic equilibrium . According to recent reports , a new diuretic , muzolimine ( MZ ) , which acts on the loop of Henle , seems to present a minor effect on carbohydrate metabolic balance . In order to determine whether this assumption was correct or not , we carried out a clinical trial on 26 type II ( non-insulin-dependent ) diabetics , in fairly good metabolic control and with moderate hypertension ( orthostatic diastolic pressure from 100 to 115 mmHg ) , comparing the effect of MZ with those of chlorthalidone ( CL ) . According to a randomized , single-blind cross-over design , the patients were treated with MZ ( 20 mg/day ) or CL ( 50 mg/day ) for the duration of 4 weeks . After the treatment period with the first drug , there was a 2 week wash-out period on placebo ( PL ) before the second drug was given . During the study , a set of metabolic and non-metabolic parameters was monitored , as were the clinostatic and orthostatic blood pressure values . The results show that the antihypertensive effect of the two drugs was the same ( both caused a more than 10 % decrease in systolic and diastolic blood pressure ) . No significant changes in plasma electrolyte levels occurred . There was a significant ( p less than 0.05 ) increase in urinary aldosterone excretion after CL ( 20.7 +/- 11 micrograms/24 hours vs. 13.3 +/- 8.5 after PL , and 14.5 +/- 7.2 after MZ ) ( mean values +/- standard deviations ) . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1826
]
]
}
] | [
{
"id": "77129",
"type": "Intervention_Pharmacological",
"text": [
"muzolimine"
],
"offsets": [
[
38,
48
]
],
"normalized": []
},
{
"id": "77130",
"type": "Intervention_Pharmacological",
"text": [
"chlorthalidone"
],
"offsets": [
[
53,
67
]
],
"normalized": []
},
{
"id": "77131",
"type": "Intervention_Pharmacological",
"text": [
"antihypertensive drug"
],
"offsets": [
[
210,
231
]
],
"normalized": []
},
{
"id": "77132",
"type": "Intervention_Pharmacological",
"text": [
"muzolimine ( MZ )"
],
"offsets": [
[
432,
449
]
],
"normalized": []
},
{
"id": "77133",
"type": "Intervention_Pharmacological",
"text": [
"MZ"
],
"offsets": [
[
445,
447
]
],
"normalized": []
},
{
"id": "77134",
"type": "Intervention_Pharmacological",
"text": [
"chlorthalidone ( CL )"
],
"offsets": [
[
868,
889
]
],
"normalized": []
},
{
"id": "77135",
"type": "Intervention_Pharmacological",
"text": [
"MZ"
],
"offsets": [
[
445,
447
]
],
"normalized": []
},
{
"id": "77136",
"type": "Intervention_Pharmacological",
"text": [
"CL"
],
"offsets": [
[
885,
887
]
],
"normalized": []
},
{
"id": "77137",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
1138,
1145
]
],
"normalized": []
},
{
"id": "77138",
"type": "Outcome_Physical",
"text": [
"metabolic equilibrium"
],
"offsets": [
[
361,
382
]
],
"normalized": []
},
{
"id": "77139",
"type": "Outcome_Physical",
"text": [
"metabolic and non-metabolic parameters"
],
"offsets": [
[
1216,
1254
]
],
"normalized": []
},
{
"id": "77140",
"type": "Outcome_Physical",
"text": [
"clinostatic and orthostatic blood pressure values"
],
"offsets": [
[
1283,
1332
]
],
"normalized": []
},
{
"id": "77141",
"type": "Outcome_Physical",
"text": [
"antihypertensive effect"
],
"offsets": [
[
1361,
1384
]
],
"normalized": []
},
{
"id": "77142",
"type": "Outcome_Physical",
"text": [
"systolic and diastolic blood pressure"
],
"offsets": [
[
1458,
1495
]
],
"normalized": []
},
{
"id": "77143",
"type": "Outcome_Physical",
"text": [
"plasma electrolyte levels"
],
"offsets": [
[
1526,
1551
]
],
"normalized": []
},
{
"id": "77144",
"type": "Outcome_Physical",
"text": [
"urinary aldosterone excretion"
],
"offsets": [
[
1620,
1649
]
],
"normalized": []
},
{
"id": "77145",
"type": "Participant_Condition",
"text": [
"type II hypertensive diabetics ."
],
"offsets": [
[
71,
103
]
],
"normalized": []
},
{
"id": "77146",
"type": "Participant_Condition",
"text": [
"hypertension in diabetic subjects"
],
"offsets": [
[
139,
172
]
],
"normalized": []
}
] | [] | [] | [] |
77147 | 389265 | [
{
"id": "77148",
"type": "document",
"text": [
"Immunotherapy using BCG during remission induction and as the sole form of maintenance in acute myeloid leukaemia . Thirty-two adults with acute myeloid leukaemia ( AML ) were randomized to receive , from the time of diagnosis , either chemotherapy alone ( C group ) or chemotherapy plus Bacille Calmette-Guérin vaccine ( BCG ) ( C+I group ) . After remission induction and consolidation , chemotherapy was stopped in both groups but BCG was continued in the C+I group . The overall survival of the C+I group was significantly increased ( P less than 0.05 ) . There was no significant increase in the duration of first remission in the C+I group ( 0.05 less than P less than 0.1 ) nor in the time from first relapse to death ( 0.05 less than P less than 0.1 ) . There was no significant difference in the incidence of first or second remissions , and the time taken to enter remission did not differ significantly between the two groups . Comparison with the results of other trials suggests that the use of maintenance chemotherapy in addition to immunotherapy produces longer remissions . Five patients in the C group developed leukaemic central-nervous-system ( CSN ) involvement , in comparison with none in the C+I group . CNS relapse did not produce a significant decrease in remission length ( P greater than 0.1 ) but reduction in survival after CNS relapse was highly significant ( P = 0.001 ) . These results suggest that administration of BCG from an early stage in the treatment of AML may protect the CNS against leukaemic infiltration and therefore serve as a simple , innocuous form of CNS prophylaxis ."
],
"offsets": [
[
0,
1618
]
]
}
] | [
{
"id": "77149",
"type": "Intervention_Pharmacological",
"text": [
"Immunotherapy"
],
"offsets": [
[
0,
13
]
],
"normalized": []
},
{
"id": "77150",
"type": "Intervention_Pharmacological",
"text": [
"BCG"
],
"offsets": [
[
20,
23
]
],
"normalized": []
},
{
"id": "77151",
"type": "Intervention_Control",
"text": [
"chemotherapy alone"
],
"offsets": [
[
236,
254
]
],
"normalized": []
},
{
"id": "77152",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
483,
491
]
],
"normalized": []
},
{
"id": "77153",
"type": "Outcome_Physical",
"text": [
"duration of first remission"
],
"offsets": [
[
601,
628
]
],
"normalized": []
},
{
"id": "77154",
"type": "Outcome_Mortality",
"text": [
"first relapse to death"
],
"offsets": [
[
702,
724
]
],
"normalized": []
},
{
"id": "77155",
"type": "Outcome_Physical",
"text": [
"incidence of first or second remissions"
],
"offsets": [
[
805,
844
]
],
"normalized": []
},
{
"id": "77156",
"type": "Outcome_Physical",
"text": [
"time taken to enter remission"
],
"offsets": [
[
855,
884
]
],
"normalized": []
},
{
"id": "77157",
"type": "Outcome_Physical",
"text": [
"remissions"
],
"offsets": [
[
834,
844
]
],
"normalized": []
},
{
"id": "77158",
"type": "Outcome_Adverse-effects",
"text": [
"leukaemic central-nervous-system ( CSN ) involvement"
],
"offsets": [
[
1130,
1182
]
],
"normalized": []
},
{
"id": "77159",
"type": "Outcome_Physical",
"text": [
"remission length"
],
"offsets": [
[
1282,
1298
]
],
"normalized": []
},
{
"id": "77160",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
483,
491
]
],
"normalized": []
},
{
"id": "77161",
"type": "Outcome_Physical",
"text": [
"leukaemic infiltration"
],
"offsets": [
[
1526,
1548
]
],
"normalized": []
},
{
"id": "77162",
"type": "Outcome_Physical",
"text": [
"prophylaxis"
],
"offsets": [
[
1605,
1616
]
],
"normalized": []
},
{
"id": "77163",
"type": "Participant_Condition",
"text": [
"acute myeloid leukaemia ."
],
"offsets": [
[
90,
115
]
],
"normalized": []
},
{
"id": "77164",
"type": "Participant_Sample-size",
"text": [
"Thirty-two"
],
"offsets": [
[
116,
126
]
],
"normalized": []
},
{
"id": "77165",
"type": "Participant_Age",
"text": [
"adults"
],
"offsets": [
[
127,
133
]
],
"normalized": []
}
] | [] | [] | [] |
77166 | 3895875 | [
{
"id": "77167",
"type": "document",
"text": [
"Prophylactic lidocaine in the early phase of suspected myocardial infarction . Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double-blind randomized trial of lidocaine vs placebo . During the 1 hour after administration of the drug the incidence of ventricular fibrillation or sustained ventricular tachycardia among the 204 patients with acute myocardial infarction was low , 1.5 % . Lidocaine , given in a 300 mg dose intramuscularly followed by 100 mg intravenously , did not prevent sustained ventricular tachycardia , although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine ( p less than 0.05 ) . The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute infarction . The mean plasma lidocaine level of patients on beta-blocking agents was no different from that in patients not on beta blocking agents . During the 1-hour study period , the incidence of central nervous system side effects was significantly greater in the lidocaine group , hypotension occurred in 11 patients , nine of whom had received lidocaine , and four patients died from asystole , three of whom had had lidocaine . We can not advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction ."
],
"offsets": [
[
0,
1510
]
]
}
] | [
{
"id": "77168",
"type": "Intervention_Pharmacological",
"text": [
"Prophylactic lidocaine"
],
"offsets": [
[
0,
22
]
],
"normalized": []
},
{
"id": "77169",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine"
],
"offsets": [
[
13,
22
]
],
"normalized": []
},
{
"id": "77170",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
243,
250
]
],
"normalized": []
},
{
"id": "77171",
"type": "Intervention_Pharmacological",
"text": [
"Lidocaine"
],
"offsets": [
[
457,
466
]
],
"normalized": []
},
{
"id": "77172",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine"
],
"offsets": [
[
13,
22
]
],
"normalized": []
},
{
"id": "77173",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine"
],
"offsets": [
[
13,
22
]
],
"normalized": []
},
{
"id": "77174",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine"
],
"offsets": [
[
13,
22
]
],
"normalized": []
},
{
"id": "77175",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine"
],
"offsets": [
[
13,
22
]
],
"normalized": []
},
{
"id": "77176",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine"
],
"offsets": [
[
13,
22
]
],
"normalized": []
},
{
"id": "77177",
"type": "Outcome_Physical",
"text": [
"incidence of ventricular fibrillation"
],
"offsets": [
[
308,
345
]
],
"normalized": []
},
{
"id": "77178",
"type": "Outcome_Physical",
"text": [
"sustained ventricular tachycardia"
],
"offsets": [
[
349,
382
]
],
"normalized": []
},
{
"id": "77179",
"type": "Outcome_Physical",
"text": [
"sustained ventricular tachycardia"
],
"offsets": [
[
349,
382
]
],
"normalized": []
},
{
"id": "77180",
"type": "Outcome_Physical",
"text": [
"number of patients with warning arrhythmias"
],
"offsets": [
[
645,
688
]
],
"normalized": []
},
{
"id": "77181",
"type": "Outcome_Physical",
"text": [
"average plasma lidocaine level"
],
"offsets": [
[
780,
810
]
],
"normalized": []
},
{
"id": "77182",
"type": "Outcome_Other",
"text": [
"minutes after"
],
"offsets": [
[
707,
720
]
],
"normalized": []
},
{
"id": "77183",
"type": "Outcome_Physical",
"text": [
"mean plasma lidocaine level"
],
"offsets": [
[
967,
994
]
],
"normalized": []
},
{
"id": "77184",
"type": "Outcome_Adverse-effects",
"text": [
"incidence of central nervous system side effects"
],
"offsets": [
[
1137,
1185
]
],
"normalized": []
},
{
"id": "77185",
"type": "Outcome_Physical",
"text": [
"hypotension"
],
"offsets": [
[
1237,
1248
]
],
"normalized": []
},
{
"id": "77186",
"type": "Outcome_Mortality",
"text": [
"died"
],
"offsets": [
[
1331,
1335
]
],
"normalized": []
},
{
"id": "77187",
"type": "Participant_Sample-size",
"text": [
"Four hundred two"
],
"offsets": [
[
79,
95
]
],
"normalized": []
},
{
"id": "77188",
"type": "Participant_Condition",
"text": [
"myocardial infarction"
],
"offsets": [
[
55,
76
]
],
"normalized": []
},
{
"id": "77189",
"type": "Participant_Sample-size",
"text": [
"204"
],
"offsets": [
[
393,
396
]
],
"normalized": []
}
] | [] | [] | [] |
77190 | 3896455 | [
{
"id": "77191",
"type": "document",
"text": [
"A randomized comparative trial of combined versus alternating therapy with cytostatic drugs and high-dose medroxyprogesteron acetate in advanced breast cancer . A prospective multicenter trial was conducted in 155 consecutive patients with Stage IV breast cancer randomly allocated to receive either ( 1 ) vincristin ( V ) 1.2 mg/m2 ( maximum dose , 2 mg ) , Adriamycin ( A ) ( doxorubicin ) 40 mg/m2 , and cyclophosphamide ( C ) 500 mg/m2 , all intravenously on day 1 , every 4 weeks , in combination with medroxyprogesteron acetate ( MPA ) 600 mg orally on days 1 through 14 , 500 mg intramuscularly on days 1 through 28 , and twice weekly afterwards ( combined chemoendocrine approach ) or ( 2 ) the same combination chemotherapy ( VAC ) for three cycles alternating with MPA in the above-mentioned dosage during 8 weeks ( alternating chemoendocrine approach ) . Results show an overall response rate of 73 % with 26 % complete responses in the combined treatment arm , whereas in the alternating arm , an overall response rate of 76 % with 20 % complete responses was observed . In patients with more than one metastatic site , response rate was higher in the combination treatment , and only in this arm were complete responses observed in these patients . Although the median duration of response was long in both treatment arms ( combination , 19 months versus alternating , 21 months ) , the median overall survival in both groups was not definitely prolonged ( 22 versus 24 months , respectively ) . However , results in subsets of patients suggest that the alternating chemoendocrine approach may be better for estrogen receptor ( ER ) -negative patients , for patients younger than 51 years of age , and for patients with a disease-free interval of 1 year or less . Patients with these parameters probably belong to the same population . It is concluded that combination of chemotherapy and high-dose MPA may be indicated in ER-positive patients when a clinical response is urgently needed . In ER-negative patients , the alternating use of both treatment modalities deserves further investigation ."
],
"offsets": [
[
0,
2110
]
]
}
] | [
{
"id": "77192",
"type": "Intervention_Pharmacological",
"text": [
"vincristin ( V )"
],
"offsets": [
[
306,
322
]
],
"normalized": []
},
{
"id": "77193",
"type": "Intervention_Pharmacological",
"text": [
"Adriamycin ( A ) ( doxorubicin )"
],
"offsets": [
[
359,
391
]
],
"normalized": []
},
{
"id": "77194",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide ( C )"
],
"offsets": [
[
407,
429
]
],
"normalized": []
},
{
"id": "77195",
"type": "Intervention_Pharmacological",
"text": [
"medroxyprogesteron acetate ( MPA )"
],
"offsets": [
[
507,
541
]
],
"normalized": []
},
{
"id": "77196",
"type": "Outcome_Other",
"text": [
"overall response rate"
],
"offsets": [
[
882,
903
]
],
"normalized": []
},
{
"id": "77197",
"type": "Outcome_Other",
"text": [
"overall response rate"
],
"offsets": [
[
882,
903
]
],
"normalized": []
},
{
"id": "77198",
"type": "Outcome_Other",
"text": [
"response rate"
],
"offsets": [
[
890,
903
]
],
"normalized": []
},
{
"id": "77199",
"type": "Outcome_Other",
"text": [
"median duration of response was long"
],
"offsets": [
[
1275,
1311
]
],
"normalized": []
},
{
"id": "77200",
"type": "Outcome_Mortality",
"text": [
"overall survival"
],
"offsets": [
[
1407,
1423
]
],
"normalized": []
},
{
"id": "77201",
"type": "Outcome_Other",
"text": [
"combination of chemotherapy and high-dose MPA may be indicated in ER-positive patients"
],
"offsets": [
[
1870,
1956
]
],
"normalized": []
},
{
"id": "77202",
"type": "Participant_Condition",
"text": [
"advanced breast cancer"
],
"offsets": [
[
136,
158
]
],
"normalized": []
},
{
"id": "77203",
"type": "Participant_Sample-size",
"text": [
"155"
],
"offsets": [
[
210,
213
]
],
"normalized": []
}
] | [] | [] | [] |
77204 | 3900301 | [
{
"id": "77205",
"type": "document",
"text": [
"Chemotherapy with cyclophosphamide , doxorubicin , vincristine , and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma : a Southwest Oncology Group Study . Between 1977 and 1983 the Southwest Oncology Group ( SWOG ) evaluated chemotherapy alone ( cyclophosphamide , doxorubicin , vincristine , prednisone ; CHOP ) or chemoimmunotherapy ( CHOP-levamisole or CHOP-levamisole-BCG ) in a randomized prospective clinical trial involving 715 eligible patients with all types of malignant lymphoma ( ML ) . Of 281 evaluable patients with favorable histologic types of ML , 171 ( 61 % ) achieved complete remission ( CR ) and there was no difference in CR rate , CR duration , or survival according to the type of initial treatment . Of 388 evaluable patients with unfavorable histologic types of ML , 194 ( 50 % ) achieved CR . Levamisole appeared to adversely affect CR rates in nodular mixed and nodular large-cell lymphoma and CR duration in patients with unfavorable histology ML . Chemoimmunotherapy with levamisole or levamisole-BCG offers no advantage in terms of CR rates , CR duration , or survival compared to CHOP chemotherapy alone , and levamisole may have had an adverse impact on outcome in certain subtypes of ML ."
],
"offsets": [
[
0,
1260
]
]
}
] | [
{
"id": "77206",
"type": "Intervention_Pharmacological",
"text": [
"Chemotherapy with cyclophosphamide , doxorubicin , vincristine , and prednisone alone or with levamisole or with levamisole plus BCG for"
],
"offsets": [
[
0,
136
]
],
"normalized": []
},
{
"id": "77207",
"type": "Intervention_Pharmacological",
"text": [
"chemotherapy alone ( cyclophosphamide , doxorubicin , vincristine , prednisone ; CHOP )"
],
"offsets": [
[
263,
350
]
],
"normalized": []
},
{
"id": "77208",
"type": "Intervention_Pharmacological",
"text": [
"chemoimmunotherapy ( CHOP-levamisole or CHOP-levamisole-BCG )"
],
"offsets": [
[
354,
415
]
],
"normalized": []
},
{
"id": "77209",
"type": "Intervention_Pharmacological",
"text": [
"Levamisole"
],
"offsets": [
[
858,
868
]
],
"normalized": []
},
{
"id": "77210",
"type": "Intervention_Pharmacological",
"text": [
"Chemoimmunotherapy with levamisole or levamisole-BCG"
],
"offsets": [
[
1016,
1068
]
],
"normalized": []
},
{
"id": "77211",
"type": "Intervention_Physical",
"text": [
"CHOP chemotherapy"
],
"offsets": [
[
1150,
1167
]
],
"normalized": []
},
{
"id": "77212",
"type": "Intervention_Pharmacological",
"text": [
"levamisole"
],
"offsets": [
[
94,
104
]
],
"normalized": []
},
{
"id": "77213",
"type": "Outcome_Physical",
"text": [
"complete remission ( CR )"
],
"offsets": [
[
625,
650
]
],
"normalized": []
},
{
"id": "77214",
"type": "Outcome_Physical",
"text": [
"CR rate , CR duration , or survival"
],
"offsets": [
[
682,
717
]
],
"normalized": []
},
{
"id": "77215",
"type": "Outcome_Physical",
"text": [
"CR"
],
"offsets": [
[
646,
648
]
],
"normalized": []
},
{
"id": "77216",
"type": "Outcome_Other",
"text": [
"."
],
"offsets": [
[
191,
192
]
],
"normalized": []
},
{
"id": "77217",
"type": "Outcome_Mortality",
"text": [
"CR rates"
],
"offsets": [
[
898,
906
]
],
"normalized": []
},
{
"id": "77218",
"type": "Outcome_Physical",
"text": [
"CR duration"
],
"offsets": [
[
692,
703
]
],
"normalized": []
},
{
"id": "77219",
"type": "Outcome_Mortality",
"text": [
"CR rates"
],
"offsets": [
[
898,
906
]
],
"normalized": []
},
{
"id": "77220",
"type": "Outcome_Adverse-effects",
"text": [
","
],
"offsets": [
[
35,
36
]
],
"normalized": []
},
{
"id": "77221",
"type": "Outcome_Mortality",
"text": [
"CR duration ,"
],
"offsets": [
[
692,
705
]
],
"normalized": []
},
{
"id": "77222",
"type": "Outcome_Adverse-effects",
"text": [
"or"
],
"offsets": [
[
40,
42
]
],
"normalized": []
},
{
"id": "77223",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
709,
717
]
],
"normalized": []
},
{
"id": "77224",
"type": "Participant_Sample-size",
"text": [
"715"
],
"offsets": [
[
469,
472
]
],
"normalized": []
},
{
"id": "77225",
"type": "Participant_Condition",
"text": [
"malignant lymphoma"
],
"offsets": [
[
137,
155
]
],
"normalized": []
},
{
"id": "77226",
"type": "Participant_Sample-size",
"text": [
"281"
],
"offsets": [
[
540,
543
]
],
"normalized": []
},
{
"id": "77227",
"type": "Participant_Condition",
"text": [
"ML"
],
"offsets": [
[
530,
532
]
],
"normalized": []
},
{
"id": "77228",
"type": "Participant_Sample-size",
"text": [
"388"
],
"offsets": [
[
766,
769
]
],
"normalized": []
}
] | [] | [] | [] |
77229 | 3903063 | [
{
"id": "77230",
"type": "document",
"text": [
"Hodgkin 's disease in childhood and adolescence : results of chemotherapy-radiotherapy in clinical stages IA-IIB . From April 1972 to May 1980 , 72 children and adolescents ( aged 5 to 19 years old , median 16 ) with Hodgkin 's disease , clinical stages IA-IIB ( IA , 18 ; II2A , two areas involved on the same side of the diaphragm , 23 ; II3+A , three areas or more , 16 ; IIB , 15 ) were prospectively treated in two successive clinical trials ( H 72 and H 77 ) . Clinical stages IA and II2A received three courses of mechlorethamine , Oncovin , procarbazine , and prednisone ( MOPP ) and supradiaphragmatic radiotherapy ( 40 Gy ) , and no laparotomy was performed . Clinical stages II3+A and IIB received either six cycles of MOPP ( H 72 ) , three cycles of MOPP , or three cycles of CCNU , vinblastine , procarbazine , and prednisone ( CVPP ) ( H 77 ) and subsequently had a laparotomy followed by supradiaphragmatic radiotherapy and a lumboaortic field if results of laparotomy were positive . Patients without evidence of mediastinal involvement did not have mediastinal radiotherapy . At the completion of therapy , the disease in 70 of 72 patients was in complete remission ( one failure , one death during treatment ) . Eight patients relapsed ( in situ , 1 ; marginal , 1 ; nonirradiated subdiaphragmatic area , 6 ) after three to 57 months of complete remission ( median 20 months ) ; one patient died after relapse . There were three deaths after complete remission of the disease ( infection , two ; acute nonlymphocytic leukemia [ ANLL ] , one ) . As of June 1984 the median follow-up was 82 months ( range , 49 to 145 months ) , the actuarial probabilities for survival and freedom from relapse for all patients being 91.6 % and 87.6 % , respectively . There was no statistical difference according to clinical stage , age ( greater than 15 or less than 15 years ) , sex , or number of cycles of chemotherapy ( six or three ) . Bone growth defects related to radiotherapy were reduced particularly in the 29 patients who did not receive mediastinal radiotherapy . None of these patients had a mediastinal relapse . Azoospermia was the rule for the male patients studied , but young girls and young women retained reproductive integrity ."
],
"offsets": [
[
0,
2253
]
]
}
] | [
{
"id": "77231",
"type": "Intervention_Pharmacological",
"text": [
"mechlorethamine , Oncovin , procarbazine , and prednisone ( MOPP )"
],
"offsets": [
[
521,
587
]
],
"normalized": []
},
{
"id": "77232",
"type": "Intervention_Physical",
"text": [
"supradiaphragmatic radiotherapy ( 40 Gy )"
],
"offsets": [
[
592,
633
]
],
"normalized": []
},
{
"id": "77233",
"type": "Intervention_Physical",
"text": [
"no laparotomy"
],
"offsets": [
[
640,
653
]
],
"normalized": []
},
{
"id": "77234",
"type": "Intervention_Pharmacological",
"text": [
"MOPP"
],
"offsets": [
[
581,
585
]
],
"normalized": []
},
{
"id": "77235",
"type": "Intervention_Pharmacological",
"text": [
"CCNU , vinblastine , procarbazine"
],
"offsets": [
[
788,
821
]
],
"normalized": []
},
{
"id": "77236",
"type": "Intervention_Pharmacological",
"text": [
"prednisone"
],
"offsets": [
[
568,
578
]
],
"normalized": []
},
{
"id": "77237",
"type": "Intervention_Surgical",
"text": [
"laparotomy"
],
"offsets": [
[
643,
653
]
],
"normalized": []
},
{
"id": "77238",
"type": "Intervention_Physical",
"text": [
"supradiaphragmatic radiotherapy"
],
"offsets": [
[
592,
623
]
],
"normalized": []
},
{
"id": "77239",
"type": "Outcome_Adverse-effects",
"text": [
"failure"
],
"offsets": [
[
1189,
1196
]
],
"normalized": []
},
{
"id": "77240",
"type": "Outcome_Mortality",
"text": [
"death"
],
"offsets": [
[
1203,
1208
]
],
"normalized": []
},
{
"id": "77241",
"type": "Outcome_Adverse-effects",
"text": [
"relapsed"
],
"offsets": [
[
1245,
1253
]
],
"normalized": []
},
{
"id": "77242",
"type": "Outcome_Adverse-effects",
"text": [
"deaths"
],
"offsets": [
[
1447,
1453
]
],
"normalized": []
},
{
"id": "77243",
"type": "Outcome_Physical",
"text": [
"nonlymphocytic leukemia"
],
"offsets": [
[
1520,
1543
]
],
"normalized": []
},
{
"id": "77244",
"type": "Outcome_Mortality",
"text": [
"the actuarial probabilities for survival and freedom from relapse"
],
"offsets": [
[
1645,
1710
]
],
"normalized": []
},
{
"id": "77245",
"type": "Outcome_Other",
"text": [
"number of cycles of chemotherapy"
],
"offsets": [
[
1892,
1924
]
],
"normalized": []
},
{
"id": "77246",
"type": "Outcome_Adverse-effects",
"text": [
"Bone growth defects related to radiotherapy"
],
"offsets": [
[
1944,
1987
]
],
"normalized": []
},
{
"id": "77247",
"type": "Outcome_Physical",
"text": [
"mediastinal relapse"
],
"offsets": [
[
2109,
2128
]
],
"normalized": []
},
{
"id": "77248",
"type": "Outcome_Physical",
"text": [
"Azoospermia"
],
"offsets": [
[
2131,
2142
]
],
"normalized": []
},
{
"id": "77249",
"type": "Participant_Condition",
"text": [
"Hodgkin 's disease"
],
"offsets": [
[
0,
18
]
],
"normalized": []
},
{
"id": "77250",
"type": "Participant_Age",
"text": [
"childhood"
],
"offsets": [
[
22,
31
]
],
"normalized": []
},
{
"id": "77251",
"type": "Participant_Age",
"text": [
"adolescence"
],
"offsets": [
[
36,
47
]
],
"normalized": []
},
{
"id": "77252",
"type": "Participant_Sample-size",
"text": [
"72"
],
"offsets": [
[
128,
130
]
],
"normalized": []
},
{
"id": "77253",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
148,
156
]
],
"normalized": []
},
{
"id": "77254",
"type": "Participant_Age",
"text": [
"adolescents"
],
"offsets": [
[
161,
172
]
],
"normalized": []
},
{
"id": "77255",
"type": "Participant_Condition",
"text": [
"Hodgkin 's disease"
],
"offsets": [
[
0,
18
]
],
"normalized": []
},
{
"id": "77256",
"type": "Participant_Condition",
"text": [
"mediastinal involvement"
],
"offsets": [
[
1029,
1052
]
],
"normalized": []
}
] | [] | [] | [] |
77257 | 3911965 | [
{
"id": "77258",
"type": "document",
"text": [
"Double-blind trial comparing the effectiveness of the homeopathic preparation Galphimia potentiation D6 , Galphimia dilution 10 ( -6 ) and placebo on pollinosis . The preparation of homeopathic drugs is based on potentiation . In this potentiation the primary substance is specially mixed with a carrier ( typically 90 % ethanol ) in the ratio 1:10 . Usually this potentiation is done repeatedly and the final drug is labeled , e.g. , \" D6 \" which means a 6 times decimal potentiation . In a controlled randomized strictly double-blind trial with 164 patients the effectiveness of homeopathically prepared Galphimia D6 , a conventional Galphimia dilution 10 ( -6 ) and a placebo was investigated for the therapy of pollinosis . The average duration of treatment was about 5 weeks . Although no statistical significance was achieved , it is remarkable that there was a clear trend for the superiority of Galphimia D6 while the Galphimia dilution 10 ( -6 ) was about equally effective compared with placebo . The study itself demonstrates that it is possible to do strictly controlled trials for homeopathic drugs and with medical practitioners ."
],
"offsets": [
[
0,
1144
]
]
}
] | [
{
"id": "77259",
"type": "Intervention_Pharmacological",
"text": [
"homeopathic preparation Galphimia potentiation D6"
],
"offsets": [
[
54,
103
]
],
"normalized": []
},
{
"id": "77260",
"type": "Intervention_Pharmacological",
"text": [
"Galphimia dilution 10 ( -6 )"
],
"offsets": [
[
106,
134
]
],
"normalized": []
},
{
"id": "77261",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
139,
146
]
],
"normalized": []
},
{
"id": "77262",
"type": "Intervention_Pharmacological",
"text": [
"homeopathic drugs"
],
"offsets": [
[
182,
199
]
],
"normalized": []
},
{
"id": "77263",
"type": "Intervention_Pharmacological",
"text": [
"ethanol"
],
"offsets": [
[
321,
328
]
],
"normalized": []
},
{
"id": "77264",
"type": "Intervention_Pharmacological",
"text": [
"D6"
],
"offsets": [
[
101,
103
]
],
"normalized": []
},
{
"id": "77265",
"type": "Intervention_Pharmacological",
"text": [
"Galphimia D6"
],
"offsets": [
[
606,
618
]
],
"normalized": []
},
{
"id": "77266",
"type": "Intervention_Pharmacological",
"text": [
"Galphimia dilution"
],
"offsets": [
[
106,
124
]
],
"normalized": []
},
{
"id": "77267",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
139,
146
]
],
"normalized": []
},
{
"id": "77268",
"type": "Intervention_Pharmacological",
"text": [
"Galphimia D6"
],
"offsets": [
[
606,
618
]
],
"normalized": []
},
{
"id": "77269",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
139,
146
]
],
"normalized": []
},
{
"id": "77270",
"type": "Intervention_Pharmacological",
"text": [
"homeopathic drugs"
],
"offsets": [
[
182,
199
]
],
"normalized": []
},
{
"id": "77271",
"type": "Outcome_Other",
"text": [
"average duration of treatment"
],
"offsets": [
[
732,
761
]
],
"normalized": []
},
{
"id": "77272",
"type": "Outcome_Other",
"text": [
"superiority"
],
"offsets": [
[
888,
899
]
],
"normalized": []
},
{
"id": "77273",
"type": "Participant_Condition",
"text": [
"pollinosis ."
],
"offsets": [
[
150,
162
]
],
"normalized": []
},
{
"id": "77274",
"type": "Participant_Sample-size",
"text": [
"164"
],
"offsets": [
[
547,
550
]
],
"normalized": []
},
{
"id": "77275",
"type": "Participant_Condition",
"text": [
"pollinosis ."
],
"offsets": [
[
150,
162
]
],
"normalized": []
}
] | [] | [] | [] |
77276 | 3923528 | [
{
"id": "77277",
"type": "document",
"text": [
"New drug trials in attention deficit disorder ."
],
"offsets": [
[
0,
47
]
]
}
] | [
{
"id": "77278",
"type": "Intervention_Pharmacological",
"text": [
"New drug trials"
],
"offsets": [
[
0,
15
]
],
"normalized": []
}
] | [] | [] | [] |
77279 | 3926042 | [
{
"id": "77280",
"type": "document",
"text": [
"Relief of pain by infusion of morphine after operation : does tolerance develop ? To see whether continuous intravenous infusion of opiates provides more effective postoperative relief of pain than conventional intramuscular injection these regimens were compared in a prospective double blind trial . Thirty patients undergoing elective cholecystectomy were allocated randomly to receive an infusion of morphine or an infusion of placebo ( control group ) for 24 hours . Both groups were allowed supplementary morphine boluses as requested . During the first 48 hours after operation the degree of pain was almost identical between the groups . Surprisingly , the group that was given the infusion of morphine received as much supplementary morphine as the control group during the first 24 hours and appreciably more during the 24 hours after the infusion had been withdrawn . Nausea and vomiting were more prevalent among the patients given the infusion of morphine . These results suggest that continuous infusion of morphine may be an inferior regimen to intermittent bolus administration in the relief of postoperative pain . This may be explained by the development of tolerance in patients who received the infusion of morphine ."
],
"offsets": [
[
0,
1237
]
]
}
] | [
{
"id": "77281",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
30,
38
]
],
"normalized": []
},
{
"id": "77282",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
30,
38
]
],
"normalized": []
},
{
"id": "77283",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
431,
438
]
],
"normalized": []
},
{
"id": "77284",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
30,
38
]
],
"normalized": []
},
{
"id": "77285",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
30,
38
]
],
"normalized": []
},
{
"id": "77286",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
30,
38
]
],
"normalized": []
},
{
"id": "77287",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
30,
38
]
],
"normalized": []
},
{
"id": "77288",
"type": "Intervention_Pharmacological",
"text": [
"morphine ."
],
"offsets": [
[
960,
970
]
],
"normalized": []
},
{
"id": "77289",
"type": "Outcome_Pain",
"text": [
"pain"
],
"offsets": [
[
10,
14
]
],
"normalized": []
},
{
"id": "77290",
"type": "Outcome_Other",
"text": [
"tolerance"
],
"offsets": [
[
62,
71
]
],
"normalized": []
},
{
"id": "77291",
"type": "Outcome_Pain",
"text": [
"postoperative relief of pain"
],
"offsets": [
[
164,
192
]
],
"normalized": []
},
{
"id": "77292",
"type": "Outcome_Pain",
"text": [
"degree of pain"
],
"offsets": [
[
589,
603
]
],
"normalized": []
},
{
"id": "77293",
"type": "Outcome_Adverse-effects",
"text": [
"Nausea and vomiting"
],
"offsets": [
[
879,
898
]
],
"normalized": []
},
{
"id": "77294",
"type": "Outcome_Pain",
"text": [
"relief of postoperative pain"
],
"offsets": [
[
1101,
1129
]
],
"normalized": []
},
{
"id": "77295",
"type": "Outcome_Other",
"text": [
"tolerance"
],
"offsets": [
[
62,
71
]
],
"normalized": []
},
{
"id": "77296",
"type": "Participant_Sample-size",
"text": [
"Thirty"
],
"offsets": [
[
302,
308
]
],
"normalized": []
},
{
"id": "77297",
"type": "Participant_Condition",
"text": [
"cholecystectomy"
],
"offsets": [
[
338,
353
]
],
"normalized": []
}
] | [] | [] | [] |
77298 | 392623 | [
{
"id": "77299",
"type": "document",
"text": [
"Controlled trial of induction of labor by vaginal suppositories containing prostaglandin E2 . A group of 84 women at 39-43 weeks of pregnancy were randomly allocated to a blind trial of induction of labor with vaginal suppositories containing inert material or either 0.2 mg or 0.4 mg of prostaglandin E2 . The suppositories were self-administered every two hours during waking hours on two successive days until labor started or 15 had been used . Side-effects were absent . Labor was established within 48 hr of insertion of the first suppository in 9.3 % of control patients , 65.4 % of those treated with 0.2 mg PGE2 and 85.7 % of those treated with 0.4 mg PGE2 . The mean Apgar scores in the three groups were the same . The mean total dose of PGE2 were 2.0 mg ( 0.2 mg group ) and 2.3 mg ( 0.4 mg group ) . It is concluded that vaginal PGE2 is an effective and acceptable method of inducing labor at term ."
],
"offsets": [
[
0,
912
]
]
}
] | [
{
"id": "77300",
"type": "Intervention_Pharmacological",
"text": [
"suppositories"
],
"offsets": [
[
50,
63
]
],
"normalized": []
},
{
"id": "77301",
"type": "Intervention_Pharmacological",
"text": [
"prostaglandin E2"
],
"offsets": [
[
75,
91
]
],
"normalized": []
},
{
"id": "77302",
"type": "Intervention_Pharmacological",
"text": [
"suppositories"
],
"offsets": [
[
50,
63
]
],
"normalized": []
},
{
"id": "77303",
"type": "Intervention_Control",
"text": [
"inert material"
],
"offsets": [
[
243,
257
]
],
"normalized": []
},
{
"id": "77304",
"type": "Intervention_Pharmacological",
"text": [
"prostaglandin E2"
],
"offsets": [
[
75,
91
]
],
"normalized": []
},
{
"id": "77305",
"type": "Intervention_Pharmacological",
"text": [
"PGE2"
],
"offsets": [
[
616,
620
]
],
"normalized": []
},
{
"id": "77306",
"type": "Intervention_Pharmacological",
"text": [
"PGE2"
],
"offsets": [
[
616,
620
]
],
"normalized": []
},
{
"id": "77307",
"type": "Intervention_Pharmacological",
"text": [
"PGE2"
],
"offsets": [
[
616,
620
]
],
"normalized": []
},
{
"id": "77308",
"type": "Intervention_Pharmacological",
"text": [
"PGE2"
],
"offsets": [
[
616,
620
]
],
"normalized": []
},
{
"id": "77309",
"type": "Outcome_Physical",
"text": [
"labor"
],
"offsets": [
[
33,
38
]
],
"normalized": []
},
{
"id": "77310",
"type": "Outcome_Physical",
"text": [
"labor"
],
"offsets": [
[
33,
38
]
],
"normalized": []
},
{
"id": "77311",
"type": "Outcome_Physical",
"text": [
"Labor was established"
],
"offsets": [
[
476,
497
]
],
"normalized": []
},
{
"id": "77312",
"type": "Outcome_Physical",
"text": [
"mean Apgar scores"
],
"offsets": [
[
672,
689
]
],
"normalized": []
},
{
"id": "77313",
"type": "Outcome_Physical",
"text": [
"mean total dose of PGE2"
],
"offsets": [
[
730,
753
]
],
"normalized": []
},
{
"id": "77314",
"type": "Outcome_Physical",
"text": [
"vaginal PGE2"
],
"offsets": [
[
834,
846
]
],
"normalized": []
},
{
"id": "77315",
"type": "Outcome_Physical",
"text": [
"method of inducing labor at term ."
],
"offsets": [
[
878,
912
]
],
"normalized": []
},
{
"id": "77316",
"type": "Participant_Condition",
"text": [
"84 women at 39-43 weeks of pregnancy"
],
"offsets": [
[
105,
141
]
],
"normalized": []
}
] | [] | [] | [] |
77317 | 3931144 | [
{
"id": "77318",
"type": "document",
"text": [
"Drug preference in normal volunteers : effects of age and time of day . These experiments assessed the influence of two variables , age of subjects and time of drug administration , on the reinforcing properties of amphetamine and of diazepam in normal volunteers . Three groups of subjects were tested : i ) a group of 40-55-year-old subjects ( AGE group ; N = 11 ) who were tested in the morning , ii ) a group of 21-35-year-old subjects ( CTL group ; N = 12 ) who were also tested in the morning , and iii ) a group of 21-35-year-olds who were tested in the late afternoon ( AFT group ; N = 13 ) . All subjects participated in three separate experiments comparing one drug ( 5 mg d , l-amphetamine , 5 mg diazepam or 10 mg diazepam ) to placebo . Each experiment consisted of nine sessions : On the first four sessions subjects sampled two color-coded capsules on alternate sessions and on the following five sessions they chose and ingested the capsule they preferred . Subjective effects of the drugs were monitored using the Profile of Mood States ( POMS ) and a shortened version of the Addiction Research Center Inventory ( ARCI ) . Subjects in all three groups chose 5 mg diazepam as often as placebo but preferred placebo to 10 mg diazepam . In contrast , they chose amphetamine either as often as or more often than placebo . The subjective effects of diazepam ( i.e . sedation ) were similar across all three groups , but after amphetamine the AGE group showed greater stimulant effects . In addition , the AFT group showed fewer positive mood effects after amphetamine than the CTL group . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1638
]
]
}
] | [
{
"id": "77319",
"type": "Intervention_Pharmacological",
"text": [
"amphetamine"
],
"offsets": [
[
215,
226
]
],
"normalized": []
},
{
"id": "77320",
"type": "Intervention_Pharmacological",
"text": [
"diazepam"
],
"offsets": [
[
234,
242
]
],
"normalized": []
},
{
"id": "77321",
"type": "Intervention_Pharmacological",
"text": [
"d , l-amphetamine"
],
"offsets": [
[
683,
700
]
],
"normalized": []
},
{
"id": "77322",
"type": "Intervention_Pharmacological",
"text": [
"diazepam"
],
"offsets": [
[
234,
242
]
],
"normalized": []
},
{
"id": "77323",
"type": "Intervention_Pharmacological",
"text": [
"diazepam"
],
"offsets": [
[
234,
242
]
],
"normalized": []
},
{
"id": "77324",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
740,
747
]
],
"normalized": []
},
{
"id": "77325",
"type": "Intervention_Pharmacological",
"text": [
"diazepam"
],
"offsets": [
[
234,
242
]
],
"normalized": []
},
{
"id": "77326",
"type": "Intervention_Pharmacological",
"text": [
"diazepam"
],
"offsets": [
[
234,
242
]
],
"normalized": []
},
{
"id": "77327",
"type": "Intervention_Pharmacological",
"text": [
"amphetamine"
],
"offsets": [
[
215,
226
]
],
"normalized": []
},
{
"id": "77328",
"type": "Intervention_Pharmacological",
"text": [
"diazepam"
],
"offsets": [
[
234,
242
]
],
"normalized": []
},
{
"id": "77329",
"type": "Outcome_Mental",
"text": [
"Profile of Mood States ( POMS )"
],
"offsets": [
[
1031,
1062
]
],
"normalized": []
},
{
"id": "77330",
"type": "Outcome_Mental",
"text": [
"shortened version of the Addiction Research Center Inventory ( ARCI ) ."
],
"offsets": [
[
1069,
1140
]
],
"normalized": []
},
{
"id": "77331",
"type": "Participant_Age",
"text": [
"a group of 40-55-year-old subjects"
],
"offsets": [
[
309,
343
]
],
"normalized": []
},
{
"id": "77332",
"type": "Participant_Sample-size",
"text": [
"N = 11"
],
"offsets": [
[
358,
364
]
],
"normalized": []
},
{
"id": "77333",
"type": "Participant_Age",
"text": [
"a group of 21-35-year-old subjects"
],
"offsets": [
[
405,
439
]
],
"normalized": []
},
{
"id": "77334",
"type": "Participant_Sample-size",
"text": [
"12"
],
"offsets": [
[
458,
460
]
],
"normalized": []
},
{
"id": "77335",
"type": "Participant_Age",
"text": [
"a group of 21-35-year-olds"
],
"offsets": [
[
511,
537
]
],
"normalized": []
}
] | [] | [] | [] |
77336 | 393286 | [
{
"id": "77337",
"type": "document",
"text": [
"A comparative study of methyldopa and labetalol in the treatment of hypertension . 1 Twenty patients with essential hypertension completed a double-blind , dose-tritrated , cross-over comparison of methyldopa and labetalol . 2 Average lying BPs ( systolic/diastolic ) were reduced by 28/15 mmHg with methyldopa and by 23/15 mmHg with labetalol . 3 Average standing BPs ( systolic/diastolic ) were reduced by 29/14 mmHg with methyldopa and by 29/15 mmHg with labetalol . 4 Both lying and standing heart rates were reduced with labetalol . 5 It is concluded that the antihypertensive properties of labetalol and methyldopa are similar but that larger patient populations are needed to study the relative incidence of subjective adverse effects ."
],
"offsets": [
[
0,
743
]
]
}
] | [
{
"id": "77338",
"type": "Intervention_Pharmacological",
"text": [
"methyldopa"
],
"offsets": [
[
23,
33
]
],
"normalized": []
},
{
"id": "77339",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
38,
47
]
],
"normalized": []
},
{
"id": "77340",
"type": "Intervention_Pharmacological",
"text": [
"methyldopa"
],
"offsets": [
[
23,
33
]
],
"normalized": []
},
{
"id": "77341",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
38,
47
]
],
"normalized": []
},
{
"id": "77342",
"type": "Intervention_Pharmacological",
"text": [
"methyldopa"
],
"offsets": [
[
23,
33
]
],
"normalized": []
},
{
"id": "77343",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
38,
47
]
],
"normalized": []
},
{
"id": "77344",
"type": "Intervention_Pharmacological",
"text": [
"methyldopa"
],
"offsets": [
[
23,
33
]
],
"normalized": []
},
{
"id": "77345",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
38,
47
]
],
"normalized": []
},
{
"id": "77346",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
38,
47
]
],
"normalized": []
},
{
"id": "77347",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
38,
47
]
],
"normalized": []
},
{
"id": "77348",
"type": "Intervention_Pharmacological",
"text": [
"methyldopa"
],
"offsets": [
[
23,
33
]
],
"normalized": []
},
{
"id": "77349",
"type": "Outcome_Physical",
"text": [
"hypertension ."
],
"offsets": [
[
68,
82
]
],
"normalized": []
},
{
"id": "77350",
"type": "Outcome_Physical",
"text": [
"Average lying BPs ( systolic/diastolic )"
],
"offsets": [
[
227,
267
]
],
"normalized": []
},
{
"id": "77351",
"type": "Outcome_Physical",
"text": [
"Average standing BPs ( systolic/diastolic )"
],
"offsets": [
[
348,
391
]
],
"normalized": []
},
{
"id": "77352",
"type": "Outcome_Physical",
"text": [
"lying and standing heart rates"
],
"offsets": [
[
477,
507
]
],
"normalized": []
},
{
"id": "77353",
"type": "Outcome_Physical",
"text": [
"antihypertensive properties"
],
"offsets": [
[
565,
592
]
],
"normalized": []
},
{
"id": "77354",
"type": "Participant_Condition",
"text": [
"hypertension"
],
"offsets": [
[
68,
80
]
],
"normalized": []
},
{
"id": "77355",
"type": "Participant_Sample-size",
"text": [
"Twenty"
],
"offsets": [
[
85,
91
]
],
"normalized": []
}
] | [] | [] | [] |
77356 | 3940160 | [
{
"id": "77357",
"type": "document",
"text": [
"[ The use of cephalosporins in hospital practice ] ."
],
"offsets": [
[
0,
52
]
]
}
] | [
{
"id": "77358",
"type": "Intervention_Pharmacological",
"text": [
"cephalosporins"
],
"offsets": [
[
13,
27
]
],
"normalized": []
},
{
"id": "77359",
"type": "Participant_Condition",
"text": [
"The use of cephalosporins in hospital practice"
],
"offsets": [
[
2,
48
]
],
"normalized": []
}
] | [] | [] | [] |
77360 | 3950826 | [
{
"id": "77361",
"type": "document",
"text": [
"Nutrient retention in preterm infants fed standard infant formulas . Our purpose was to compare nitrogen , mineral , and zinc balance in preterm infants fed standard infant formulas , Similac With Iron and Similac With Whey + Iron . Nitrogen and magnesium balances were similar during both feeds , and met estimated fetal requirements . Infants absorbed and retained ( milligrams per kilogram per day ) more calcium , phosphorus , and zinc when fed Similac With Iron . However , retention of calcium , phosphorus ( both formulas ) , and zinc ( Similac With Whey + Iron ) was inadequate to meet estimated fetal requirements . These findings are important in the rapidly growing preterm infant , who is already at risk for the development of rickets and zinc deficiency and may be fed either formula on discharge from the newborn nursery ."
],
"offsets": [
[
0,
837
]
]
}
] | [
{
"id": "77362",
"type": "Intervention_Pharmacological",
"text": [
"standard infant formulas"
],
"offsets": [
[
42,
66
]
],
"normalized": []
},
{
"id": "77363",
"type": "Intervention_Pharmacological",
"text": [
"Similac With Iron and Similac With Whey + Iron"
],
"offsets": [
[
184,
230
]
],
"normalized": []
},
{
"id": "77364",
"type": "Intervention_Pharmacological",
"text": [
"Similac With Iron"
],
"offsets": [
[
184,
201
]
],
"normalized": []
},
{
"id": "77365",
"type": "Outcome_Physical",
"text": [
"compare nitrogen , mineral , and zinc balance"
],
"offsets": [
[
88,
133
]
],
"normalized": []
},
{
"id": "77366",
"type": "Outcome_Physical",
"text": [
"Nitrogen and magnesium balances"
],
"offsets": [
[
233,
264
]
],
"normalized": []
},
{
"id": "77367",
"type": "Outcome_Physical",
"text": [
"calcium , phosphorus , and zinc"
],
"offsets": [
[
408,
439
]
],
"normalized": []
},
{
"id": "77368",
"type": "Outcome_Physical",
"text": [
"retention of calcium , phosphorus ( both formulas ) , and zinc"
],
"offsets": [
[
479,
541
]
],
"normalized": []
},
{
"id": "77369",
"type": "Participant_Condition",
"text": [
"preterm"
],
"offsets": [
[
22,
29
]
],
"normalized": []
},
{
"id": "77370",
"type": "Participant_Condition",
"text": [
"preterm"
],
"offsets": [
[
22,
29
]
],
"normalized": []
},
{
"id": "77371",
"type": "Participant_Age",
"text": [
"preterm infant"
],
"offsets": [
[
22,
36
]
],
"normalized": []
}
] | [] | [] | [] |
77372 | 3954130 | [
{
"id": "77373",
"type": "document",
"text": [
"Response to tubular airway resistance in normal subjects and postoperative patients . Critically ill patients must often breathe spontaneously through an endotracheal tube that acts as a fixed inspiratory and expiratory tubular airway resistor . Although this practice is common , its effect on the pattern of breathing is not known . The mean breathing patterns of seven normal , healthy male subjects and eight male patients who had undergone upper abdominal surgery 2-4 days previously were studied breathing through a mouthpiece fitted in random order with a 5 , 6 , 7 , 8 , or 15 mm diameter ( 17 mm long ) resistor . These diameters were selected because they simulate the pressure-flow relationships of adult endotracheal tubes . With the 15 mm aperture , the patients had a greater breathing frequency ( f ) than did the normal subjects ( 21 +/- 5 [ SD ] vs. 14 +/- 4 breaths/min , P less than 0.01 ) as well as a smaller mean tidal volume ( VT ) . In both groups , minute ventilation ( VE ) and f progressively decreased as resistance was increased by decreasing the aperture size from 15 to 16 mm . In the normal subjects but not the patients , VT also progressively decreased . When the diameter was decreased from 6 mm to 5 mm , there were increases in VT and decreases in f that were more marked in the normal subjects . In both groups , the changes in VE were accompanied by decreases in mean and peak inspiratory and expiratory flow rates . Throughout the study , oxygen consumption ( VO2 ) and carbon dioxide production ( VCO2 ) did not change . This , coupled with the decreases in VE resulted in decreases in the ventilatory equivalents to CO2 and O2 ( VE/VCO2 , VE/VO2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1727
]
]
}
] | [
{
"id": "77374",
"type": "Intervention_Physical",
"text": [
"tubular airway resistance"
],
"offsets": [
[
12,
37
]
],
"normalized": []
},
{
"id": "77375",
"type": "Intervention_Surgical",
"text": [
"endotracheal tube"
],
"offsets": [
[
154,
171
]
],
"normalized": []
},
{
"id": "77376",
"type": "Intervention_Physical",
"text": [
"mouthpiece fitted in random order with a 5 , 6 , 7 , 8 , or 15 mm diameter ( 17 mm long ) resistor ."
],
"offsets": [
[
522,
622
]
],
"normalized": []
},
{
"id": "77377",
"type": "Outcome_Physical",
"text": [
"breathing frequency ( f )"
],
"offsets": [
[
790,
815
]
],
"normalized": []
},
{
"id": "77378",
"type": "Outcome_Physical",
"text": [
"mean tidal volume ( VT ) ."
],
"offsets": [
[
930,
956
]
],
"normalized": []
},
{
"id": "77379",
"type": "Outcome_Physical",
"text": [
"minute ventilation ( VE )"
],
"offsets": [
[
974,
999
]
],
"normalized": []
},
{
"id": "77380",
"type": "Outcome_Physical",
"text": [
"f"
],
"offsets": [
[
116,
117
]
],
"normalized": []
},
{
"id": "77381",
"type": "Outcome_Physical",
"text": [
"VT"
],
"offsets": [
[
950,
952
]
],
"normalized": []
},
{
"id": "77382",
"type": "Outcome_Physical",
"text": [
"VT"
],
"offsets": [
[
950,
952
]
],
"normalized": []
},
{
"id": "77383",
"type": "Outcome_Physical",
"text": [
"f"
],
"offsets": [
[
116,
117
]
],
"normalized": []
},
{
"id": "77384",
"type": "Outcome_Physical",
"text": [
"changes in VE"
],
"offsets": [
[
1355,
1368
]
],
"normalized": []
},
{
"id": "77385",
"type": "Outcome_Physical",
"text": [
"peak inspiratory and expiratory flow rates"
],
"offsets": [
[
1411,
1453
]
],
"normalized": []
},
{
"id": "77386",
"type": "Outcome_Physical",
"text": [
"oxygen consumption ( VO2 ) and carbon dioxide production ( VCO2 )"
],
"offsets": [
[
1479,
1544
]
],
"normalized": []
},
{
"id": "77387",
"type": "Participant_Condition",
"text": [
"normal"
],
"offsets": [
[
41,
47
]
],
"normalized": []
},
{
"id": "77388",
"type": "Participant_Condition",
"text": [
"Critically ill"
],
"offsets": [
[
86,
100
]
],
"normalized": []
},
{
"id": "77389",
"type": "Participant_Sample-size",
"text": [
"seven"
],
"offsets": [
[
366,
371
]
],
"normalized": []
},
{
"id": "77390",
"type": "Participant_Condition",
"text": [
"normal , healthy"
],
"offsets": [
[
372,
388
]
],
"normalized": []
},
{
"id": "77391",
"type": "Participant_Sex",
"text": [
"male"
],
"offsets": [
[
389,
393
]
],
"normalized": []
},
{
"id": "77392",
"type": "Participant_Sample-size",
"text": [
"eight"
],
"offsets": [
[
407,
412
]
],
"normalized": []
},
{
"id": "77393",
"type": "Participant_Sex",
"text": [
"male"
],
"offsets": [
[
389,
393
]
],
"normalized": []
}
] | [] | [] | [] |
77394 | 3957541 | [
{
"id": "77395",
"type": "document",
"text": [
"An analysis of the mortality effect in a breast cancer screening study . In order to better understand the effect of breast cancer screening on mortality , we use the theory of competing risks to analyse deaths from the long-term follow-up of the HIP breast cancer screening trial . We conclude that some , but not all , of the breast cancer cases detected early as a result of screening realized a benefit in terms of elimination of the risk of breast cancer mortality . Breast cancer screening appears not to affect the rate of mortality from causes of death other than breast cancer . Methodologically , we demonstrate the importance of analysing mortality separately for the breast cancer cases as well as for the entire population in a trial ."
],
"offsets": [
[
0,
748
]
]
}
] | [
{
"id": "77396",
"type": "Intervention_Physical",
"text": [
"breast cancer screening"
],
"offsets": [
[
41,
64
]
],
"normalized": []
},
{
"id": "77397",
"type": "Intervention_Physical",
"text": [
"HIP breast cancer screening trial"
],
"offsets": [
[
247,
280
]
],
"normalized": []
},
{
"id": "77398",
"type": "Intervention_Physical",
"text": [
"screening"
],
"offsets": [
[
55,
64
]
],
"normalized": []
},
{
"id": "77399",
"type": "Intervention_Physical",
"text": [
"Breast cancer screening"
],
"offsets": [
[
472,
495
]
],
"normalized": []
},
{
"id": "77400",
"type": "Outcome_Mortality",
"text": [
"breast cancer mortality ."
],
"offsets": [
[
446,
471
]
],
"normalized": []
},
{
"id": "77401",
"type": "Outcome_Mortality",
"text": [
"rate of mortality"
],
"offsets": [
[
522,
539
]
],
"normalized": []
},
{
"id": "77402",
"type": "Participant_Condition",
"text": [
"breast cancer"
],
"offsets": [
[
41,
54
]
],
"normalized": []
},
{
"id": "77403",
"type": "Participant_Condition",
"text": [
"breast cancer"
],
"offsets": [
[
41,
54
]
],
"normalized": []
},
{
"id": "77404",
"type": "Participant_Condition",
"text": [
"HIP breast cancer"
],
"offsets": [
[
247,
264
]
],
"normalized": []
},
{
"id": "77405",
"type": "Participant_Condition",
"text": [
"breast cancer"
],
"offsets": [
[
41,
54
]
],
"normalized": []
},
{
"id": "77406",
"type": "Participant_Condition",
"text": [
"breast cancer"
],
"offsets": [
[
41,
54
]
],
"normalized": []
},
{
"id": "77407",
"type": "Participant_Condition",
"text": [
"breast cancer"
],
"offsets": [
[
41,
54
]
],
"normalized": []
}
] | [] | [] | [] |
77408 | 3960619 | [
{
"id": "77409",
"type": "document",
"text": [
"Zinc and copper balances in preterm infants . Preterm infants are at risk for copper and zinc depletion if sufficient quantities of these nutrients are not provided in a bioavailable form in postnatal life . The purpose of this study was to determine whether the use of a whey-predominant , 50 % medium chain triglyceride formula with relatively high concentrations of zinc and copper would promote the achievement of the in utero accretion rate for zinc and copper in the preterm infant . Two groups of five preterm infants were fed a diet containing 12.5 mg/L of zinc and either 0.9 mg/L or 2.1 mg/L of copper . Seventy-two-hour metabolic balance studies were performed at an average postconceptual age of 34 weeks and an average weight of 1,549 g. All infants were in positive zinc balance and nine of ten achieved the in utero accretion rate for zinc for a 34-week gestation fetus ( greater than or equal to 0.432 mg/d ) . Three infants receiving the high copper formula and two receiving the lower copper formula were in positive copper balance . Two infants from each group achieved the in utero accretion rate for copper for a 34-week gestation fetus ( 0.088 mg/d ) . A formula that provides 12.5 mg/L of zinc permits positive zinc balance and zinc retention similar to in utero rates . A formula that provides as much as 2.1 mg/L of copper , however , may not always permit positive copper balance ."
],
"offsets": [
[
0,
1407
]
]
}
] | [
{
"id": "77410",
"type": "Intervention_Pharmacological",
"text": [
"Zinc and copper balances"
],
"offsets": [
[
0,
24
]
],
"normalized": []
},
{
"id": "77411",
"type": "Intervention_Pharmacological",
"text": [
"whey-predominant , 50 % medium chain triglyceride formula with relatively high concentrations of zinc"
],
"offsets": [
[
272,
373
]
],
"normalized": []
},
{
"id": "77412",
"type": "Intervention_Pharmacological",
"text": [
"copper"
],
"offsets": [
[
9,
15
]
],
"normalized": []
},
{
"id": "77413",
"type": "Intervention_Pharmacological",
"text": [
"12.5 mg/L of zinc"
],
"offsets": [
[
552,
569
]
],
"normalized": []
},
{
"id": "77414",
"type": "Intervention_Pharmacological",
"text": [
"0.9 mg/L or 2.1 mg/L of copper ."
],
"offsets": [
[
581,
613
]
],
"normalized": []
},
{
"id": "77415",
"type": "Outcome_Physical",
"text": [
"Zinc and copper balances"
],
"offsets": [
[
0,
24
]
],
"normalized": []
},
{
"id": "77416",
"type": "Outcome_Physical",
"text": [
"in utero accretion rate for zinc and copper"
],
"offsets": [
[
422,
465
]
],
"normalized": []
},
{
"id": "77417",
"type": "Outcome_Physical",
"text": [
"positive zinc balance"
],
"offsets": [
[
771,
792
]
],
"normalized": []
},
{
"id": "77418",
"type": "Outcome_Physical",
"text": [
"in utero accretion rate for zinc"
],
"offsets": [
[
422,
454
]
],
"normalized": []
},
{
"id": "77419",
"type": "Outcome_Physical",
"text": [
"positive copper balance"
],
"offsets": [
[
1026,
1049
]
],
"normalized": []
},
{
"id": "77420",
"type": "Outcome_Physical",
"text": [
"positive zinc balance and zinc retention"
],
"offsets": [
[
1225,
1265
]
],
"normalized": []
},
{
"id": "77421",
"type": "Participant_Condition",
"text": [
"preterm"
],
"offsets": [
[
28,
35
]
],
"normalized": []
},
{
"id": "77422",
"type": "Participant_Age",
"text": [
"infants"
],
"offsets": [
[
36,
43
]
],
"normalized": []
},
{
"id": "77423",
"type": "Participant_Age",
"text": [
"infants"
],
"offsets": [
[
36,
43
]
],
"normalized": []
},
{
"id": "77424",
"type": "Participant_Condition",
"text": [
"preterm"
],
"offsets": [
[
28,
35
]
],
"normalized": []
},
{
"id": "77425",
"type": "Participant_Age",
"text": [
"infant"
],
"offsets": [
[
36,
42
]
],
"normalized": []
},
{
"id": "77426",
"type": "Participant_Sample-size",
"text": [
"five"
],
"offsets": [
[
504,
508
]
],
"normalized": []
}
] | [] | [] | [] |
77427 | 396063 | [
{
"id": "77428",
"type": "document",
"text": [
"Haemodynamic profile of angiotensin II antagonism in essential hypertensive patients . 1 . The haemodynamic response to antagonistic ( 10 microgram min-1 kg-1 ) and agonistic ( 40 microgram min-1 kg-1 ) doses of saralasin was studied in young essential hypertensive patients . Blood pressure behaviour alone was thought to be inadequate to describe the response pattern . 2 . Pre-saralasin setting of the renin-angiotensin axis was varied with salt intake ( 15 and 290 mmol of Na+/day ) each for 10 days . This failed to influence blood pressure or plasma volume . 3 . Antagonist blockade after low salt lowered blood pressure in three patients with the highest plasma renin values . Cardiac output rose in two of these , but it dropped in all others . 4 . Decreases in cardiac output occurred with both doses of saralasin and even with suppression of the renin-angiotensin axis . This response is therefore unlikely to be due to removal of myocardial or venous angiotensin effects . 5 . The renin-angiotensin system played a part in maintenance of blood pressure only with severe salt restriction and in a small proportion of cases . 6 . No heart rate effect was seen with sarcalasin . 7 . Blood pressure and total peripheral resistance responses were dependent on pre- ( antagonist/agonist ) setting , but heart rate and cardiac output were not influenced by this factor ."
],
"offsets": [
[
0,
1374
]
]
}
] | [
{
"id": "77429",
"type": "Intervention_Pharmacological",
"text": [
"angiotensin II antagonism"
],
"offsets": [
[
24,
49
]
],
"normalized": []
},
{
"id": "77430",
"type": "Intervention_Pharmacological",
"text": [
"antagonistic"
],
"offsets": [
[
120,
132
]
],
"normalized": []
},
{
"id": "77431",
"type": "Intervention_Pharmacological",
"text": [
"agonistic"
],
"offsets": [
[
123,
132
]
],
"normalized": []
},
{
"id": "77432",
"type": "Intervention_Pharmacological",
"text": [
"saralasin"
],
"offsets": [
[
212,
221
]
],
"normalized": []
},
{
"id": "77433",
"type": "Intervention_Pharmacological",
"text": [
"renin-angiotensin axis"
],
"offsets": [
[
405,
427
]
],
"normalized": []
},
{
"id": "77434",
"type": "Outcome_Physical",
"text": [
"Blood pressure behaviour"
],
"offsets": [
[
277,
301
]
],
"normalized": []
},
{
"id": "77435",
"type": "Outcome_Physical",
"text": [
"blood pressure or plasma volume ."
],
"offsets": [
[
531,
564
]
],
"normalized": []
},
{
"id": "77436",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
531,
545
]
],
"normalized": []
},
{
"id": "77437",
"type": "Outcome_Physical",
"text": [
"Cardiac output"
],
"offsets": [
[
684,
698
]
],
"normalized": []
},
{
"id": "77438",
"type": "Outcome_Physical",
"text": [
"cardiac output"
],
"offsets": [
[
770,
784
]
],
"normalized": []
},
{
"id": "77439",
"type": "Outcome_Physical",
"text": [
"myocardial or venous angiotensin effects ."
],
"offsets": [
[
941,
983
]
],
"normalized": []
},
{
"id": "77440",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
531,
545
]
],
"normalized": []
},
{
"id": "77441",
"type": "Outcome_Physical",
"text": [
"heart rate effect"
],
"offsets": [
[
1142,
1159
]
],
"normalized": []
},
{
"id": "77442",
"type": "Outcome_Physical",
"text": [
"Blood pressure and total peripheral resistance responses"
],
"offsets": [
[
1191,
1247
]
],
"normalized": []
},
{
"id": "77443",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
1142,
1152
]
],
"normalized": []
},
{
"id": "77444",
"type": "Outcome_Physical",
"text": [
"cardiac output"
],
"offsets": [
[
770,
784
]
],
"normalized": []
}
] | [] | [] | [] |
77445 | 396086 | [
{
"id": "77446",
"type": "document",
"text": [
"Effect of increasing doses of labetalol on blood pressure , plasma renin activity and aldosterone in hypertensive patients . 1 . Four different doses of labetalol ( 150 , 300 , 600 and 900 mg/day ) were given for 1 week to each of four groups of patients with essential hypertension ( six patients for each group ) . 2 . Labetalol decreased mean blood pressure and heart rate to the same extent on the first and the seventh days of treatment . Only standing blood pressure showed a dose-dependent inhibition both in the supine and upright position . 3 . Labetalol exerted a net inhibitory effect on plasma renin activity , which was related to basal renin values and was already maximal at the lowest doses . This effect was well maintained in the supine position . This effect was well maintained in the supine position , although during standing it tended to be less evident with increasing doses . 4 . Urinary aldosterone was decreased in a dose-dependent fashion and its changes were largely independent fashion and its changes were largely independent of plasma renin activity . 5 . Neither basal values nor changes of renin and aldosterone were related to the hypotensive effect of labetalol . 6 . During labetalol treatment urinary sodium excretion fell for 2-3 days and then returned to basal values . The retentive effect of labetalol on sodium was directly related to the decrease of blood pressure , and the successive sodium escape might be explained either by the observed increase of plasma volume ( indirectly measured by packed cell volume ) or by aldosterone inhibition ."
],
"offsets": [
[
0,
1588
]
]
}
] | [
{
"id": "77447",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
30,
39
]
],
"normalized": []
},
{
"id": "77448",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
30,
39
]
],
"normalized": []
},
{
"id": "77449",
"type": "Intervention_Pharmacological",
"text": [
"Labetalol"
],
"offsets": [
[
321,
330
]
],
"normalized": []
},
{
"id": "77450",
"type": "Intervention_Pharmacological",
"text": [
"Labetalol"
],
"offsets": [
[
321,
330
]
],
"normalized": []
},
{
"id": "77451",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
30,
39
]
],
"normalized": []
},
{
"id": "77452",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
30,
39
]
],
"normalized": []
},
{
"id": "77453",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
43,
57
]
],
"normalized": []
},
{
"id": "77454",
"type": "Outcome_Physical",
"text": [
"plasma renin activity"
],
"offsets": [
[
60,
81
]
],
"normalized": []
},
{
"id": "77455",
"type": "Outcome_Physical",
"text": [
"aldosterone"
],
"offsets": [
[
86,
97
]
],
"normalized": []
},
{
"id": "77456",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
43,
57
]
],
"normalized": []
},
{
"id": "77457",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
365,
375
]
],
"normalized": []
},
{
"id": "77458",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
43,
57
]
],
"normalized": []
},
{
"id": "77459",
"type": "Outcome_Physical",
"text": [
"plasma renin activity"
],
"offsets": [
[
60,
81
]
],
"normalized": []
},
{
"id": "77460",
"type": "Outcome_Physical",
"text": [
"Urinary aldosterone"
],
"offsets": [
[
905,
924
]
],
"normalized": []
},
{
"id": "77461",
"type": "Outcome_Physical",
"text": [
"basal values nor changes of renin"
],
"offsets": [
[
1096,
1129
]
],
"normalized": []
},
{
"id": "77462",
"type": "Outcome_Physical",
"text": [
"aldosterone"
],
"offsets": [
[
86,
97
]
],
"normalized": []
},
{
"id": "77463",
"type": "Outcome_Physical",
"text": [
"urinary sodium excretion fell"
],
"offsets": [
[
1231,
1260
]
],
"normalized": []
},
{
"id": "77464",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
43,
57
]
],
"normalized": []
},
{
"id": "77465",
"type": "Outcome_Physical",
"text": [
"successive sodium escape"
],
"offsets": [
[
1419,
1443
]
],
"normalized": []
},
{
"id": "77466",
"type": "Participant_Condition",
"text": [
"hypertensive"
],
"offsets": [
[
101,
113
]
],
"normalized": []
},
{
"id": "77467",
"type": "Participant_Condition",
"text": [
"essential hypertension"
],
"offsets": [
[
260,
282
]
],
"normalized": []
},
{
"id": "77468",
"type": "Participant_Sample-size",
"text": [
"six"
],
"offsets": [
[
285,
288
]
],
"normalized": []
}
] | [] | [] | [] |
77469 | 3962622 | [
{
"id": "77470",
"type": "document",
"text": [
"The effect of polyvinylpyrrolidone-iodine as an disinfectant in eye surgery . 105 patients admitted for cataract surgery were treated pre-operatively with polyvinylpyrrolidone-iodine ( PVP-I ) as a disinfectant , and consecutive bacterial cultures were obtained before initiating surgery and at the end of the operation . A control group ( n = 99 ) only had a standard disinfection procedure of the eye ( including instillation of Terramycin cum polymyxin B cream in the conjunctival sac the evening before surgery ) . The cultures obtained from the conjunctival sac of the control group principally showed growth of Staph . albus and Staph . aureus , and to a minor degree diphtheroids ( Corynebacterium species ) . Proteus mirabilis , Escherichia coli and micrococci . There was a significant quantitative diminished growth ( P less than 0.05 ) of bacteria in the group of patients treated with PVP-I compared to the control group . Concerning the growth of Staph . albus , this was reduced to almost one third and other bacteria were almost eliminated in the group receiving PVP-I . As we disclosed no toxic or allergic reaction post-operatively which could be related to the use of PVP-I as a disinfectant , this agent seems to constitute an effective pre-operative antimicrobial treatment , taking into consideration the broad antimicrobial spectrum of PVP-I shown by other authors ."
],
"offsets": [
[
0,
1388
]
]
}
] | [
{
"id": "77471",
"type": "Intervention_Pharmacological",
"text": [
"polyvinylpyrrolidone-iodine"
],
"offsets": [
[
14,
41
]
],
"normalized": []
},
{
"id": "77472",
"type": "Intervention_Pharmacological",
"text": [
"polyvinylpyrrolidone-iodine ( PVP-I )"
],
"offsets": [
[
155,
192
]
],
"normalized": []
},
{
"id": "77473",
"type": "Intervention_Control",
"text": [
"standard disinfection procedure"
],
"offsets": [
[
360,
391
]
],
"normalized": []
},
{
"id": "77474",
"type": "Intervention_Pharmacological",
"text": [
"Terramycin cum polymyxin B cream"
],
"offsets": [
[
431,
463
]
],
"normalized": []
},
{
"id": "77475",
"type": "Intervention_Pharmacological",
"text": [
"PVP-I"
],
"offsets": [
[
185,
190
]
],
"normalized": []
},
{
"id": "77476",
"type": "Intervention_Pharmacological",
"text": [
"PVP-I"
],
"offsets": [
[
185,
190
]
],
"normalized": []
},
{
"id": "77477",
"type": "Intervention_Pharmacological",
"text": [
"PVP-I"
],
"offsets": [
[
185,
190
]
],
"normalized": []
},
{
"id": "77478",
"type": "Intervention_Pharmacological",
"text": [
"PVP-I"
],
"offsets": [
[
185,
190
]
],
"normalized": []
},
{
"id": "77479",
"type": "Outcome_Physical",
"text": [
"disinfectant"
],
"offsets": [
[
48,
60
]
],
"normalized": []
},
{
"id": "77480",
"type": "Outcome_Physical",
"text": [
"standard disinfection"
],
"offsets": [
[
360,
381
]
],
"normalized": []
},
{
"id": "77481",
"type": "Outcome_Other",
"text": [
"significant quantitative diminished growth"
],
"offsets": [
[
783,
825
]
],
"normalized": []
},
{
"id": "77482",
"type": "Outcome_Adverse-effects",
"text": [
"toxic or allergic reaction post-operatively"
],
"offsets": [
[
1105,
1148
]
],
"normalized": []
},
{
"id": "77483",
"type": "Outcome_Other",
"text": [
"effective"
],
"offsets": [
[
1246,
1255
]
],
"normalized": []
},
{
"id": "77484",
"type": "Participant_Sample-size",
"text": [
"105"
],
"offsets": [
[
78,
81
]
],
"normalized": []
},
{
"id": "77485",
"type": "Participant_Condition",
"text": [
"cataract"
],
"offsets": [
[
104,
112
]
],
"normalized": []
},
{
"id": "77486",
"type": "Participant_Sample-size",
"text": [
"99"
],
"offsets": [
[
344,
346
]
],
"normalized": []
}
] | [] | [] | [] |
77487 | 3963358 | [
{
"id": "77488",
"type": "document",
"text": [
"[ Aortofemoral bifurcation bypass . Effect of the anesthesia procedure ( NLA , thoracic continuous catheter peridural anesthesia ) on circulation , respiration and metabolism . Homeostasis and oxygen transport ] . 50 patients were investigated during induction of anaesthesia and infrarenal aortic bypass surgery . 26 were operated on under neuroleptanaesthesia ( NA group ) and 24 under continuous epidural combined with a light general anaesthesia ( epidural group ) . Blood losses were replaced with 5 per cent human albumin , red cell concentrates , and fresh frozen plasma . Ringer lactate solution was used to replace the functional extracellular fluid volume . During induction and maintenance of anaesthesia body temperature fell ( NA group from 36.7 to 35.3 degrees C ; epidural group from 36.7 to 34.9 degrees C ) but no statistically significant difference could be found between the groups , in spite of better surface perfusion of the lower part of the body in the epidural group . The increase of plasma glucose concentration was lower in the epidural group as compared to the NA group . Stress mediated hypokalaemia was of the same degree in both groups , the median values of the plasma potassium concentrations being in the lower reference range ( 3.5-3.7 mmol X 1 ( -1 ] , although large amounts of red cell concentrates were given . During clamping of the aorta a moderate compensated acidosis developed in both groups . Declamping caused a more marked increase of paCO2 and a greater fall of pH in the NA group as compared to the epidural group . Induction of anaesthesia was followed by a fall in oxygen uptake ( NA group from 221 to 163 ml X min-1 ; epidural group from 230 to 189 ml X min-1 ) which appears to be delayed in the epidural group , with a short lasting statistically significant difference between the groups after eventration of the gut ( NA group : 162 ml X min-1 less than epidural group 184 ml X min-1 ) . Later on , oxygen uptake was equal in both groups , with no further changes due to clamping or declamping of the aorta . At the end of the operation , when nitrous oxide had been turned of , the oxygen uptake increased considerably in several patients , despite continuing artificial ventilation and intravenous hypnotics and analgesics having been given . Eventration and exterioration of the gut caused the most marked changes in haemodynamics and oxygen transport with significant differences between the groups . Immediately after eventration there was a sudden fall in paO2 in both groups ( NA group from 99 to 83 mm Hg ; epidural group from 96 to 84 mm Hg ) and an increase of the calculated intrapulmonary right-to-left-shunt ( NA group from 7 to 21 % ; epidural group from 10 to 19 % ) . ( ABSTRACT TRUNCATED AT 400 WORDS )"
],
"offsets": [
[
0,
2777
]
]
}
] | [
{
"id": "77489",
"type": "Intervention_Surgical",
"text": [
"Aortofemoral bifurcation bypass"
],
"offsets": [
[
2,
33
]
],
"normalized": []
},
{
"id": "77490",
"type": "Intervention_Physical",
"text": [
"NLA , thoracic continuous catheter peridural anesthesia"
],
"offsets": [
[
73,
128
]
],
"normalized": []
},
{
"id": "77491",
"type": "Intervention_Surgical",
"text": [
"infrarenal aortic bypass surgery"
],
"offsets": [
[
280,
312
]
],
"normalized": []
},
{
"id": "77492",
"type": "Intervention_Physical",
"text": [
"neuroleptanaesthesia ( NA group )"
],
"offsets": [
[
341,
374
]
],
"normalized": []
},
{
"id": "77493",
"type": "Intervention_Physical",
"text": [
"continuous epidural combined with a light general anaesthesia ( epidural group )"
],
"offsets": [
[
388,
468
]
],
"normalized": []
},
{
"id": "77494",
"type": "Intervention_Pharmacological",
"text": [
"Ringer lactate solution"
],
"offsets": [
[
580,
603
]
],
"normalized": []
},
{
"id": "77495",
"type": "Outcome_Physical",
"text": [
"surface perfusion"
],
"offsets": [
[
923,
940
]
],
"normalized": []
},
{
"id": "77496",
"type": "Outcome_Physical",
"text": [
"plasma glucose concentration"
],
"offsets": [
[
1011,
1039
]
],
"normalized": []
},
{
"id": "77497",
"type": "Outcome_Physical",
"text": [
"Stress mediated hypokalaemia"
],
"offsets": [
[
1102,
1130
]
],
"normalized": []
},
{
"id": "77498",
"type": "Outcome_Physical",
"text": [
"median values of the plasma potassium concentrations"
],
"offsets": [
[
1175,
1227
]
],
"normalized": []
},
{
"id": "77499",
"type": "Outcome_Physical",
"text": [
"moderate compensated acidosis"
],
"offsets": [
[
1383,
1412
]
],
"normalized": []
},
{
"id": "77500",
"type": "Outcome_Physical",
"text": [
"marked increase of paCO2"
],
"offsets": [
[
1465,
1489
]
],
"normalized": []
},
{
"id": "77501",
"type": "Outcome_Physical",
"text": [
"greater fall of pH"
],
"offsets": [
[
1496,
1514
]
],
"normalized": []
},
{
"id": "77502",
"type": "Outcome_Physical",
"text": [
"fall in oxygen uptake"
],
"offsets": [
[
1610,
1631
]
],
"normalized": []
},
{
"id": "77503",
"type": "Outcome_Physical",
"text": [
"oxygen uptake"
],
"offsets": [
[
1618,
1631
]
],
"normalized": []
},
{
"id": "77504",
"type": "Outcome_Physical",
"text": [
"oxygen uptake"
],
"offsets": [
[
1618,
1631
]
],
"normalized": []
},
{
"id": "77505",
"type": "Participant_Sample-size",
"text": [
"50"
],
"offsets": [
[
214,
216
]
],
"normalized": []
},
{
"id": "77506",
"type": "Participant_Condition",
"text": [
"anaesthesia"
],
"offsets": [
[
264,
275
]
],
"normalized": []
},
{
"id": "77507",
"type": "Participant_Condition",
"text": [
"infrarenal aortic bypass surgery"
],
"offsets": [
[
280,
312
]
],
"normalized": []
},
{
"id": "77508",
"type": "Participant_Sample-size",
"text": [
"26"
],
"offsets": [
[
315,
317
]
],
"normalized": []
},
{
"id": "77509",
"type": "Participant_Condition",
"text": [
"neuroleptanaesthesia"
],
"offsets": [
[
341,
361
]
],
"normalized": []
},
{
"id": "77510",
"type": "Participant_Sample-size",
"text": [
"24"
],
"offsets": [
[
379,
381
]
],
"normalized": []
},
{
"id": "77511",
"type": "Participant_Condition",
"text": [
"light general anaesthesia"
],
"offsets": [
[
424,
449
]
],
"normalized": []
}
] | [] | [] | [] |
77512 | 3976757 | [
{
"id": "77513",
"type": "document",
"text": [
"Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate . Eighty pregnant women at high risk of giving birth prematurely were divided randomly into two groups . Treatment with either 17 alpha-hydroxyprogesterone caproate , 250 mg by intramuscular injection once a week , or a placebo was given in a double-blind fashion . Imminent premature labor occurred in 29.0 % of the treated group and in 59.4 % of the control group ( p less than 0.025 ) . The rate of premature deliveries was also significantly lower in the treated group ( 16.1 % ) than in the control group ( 37.82 % ) ( p less than 0.05 ) . There were no cases of perinatal death or fetal malformations in either group . The mean birth weight of all infants of the treated group was significantly higher than in those of the control group ( 3111.9 +/- 905 gm versus 2680 +/- 813.4 gm , p less than 0.05 ) . The results support treatment with progesterone caproate for the prevention of premature labor ."
],
"offsets": [
[
0,
978
]
]
}
] | [
{
"id": "77514",
"type": "Intervention_Pharmacological",
"text": [
"17 alpha-hydroxyprogesterone caproate"
],
"offsets": [
[
33,
70
]
],
"normalized": []
},
{
"id": "77515",
"type": "Intervention_Pharmacological",
"text": [
"17 alpha-hydroxyprogesterone caproate"
],
"offsets": [
[
33,
70
]
],
"normalized": []
},
{
"id": "77516",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
291,
298
]
],
"normalized": []
},
{
"id": "77517",
"type": "Intervention_Control",
"text": [
"control"
],
"offsets": [
[
423,
430
]
],
"normalized": []
},
{
"id": "77518",
"type": "Intervention_Pharmacological",
"text": [
"progesterone caproate"
],
"offsets": [
[
49,
70
]
],
"normalized": []
},
{
"id": "77519",
"type": "Outcome_Physical",
"text": [
"rate of premature deliveries"
],
"offsets": [
[
465,
493
]
],
"normalized": []
},
{
"id": "77520",
"type": "Outcome_Mortality",
"text": [
"perinatal death"
],
"offsets": [
[
639,
654
]
],
"normalized": []
},
{
"id": "77521",
"type": "Outcome_Adverse-effects",
"text": [
"fetal malformations"
],
"offsets": [
[
658,
677
]
],
"normalized": []
},
{
"id": "77522",
"type": "Outcome_Physical",
"text": [
"mean birth weight"
],
"offsets": [
[
700,
717
]
],
"normalized": []
},
{
"id": "77523",
"type": "Participant_Sample-size",
"text": [
"Eighty"
],
"offsets": [
[
73,
79
]
],
"normalized": []
},
{
"id": "77524",
"type": "Participant_Condition",
"text": [
"pregnant women"
],
"offsets": [
[
80,
94
]
],
"normalized": []
},
{
"id": "77525",
"type": "Participant_Condition",
"text": [
"high risk of giving birth prematurely"
],
"offsets": [
[
98,
135
]
],
"normalized": []
}
] | [] | [] | [] |
77526 | 3998250 | [
{
"id": "77527",
"type": "document",
"text": [
"Psychophysiological outcome of behavioral and pharmacological treatments of agoraphobia ."
],
"offsets": [
[
0,
89
]
]
}
] | [
{
"id": "77528",
"type": "Intervention_Educational",
"text": [
"behavioral"
],
"offsets": [
[
31,
41
]
],
"normalized": []
},
{
"id": "77529",
"type": "Intervention_Pharmacological",
"text": [
"pharmacological treatments"
],
"offsets": [
[
46,
72
]
],
"normalized": []
},
{
"id": "77530",
"type": "Outcome_Mental",
"text": [
"Psychophysiological"
],
"offsets": [
[
0,
19
]
],
"normalized": []
},
{
"id": "77531",
"type": "Participant_Condition",
"text": [
"agoraphobia ."
],
"offsets": [
[
76,
89
]
],
"normalized": []
}
] | [] | [] | [] |
77532 | 4004503 | [
{
"id": "77533",
"type": "document",
"text": [
"Therapist success and its determinants . This study examined the relatively unexplored contribution of the therapist 's performance in determining outcomes of treatment . Nine therapists were studied : three performed supportive-expressive psychotherapy ; three , cognitive-behavioral psychotherapy ; and three , drug counseling . Profound differences were discovered in the therapists ' success with the patients in their case loads . Four potential determinants of these differences were explored : patient factors ; therapist factors ; patient-therapist relationship factors ; and therapy factors . Results showed that patient characteristics within each case load ( after random assignments ) were similar and disclosed no differences that would have explained the differences in success ; therapist 's personal qualities were correlated with outcomes but not significantly ( mean r = .32 ) ; an early-in-treatment measure of the patient-therapist relationship , the Helping Alliance Questionnaire , yielded significant correlations with outcomes ( mean r = .65 ) ; among the therapy techniques , \" purity \" provided significant correlations with outcomes ( mean r = .44 ) , both across therapists and within each therapist 's case load . The three therapist-related factors were moderately associated with each other ."
],
"offsets": [
[
0,
1323
]
]
}
] | [
{
"id": "77534",
"type": "Intervention_Psychological",
"text": [
"studied : three performed supportive-expressive psychotherapy ; three , cognitive-behavioral psychotherapy ; and three , drug counseling ."
],
"offsets": [
[
192,
330
]
],
"normalized": []
},
{
"id": "77535",
"type": "Outcome_Other",
"text": [
"Therapist success"
],
"offsets": [
[
0,
17
]
],
"normalized": []
},
{
"id": "77536",
"type": "Outcome_Other",
"text": [
"therapist 's performance"
],
"offsets": [
[
107,
131
]
],
"normalized": []
},
{
"id": "77537",
"type": "Outcome_Other",
"text": [
"patient factors ; therapist factors"
],
"offsets": [
[
501,
536
]
],
"normalized": []
},
{
"id": "77538",
"type": "Outcome_Mental",
"text": [
"patient-therapist relationship factors"
],
"offsets": [
[
539,
577
]
],
"normalized": []
},
{
"id": "77539",
"type": "Outcome_Other",
"text": [
"therapy factors"
],
"offsets": [
[
584,
599
]
],
"normalized": []
},
{
"id": "77540",
"type": "Outcome_Other",
"text": [
"therapist 's personal qualities"
],
"offsets": [
[
794,
825
]
],
"normalized": []
},
{
"id": "77541",
"type": "Outcome_Mental",
"text": [
"patient-therapist relationship , the Helping Alliance Questionnaire"
],
"offsets": [
[
934,
1001
]
],
"normalized": []
},
{
"id": "77542",
"type": "Outcome_Other",
"text": [
"purity"
],
"offsets": [
[
1103,
1109
]
],
"normalized": []
}
] | [] | [] | [] |
77543 | 4016785 | [
{
"id": "77544",
"type": "document",
"text": [
"Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon . It is unclear from preliminary laboratory studies whether a high- or a low-dose interferon treatment strategy is optimal . As part of an ongoing study of mechanisms of interferon action , we have evaluated toxicity in a two-arm protocol in which patients were randomly assigned to receive lymphoblastoid interferon by either a low-dose treatment strategy ( 2 X 10 ( 6 ) units/m2 daily X 28 days then daily X 5 days every other week by im injection ) or a high-dose treatment strategy ( 5 X 10 ( 6 ) units/m2 by continuous iv infusion over 24 hours , escalating by 5 X 10 ( 6 ) units/m2/day as tolerated over 10 days , repeated every 28 days ) . The main toxic effects in both arms were fever , fatigue , and anorexia . Marked interpatient differences within each dose arm were greater than differences between arms . Additional significant toxic effects included nausea and vomiting , hypotension , leukopenia , thrombocytopenia , and evidence of hepatic toxicity . Minor changes in serum electrolytes were noted . Coagulation studies were normal . The dose-limiting toxic effect for the high-dose arm was myelosuppression . Median maximum tolerated dose among high-dose strategy patients was 18 X 10 ( 6 ) units/m2 , but there was marked interpatient variation . We conclude that both dose schedules were relatively well-tolerated . Because of individual variation in tolerance , high-dose treatment should include a dose escalation strategy ."
],
"offsets": [
[
0,
1566
]
]
}
] | [
{
"id": "77545",
"type": "Intervention_Pharmacological",
"text": [
"lymphoblastoid interferon ."
],
"offsets": [
[
94,
121
]
],
"normalized": []
},
{
"id": "77546",
"type": "Intervention_Pharmacological",
"text": [
"high- or a low-dose interferon"
],
"offsets": [
[
182,
212
]
],
"normalized": []
},
{
"id": "77547",
"type": "Intervention_Pharmacological",
"text": [
"interferon"
],
"offsets": [
[
109,
119
]
],
"normalized": []
},
{
"id": "77548",
"type": "Intervention_Pharmacological",
"text": [
"lymphoblastoid interferon"
],
"offsets": [
[
94,
119
]
],
"normalized": []
},
{
"id": "77549",
"type": "Outcome_Adverse-effects",
"text": [
"toxicity"
],
"offsets": [
[
25,
33
]
],
"normalized": []
},
{
"id": "77550",
"type": "Outcome_Adverse-effects",
"text": [
"toxicity"
],
"offsets": [
[
25,
33
]
],
"normalized": []
},
{
"id": "77551",
"type": "Outcome_Adverse-effects",
"text": [
"main toxic effects"
],
"offsets": [
[
771,
789
]
],
"normalized": []
},
{
"id": "77552",
"type": "Outcome_Adverse-effects",
"text": [
"fever , fatigue , and anorexia ."
],
"offsets": [
[
808,
840
]
],
"normalized": []
},
{
"id": "77553",
"type": "Outcome_Adverse-effects",
"text": [
"significant toxic effects included nausea and vomiting , hypotension , leukopenia , thrombocytopenia , and evidence of hepatic toxicity"
],
"offsets": [
[
950,
1085
]
],
"normalized": []
},
{
"id": "77554",
"type": "Outcome_Adverse-effects",
"text": [
"changes in serum electrolytes"
],
"offsets": [
[
1094,
1123
]
],
"normalized": []
},
{
"id": "77555",
"type": "Outcome_Physical",
"text": [
"Coagulation studies"
],
"offsets": [
[
1137,
1156
]
],
"normalized": []
},
{
"id": "77556",
"type": "Outcome_Adverse-effects",
"text": [
"toxic effect"
],
"offsets": [
[
776,
788
]
],
"normalized": []
},
{
"id": "77557",
"type": "Outcome_Adverse-effects",
"text": [
"myelosuppression"
],
"offsets": [
[
1228,
1244
]
],
"normalized": []
},
{
"id": "77558",
"type": "Outcome_Other",
"text": [
"maximum tolerated dose"
],
"offsets": [
[
1254,
1276
]
],
"normalized": []
},
{
"id": "77559",
"type": "Outcome_Other",
"text": [
"relatively well-tolerated ."
],
"offsets": [
[
1428,
1455
]
],
"normalized": []
},
{
"id": "77560",
"type": "Outcome_Other",
"text": [
"tolerance"
],
"offsets": [
[
1491,
1500
]
],
"normalized": []
},
{
"id": "77561",
"type": "Participant_Condition",
"text": [
"lymphoblastoid interferon"
],
"offsets": [
[
94,
119
]
],
"normalized": []
}
] | [] | [] | [] |
77562 | 4025245 | [
{
"id": "77563",
"type": "document",
"text": [
"Mass inoculation in a community : the effect of primary prevention of stress reactions . This study assessed the effectiveness of a brief , situation-specific , group-administered preparatory intervention in a nonclient school population undergoing mass inoculation against rubella . Fifty-one girls were randomly assigned to practice , no-practice , or control groups . Both the practice and the no-practice groups received information that described the inoculation procedure and how to cope with it by using cognitive-behavioral coping skills . The practice group was encouraged to perform coping techniques of this type , whereas the no-practice group was told only that the intervention would help them during the inoculation . Subjects in both practice and no-practice groups reported less anxiety and exhibited more cooperative behavior during inoculation than subjects in the control group , and those who were guided and prompted to actively practice derived greater benefit ."
],
"offsets": [
[
0,
985
]
]
}
] | [
{
"id": "77564",
"type": "Intervention_Physical",
"text": [
"mass inoculation against rubella"
],
"offsets": [
[
249,
281
]
],
"normalized": []
},
{
"id": "77565",
"type": "Intervention_Physical",
"text": [
"practice , no-practice , or"
],
"offsets": [
[
326,
353
]
],
"normalized": []
},
{
"id": "77566",
"type": "Intervention_Control",
"text": [
"control groups"
],
"offsets": [
[
354,
368
]
],
"normalized": []
},
{
"id": "77567",
"type": "Outcome_Mental",
"text": [
"stress reactions"
],
"offsets": [
[
70,
86
]
],
"normalized": []
},
{
"id": "77568",
"type": "Outcome_Mental",
"text": [
"anxiety"
],
"offsets": [
[
796,
803
]
],
"normalized": []
},
{
"id": "77569",
"type": "Outcome_Mental",
"text": [
"cooperative behavior"
],
"offsets": [
[
823,
843
]
],
"normalized": []
}
] | [] | [] | [] |
77570 | 4037540 | [
{
"id": "77571",
"type": "document",
"text": [
"Differential inhibition of bronchoconstriction by the calcium channel blockers , verapamil and nifedipine . Recent studies have demonstrated that the calcium channel blocking agents can inhibit experimentally induced bronchoconstriction in asthmatics , but their protective action has been variable . To clarify the influence of stimulus intensity and choice of calcium blocker on these reported differences in outcome , we performed noncumulative thermal stimulus-response curves using isocapnic hyperventilation of cold air in 8 asthmatics . Subjects received pretreatment with orally administered nifedipine ( 20 mg ) , intravenously administered verapamil ( 10 mg bolus followed by a continuous infusion ) , or appropriate placebos in a randomized , double-blind fashion . Verapamil afforded no consistent protection against the thermal challenges , whereas nifedipine significantly blunted the bronchoconstrictor response to stimuli of low ( p less than 0.02 ) and middle ( p less than 0.03 ) intensity . At the highest thermal burden , the effect of nifedipine was inconsistent and not significantly different from that of placebo . These results indicate that the protection from bronchoconstriction afforded by the calcium channel blockers depends on the choice of agent and the intensity of the bronchoconstricting stimulus , and they raise the possibility that the contribution of transmembrane calcium ion influx to the pathogenesis of bronchoconstriction may vary according to stimulus intensity ."
],
"offsets": [
[
0,
1509
]
]
}
] | [
{
"id": "77572",
"type": "Intervention_Pharmacological",
"text": [
"calcium channel blockers"
],
"offsets": [
[
54,
78
]
],
"normalized": []
},
{
"id": "77573",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
81,
90
]
],
"normalized": []
},
{
"id": "77574",
"type": "Intervention_Pharmacological",
"text": [
"nifedipine"
],
"offsets": [
[
95,
105
]
],
"normalized": []
},
{
"id": "77575",
"type": "Intervention_Physical",
"text": [
"calcium channel blocking agents"
],
"offsets": [
[
150,
181
]
],
"normalized": []
},
{
"id": "77576",
"type": "Intervention_Pharmacological",
"text": [
"nifedipine"
],
"offsets": [
[
95,
105
]
],
"normalized": []
},
{
"id": "77577",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
81,
90
]
],
"normalized": []
},
{
"id": "77578",
"type": "Intervention_Control",
"text": [
"placebos"
],
"offsets": [
[
727,
735
]
],
"normalized": []
},
{
"id": "77579",
"type": "Intervention_Pharmacological",
"text": [
"nifedipine"
],
"offsets": [
[
95,
105
]
],
"normalized": []
},
{
"id": "77580",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
727,
734
]
],
"normalized": []
},
{
"id": "77581",
"type": "Intervention_Physical",
"text": [
"calcium channel blockers"
],
"offsets": [
[
54,
78
]
],
"normalized": []
},
{
"id": "77582",
"type": "Outcome_Physical",
"text": [
"Differential inhibition of bronchoconstriction"
],
"offsets": [
[
0,
46
]
],
"normalized": []
},
{
"id": "77583",
"type": "Outcome_Physical",
"text": [
"experimentally induced bronchoconstriction"
],
"offsets": [
[
194,
236
]
],
"normalized": []
},
{
"id": "77584",
"type": "Outcome_Physical",
"text": [
"bronchoconstrictor response to stimuli of low"
],
"offsets": [
[
899,
944
]
],
"normalized": []
},
{
"id": "77585",
"type": "Outcome_Physical",
"text": [
"effect of nifedipine"
],
"offsets": [
[
1046,
1066
]
],
"normalized": []
},
{
"id": "77586",
"type": "Outcome_Physical",
"text": [
"protection from bronchoconstriction"
],
"offsets": [
[
1171,
1206
]
],
"normalized": []
},
{
"id": "77587",
"type": "Participant_Condition",
"text": [
"asthmatics"
],
"offsets": [
[
240,
250
]
],
"normalized": []
},
{
"id": "77588",
"type": "Participant_Sample-size",
"text": [
"8"
],
"offsets": [
[
529,
530
]
],
"normalized": []
},
{
"id": "77589",
"type": "Participant_Condition",
"text": [
"asthmatics"
],
"offsets": [
[
240,
250
]
],
"normalized": []
}
] | [] | [] | [] |
77590 | 404962 | [
{
"id": "77591",
"type": "document",
"text": [
"Comparative trial of carbenicillin and ampicillin therapy for purulent meningitis . A randomized therapeutic trial of carbenicillin ( CB ) or ampicillin ( AMP ) in purulent meningitis was performed in 86 pediatric and adult patients ( 41 Haemophilus influenzae , 22 Streptococcus pneumoniae , 13 Neisseria meningitidis , and 10 of unknown etiology ) . All isolates , incuding H. influenzae , were susceptible to CB and AMP . Median cerebrospinal fluid ( CSF ) antibiotic concentrations were 0.85 and 1.60 mug/ml for CB and AMP , respectively , during administration of daily doses of 400 mg/kg and 0.65 and 0.45 mug/ml , respectively , on daily doses of 200 mg/kg . Higher CSF concentrations , up to a median concentration of 4.5 mug/ml , were observed in patients with CSF protein concentrations > /=75 mg/100 ml . Clinical responses were equivalent on either antibiotic regimen . Among AMP patients ( 45 ) , 8 had significant residua and 3 died ; among CB patients ( 41 ) , 5 had residua and none died . However , 38 % of H. influenzae patients treated with CB had positive CSF cultures on day 1 follow-up lumbar punctures , compared with only 5.8 % of AMP patients with H. influenzae . The significance of a delay of CSF sterilization among CB-treated patients is unknown , since there was no correlation between persistence of hemophilus organisms and the frequency of adverse outcome . AMP and CB are equivalent for the treatment of bacterial meningitis due to susceptible organisms ."
],
"offsets": [
[
0,
1489
]
]
}
] | [
{
"id": "77592",
"type": "Intervention_Pharmacological",
"text": [
"carbenicillin"
],
"offsets": [
[
21,
34
]
],
"normalized": []
},
{
"id": "77593",
"type": "Intervention_Pharmacological",
"text": [
"ampicillin"
],
"offsets": [
[
39,
49
]
],
"normalized": []
},
{
"id": "77594",
"type": "Intervention_Pharmacological",
"text": [
"carbenicillin ( CB ) or ampicillin ( AMP )"
],
"offsets": [
[
118,
160
]
],
"normalized": []
},
{
"id": "77595",
"type": "Intervention_Pharmacological",
"text": [
"AMP"
],
"offsets": [
[
155,
158
]
],
"normalized": []
},
{
"id": "77596",
"type": "Intervention_Pharmacological",
"text": [
"CB"
],
"offsets": [
[
134,
136
]
],
"normalized": []
},
{
"id": "77597",
"type": "Intervention_Pharmacological",
"text": [
"CB"
],
"offsets": [
[
134,
136
]
],
"normalized": []
},
{
"id": "77598",
"type": "Intervention_Pharmacological",
"text": [
"AMP"
],
"offsets": [
[
155,
158
]
],
"normalized": []
},
{
"id": "77599",
"type": "Intervention_Pharmacological",
"text": [
"CB"
],
"offsets": [
[
134,
136
]
],
"normalized": []
},
{
"id": "77600",
"type": "Outcome_Physical",
"text": [
"cerebrospinal fluid ( CSF ) antibiotic concentrations"
],
"offsets": [
[
432,
485
]
],
"normalized": []
},
{
"id": "77601",
"type": "Outcome_Physical",
"text": [
"Higher CSF concentrations"
],
"offsets": [
[
666,
691
]
],
"normalized": []
},
{
"id": "77602",
"type": "Outcome_Physical",
"text": [
"Clinical responses"
],
"offsets": [
[
816,
834
]
],
"normalized": []
},
{
"id": "77603",
"type": "Outcome_Adverse-effects",
"text": [
"had significant residua"
],
"offsets": [
[
912,
935
]
],
"normalized": []
},
{
"id": "77604",
"type": "Outcome_Mortality",
"text": [
"died ;"
],
"offsets": [
[
942,
948
]
],
"normalized": []
},
{
"id": "77605",
"type": "Outcome_Physical",
"text": [
"positive CSF cultures"
],
"offsets": [
[
1067,
1088
]
],
"normalized": []
},
{
"id": "77606",
"type": "Outcome_Physical",
"text": [
"delay of CSF sterilization"
],
"offsets": [
[
1211,
1237
]
],
"normalized": []
},
{
"id": "77607",
"type": "Participant_Condition",
"text": [
"purulent meningitis"
],
"offsets": [
[
62,
81
]
],
"normalized": []
},
{
"id": "77608",
"type": "Participant_Sample-size",
"text": [
"86"
],
"offsets": [
[
201,
203
]
],
"normalized": []
},
{
"id": "77609",
"type": "Participant_Age",
"text": [
"pediatric"
],
"offsets": [
[
204,
213
]
],
"normalized": []
},
{
"id": "77610",
"type": "Participant_Age",
"text": [
"adult"
],
"offsets": [
[
218,
223
]
],
"normalized": []
},
{
"id": "77611",
"type": "Participant_Sample-size",
"text": [
"41 Haemophilus influenzae"
],
"offsets": [
[
235,
260
]
],
"normalized": []
},
{
"id": "77612",
"type": "Participant_Sample-size",
"text": [
"22 Streptococcus pneumoniae"
],
"offsets": [
[
263,
290
]
],
"normalized": []
},
{
"id": "77613",
"type": "Participant_Sample-size",
"text": [
"13 Neisseria meningitidis"
],
"offsets": [
[
293,
318
]
],
"normalized": []
},
{
"id": "77614",
"type": "Participant_Sample-size",
"text": [
"10"
],
"offsets": [
[
325,
327
]
],
"normalized": []
},
{
"id": "77615",
"type": "Participant_Condition",
"text": [
"influenzae"
],
"offsets": [
[
250,
260
]
],
"normalized": []
},
{
"id": "77616",
"type": "Participant_Condition",
"text": [
"influenzae"
],
"offsets": [
[
250,
260
]
],
"normalized": []
}
] | [] | [] | [] |
77617 | 4077545 | [
{
"id": "77618",
"type": "document",
"text": [
"A study of a Self-Care Rehabilitation Program in pediatric asthma . The Self-Care Rehabilitation in Pediatric Asthma ( SCRPA ) project was designed to ascertain the level to which children with asthma are able to acquire the asthma knowledge and skills presented in a self-management training program conducted by the American Lung Association of Utah and the effect of such training on the asthma experience . The preschool SCRPA Curriculum ( ages 2-5 ) consisted of six 1-hour classes scheduled twice a week for 3 weeks . The first and last classes were for one or both parents only , and the middle four sessions were for the child and parent ( s ) . The school-age SCRPA curriculum ( ages 6-14 ) consisted of eight 90-minute classes for both child and parent ( s ) scheduled twice a week for 4 weeks . Private physicians referred 21 preschool children and 38 school-age children into the program . The school-age children were randomly assigned to a study or control group , and the preschool children served as their own controls . A comparison of asthma episodes during the 3 months before and after training showed a statistically significant decrease in the number of episodes but no change in severity in the preschool , school study , and school control groups . The decrease in episodes for the control groups suggest that the family record keeping required of all subjects may have a beneficial effect , a phenomenon worth further investigation . Also , the school-age group , in pre- and posttesting , demonstrated that the SCRPA curriculum increased knowledge and skills in the study group , changes not found in the control group ."
],
"offsets": [
[
0,
1646
]
]
}
] | [
{
"id": "77619",
"type": "Intervention_Educational",
"text": [
"Self-Care Rehabilitation Program"
],
"offsets": [
[
13,
45
]
],
"normalized": []
},
{
"id": "77620",
"type": "Intervention_Educational",
"text": [
"Self-Care Rehabilitation"
],
"offsets": [
[
13,
37
]
],
"normalized": []
},
{
"id": "77621",
"type": "Intervention_Educational",
"text": [
"six 1-hour classes scheduled twice a week for 3 weeks"
],
"offsets": [
[
468,
521
]
],
"normalized": []
},
{
"id": "77622",
"type": "Intervention_Educational",
"text": [
"eight 90-minute classes for both child and parent ( s ) scheduled"
],
"offsets": [
[
713,
778
]
],
"normalized": []
},
{
"id": "77623",
"type": "Intervention_Educational",
"text": [
"SCRPA"
],
"offsets": [
[
119,
124
]
],
"normalized": []
},
{
"id": "77624",
"type": "Outcome_Mental",
"text": [
"decrease in the number of episodes"
],
"offsets": [
[
1150,
1184
]
],
"normalized": []
},
{
"id": "77625",
"type": "Outcome_Mental",
"text": [
"severity"
],
"offsets": [
[
1202,
1210
]
],
"normalized": []
},
{
"id": "77626",
"type": "Outcome_Mental",
"text": [
"episodes"
],
"offsets": [
[
1060,
1068
]
],
"normalized": []
},
{
"id": "77627",
"type": "Outcome_Mental",
"text": [
"knowledge and skills"
],
"offsets": [
[
232,
252
]
],
"normalized": []
},
{
"id": "77628",
"type": "Participant_Condition",
"text": [
"asthma"
],
"offsets": [
[
59,
65
]
],
"normalized": []
},
{
"id": "77629",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
180,
188
]
],
"normalized": []
},
{
"id": "77630",
"type": "Participant_Condition",
"text": [
"asthma"
],
"offsets": [
[
59,
65
]
],
"normalized": []
},
{
"id": "77631",
"type": "Participant_Condition",
"text": [
"asthma"
],
"offsets": [
[
59,
65
]
],
"normalized": []
},
{
"id": "77632",
"type": "Participant_Age",
"text": [
"preschool"
],
"offsets": [
[
415,
424
]
],
"normalized": []
},
{
"id": "77633",
"type": "Participant_Age",
"text": [
"( ages 2-5 )"
],
"offsets": [
[
442,
454
]
],
"normalized": []
},
{
"id": "77634",
"type": "Participant_Age",
"text": [
"parents"
],
"offsets": [
[
572,
579
]
],
"normalized": []
},
{
"id": "77635",
"type": "Participant_Age",
"text": [
"child and parent ( s )"
],
"offsets": [
[
629,
651
]
],
"normalized": []
},
{
"id": "77636",
"type": "Participant_Age",
"text": [
"ages 6-14"
],
"offsets": [
[
688,
697
]
],
"normalized": []
},
{
"id": "77637",
"type": "Participant_Age",
"text": [
"child and parent ( s )"
],
"offsets": [
[
629,
651
]
],
"normalized": []
},
{
"id": "77638",
"type": "Participant_Sample-size",
"text": [
"21"
],
"offsets": [
[
834,
836
]
],
"normalized": []
},
{
"id": "77639",
"type": "Participant_Age",
"text": [
"preschool children"
],
"offsets": [
[
837,
855
]
],
"normalized": []
},
{
"id": "77640",
"type": "Participant_Age",
"text": [
"38 school-age children"
],
"offsets": [
[
860,
882
]
],
"normalized": []
},
{
"id": "77641",
"type": "Participant_Age",
"text": [
"school-age children"
],
"offsets": [
[
863,
882
]
],
"normalized": []
},
{
"id": "77642",
"type": "Participant_Age",
"text": [
"preschool children"
],
"offsets": [
[
837,
855
]
],
"normalized": []
}
] | [] | [] | [] |
77643 | 4085165 | [
{
"id": "77644",
"type": "document",
"text": [
"Chronic lateral humeral epicondylitis -- a double-blind controlled assessment of pulsed electromagnetic field therapy . Pulsed electromagnetic fields ( PEMF ) have been shown to be beneficial in the treatment of rotator cuff tendinitis . As lateral humeral epicondylitis ( tennis elbow ) is a similar chronic tendon lesion , 30 patients with both clinical and thermographic evidence of tennis elbow were randomly allocated to receive either active or inactive PEMF therapy . Treatment was continued for a minimum period of eight weeks . At this time there was no statistical difference between the two groups ."
],
"offsets": [
[
0,
610
]
]
}
] | [
{
"id": "77645",
"type": "Intervention_Physical",
"text": [
"pulsed electromagnetic field therapy"
],
"offsets": [
[
81,
117
]
],
"normalized": []
},
{
"id": "77646",
"type": "Intervention_Physical",
"text": [
"Pulsed electromagnetic fields ( PEMF )"
],
"offsets": [
[
120,
158
]
],
"normalized": []
},
{
"id": "77647",
"type": "Intervention_Physical",
"text": [
"randomly allocated to receive either active"
],
"offsets": [
[
404,
447
]
],
"normalized": []
},
{
"id": "77648",
"type": "Intervention_Control",
"text": [
"inactive"
],
"offsets": [
[
451,
459
]
],
"normalized": []
},
{
"id": "77649",
"type": "Intervention_Physical",
"text": [
"PEMF therapy"
],
"offsets": [
[
460,
472
]
],
"normalized": []
},
{
"id": "77650",
"type": "Outcome_Other",
"text": [
"no statistical difference"
],
"offsets": [
[
560,
585
]
],
"normalized": []
}
] | [] | [] | [] |
77651 | 4101734 | [
{
"id": "77652",
"type": "document",
"text": [
"Fluorouracil as an adjuvant to surgery in carcinoma of the colon ."
],
"offsets": [
[
0,
66
]
]
}
] | [
{
"id": "77653",
"type": "Intervention_Pharmacological",
"text": [
"Fluorouracil"
],
"offsets": [
[
0,
12
]
],
"normalized": []
},
{
"id": "77654",
"type": "Intervention_Surgical",
"text": [
"surgery"
],
"offsets": [
[
31,
38
]
],
"normalized": []
},
{
"id": "77655",
"type": "Participant_Condition",
"text": [
"carcinoma of the colon"
],
"offsets": [
[
42,
64
]
],
"normalized": []
}
] | [] | [] | [] |
77656 | 4127641 | [
{
"id": "77657",
"type": "document",
"text": [
"Comparison of the potassium- retaining effects of amiloride and spironolactone in hypertensive patients with thiazide-induced hypokalaemia ."
],
"offsets": [
[
0,
140
]
]
}
] | [
{
"id": "77658",
"type": "Intervention_Pharmacological",
"text": [
"amiloride and spironolactone"
],
"offsets": [
[
50,
78
]
],
"normalized": []
},
{
"id": "77659",
"type": "Outcome_Physical",
"text": [
"potassium- retaining effects"
],
"offsets": [
[
18,
46
]
],
"normalized": []
},
{
"id": "77660",
"type": "Participant_Condition",
"text": [
"hypertensive"
],
"offsets": [
[
82,
94
]
],
"normalized": []
},
{
"id": "77661",
"type": "Participant_Condition",
"text": [
"thiazide-induced hypokalaemia"
],
"offsets": [
[
109,
138
]
],
"normalized": []
}
] | [] | [] | [] |
77662 | 4154124 | [
{
"id": "77663",
"type": "document",
"text": [
"Bites by the saw-scaled or carpet viper ( Echis carinatus ) : trial of two specific antivenoms . Echis carinatus is the most important cause of morbidity and mortality from snake bite in Nigeria and in many other parts of the world . Forty-six patients with systemic poisoning by this snake were given echis antivenom made either by the South African Institute for Medical Research ( S.A.I.M.R . ) or by Behringwerke ( North and West African polyvalent antivenom ) . A simple test of blood coagulability was used to assess whether an adequate neutralizing dose of antivenom had been given . An average of 15.2 ml S.A.I.M.R . antivenom restored normal coagulability permanently in all 23 patients in one group , but in the other group receiving an average dose of 37.9 ml Behringwerke antivenom normal clotting resulted in only 18 out of 23 patients . Local tissue swelling was similar in both groups , but local necrosis occurred in three patients treated with Behringwerke antivenom and in none given S.A.I.M.R . antivenom ."
],
"offsets": [
[
0,
1025
]
]
}
] | [
{
"id": "77664",
"type": "Intervention_Pharmacological",
"text": [
"echis antivenom made either by the South African Institute for Medical Research ( S.A.I.M.R . )"
],
"offsets": [
[
302,
397
]
],
"normalized": []
},
{
"id": "77665",
"type": "Intervention_Pharmacological",
"text": [
"S.A.I.M.R ."
],
"offsets": [
[
384,
395
]
],
"normalized": []
},
{
"id": "77666",
"type": "Intervention_Pharmacological",
"text": [
"Behringwerke antivenom"
],
"offsets": [
[
771,
793
]
],
"normalized": []
},
{
"id": "77667",
"type": "Intervention_Pharmacological",
"text": [
"Behringwerke antivenom"
],
"offsets": [
[
771,
793
]
],
"normalized": []
},
{
"id": "77668",
"type": "Outcome_Physical",
"text": [
"blood coagulability"
],
"offsets": [
[
484,
503
]
],
"normalized": []
},
{
"id": "77669",
"type": "Outcome_Physical",
"text": [
"normal coagulability"
],
"offsets": [
[
644,
664
]
],
"normalized": []
},
{
"id": "77670",
"type": "Outcome_Physical",
"text": [
"normal clotting"
],
"offsets": [
[
794,
809
]
],
"normalized": []
},
{
"id": "77671",
"type": "Outcome_Physical",
"text": [
"Local tissue swelling"
],
"offsets": [
[
851,
872
]
],
"normalized": []
},
{
"id": "77672",
"type": "Outcome_Physical",
"text": [
"local necrosis"
],
"offsets": [
[
906,
920
]
],
"normalized": []
},
{
"id": "77673",
"type": "Participant_Sample-size",
"text": [
"Forty-six"
],
"offsets": [
[
234,
243
]
],
"normalized": []
},
{
"id": "77674",
"type": "Participant_Condition",
"text": [
"systemic poisoning by this snake"
],
"offsets": [
[
258,
290
]
],
"normalized": []
},
{
"id": "77675",
"type": "Participant_Sample-size",
"text": [
"23"
],
"offsets": [
[
684,
686
]
],
"normalized": []
},
{
"id": "77676",
"type": "Participant_Condition",
"text": [
"patients in one group"
],
"offsets": [
[
687,
708
]
],
"normalized": []
}
] | [] | [] | [] |
77677 | 4157501 | [
{
"id": "77678",
"type": "document",
"text": [
"Potassium , glucose , and insulin in treatment of myocardial infarction ."
],
"offsets": [
[
0,
73
]
]
}
] | [
{
"id": "77679",
"type": "Intervention_Pharmacological",
"text": [
"Potassium , glucose , and insulin"
],
"offsets": [
[
0,
33
]
],
"normalized": []
},
{
"id": "77680",
"type": "Outcome_Other",
"text": [
"treatment"
],
"offsets": [
[
37,
46
]
],
"normalized": []
},
{
"id": "77681",
"type": "Outcome_Physical",
"text": [
"myocardial infarction ."
],
"offsets": [
[
50,
73
]
],
"normalized": []
},
{
"id": "77682",
"type": "Participant_Condition",
"text": [
"myocardial infarction ."
],
"offsets": [
[
50,
73
]
],
"normalized": []
}
] | [] | [] | [] |
77683 | 4165041 | [
{
"id": "77684",
"type": "document",
"text": [
"Beta-cytotrophic effects of glucose , glucagon , and tolbutamide in man ."
],
"offsets": [
[
0,
73
]
]
}
] | [
{
"id": "77685",
"type": "Intervention_Pharmacological",
"text": [
"glucose"
],
"offsets": [
[
28,
35
]
],
"normalized": []
},
{
"id": "77686",
"type": "Intervention_Pharmacological",
"text": [
"glucagon"
],
"offsets": [
[
38,
46
]
],
"normalized": []
},
{
"id": "77687",
"type": "Intervention_Pharmacological",
"text": [
"tolbutamide"
],
"offsets": [
[
53,
64
]
],
"normalized": []
},
{
"id": "77688",
"type": "Outcome_Adverse-effects",
"text": [
"Beta-cytotrophic effects"
],
"offsets": [
[
0,
24
]
],
"normalized": []
},
{
"id": "77689",
"type": "Participant_Condition",
"text": [
"glucose , glucagon , and tolbutamide in man"
],
"offsets": [
[
28,
71
]
],
"normalized": []
}
] | [] | [] | [] |
77690 | 417361 | [
{
"id": "77691",
"type": "document",
"text": [
"Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia . The effects of piracetam ( Nootropil , UCB6215 ) on mental functions and on regional cerebral blood flow ( rCBF ) were investigated in eight patients in the presenile age who displayed symptoms of moderate dementia . The double-blind crossover design included nine measurement occasions , each involving rCBF measurement by the 133-Xe inhalation method , ratings of symptoms of dementia , personality changes , and side effects , and a psychometric investigation . Three investigations were included in each of three treatment periods . The first investigation in a period was made without medication . Then either placebo or piracetam 4.8 g/day or 9.6 g/day was given during four weeks with measurements after 2 weekks and 4 weeks . There were intervals of 4 weeks without medication between the treatment periods . Piracetam had no significant effect on either mental functions or rCBF ."
],
"offsets": [
[
0,
999
]
]
}
] | [
{
"id": "77692",
"type": "Intervention_Pharmacological",
"text": [
"piracetam"
],
"offsets": [
[
11,
20
]
],
"normalized": []
},
{
"id": "77693",
"type": "Intervention_Pharmacological",
"text": [
"piracetam"
],
"offsets": [
[
11,
20
]
],
"normalized": []
},
{
"id": "77694",
"type": "Intervention_Pharmacological",
"text": [
"133-Xe inhalation method"
],
"offsets": [
[
438,
462
]
],
"normalized": []
},
{
"id": "77695",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
725,
732
]
],
"normalized": []
},
{
"id": "77696",
"type": "Intervention_Pharmacological",
"text": [
"piracetam"
],
"offsets": [
[
11,
20
]
],
"normalized": []
},
{
"id": "77697",
"type": "Intervention_Pharmacological",
"text": [
"Piracetam"
],
"offsets": [
[
927,
936
]
],
"normalized": []
},
{
"id": "77698",
"type": "Outcome_Physical",
"text": [
"cerebral blood flow"
],
"offsets": [
[
33,
52
]
],
"normalized": []
},
{
"id": "77699",
"type": "Outcome_Mental",
"text": [
"mental functions"
],
"offsets": [
[
57,
73
]
],
"normalized": []
},
{
"id": "77700",
"type": "Outcome_Mental",
"text": [
"mental functions"
],
"offsets": [
[
57,
73
]
],
"normalized": []
},
{
"id": "77701",
"type": "Outcome_Physical",
"text": [
"regional cerebral blood flow ( rCBF )"
],
"offsets": [
[
186,
223
]
],
"normalized": []
},
{
"id": "77702",
"type": "Outcome_Physical",
"text": [
"rCBF measurement"
],
"offsets": [
[
414,
430
]
],
"normalized": []
},
{
"id": "77703",
"type": "Outcome_Mental",
"text": [
"mental functions"
],
"offsets": [
[
57,
73
]
],
"normalized": []
},
{
"id": "77704",
"type": "Outcome_Mental",
"text": [
"rCBF"
],
"offsets": [
[
217,
221
]
],
"normalized": []
},
{
"id": "77705",
"type": "Participant_Condition",
"text": [
"patients with organic dementia ."
],
"offsets": [
[
77,
109
]
],
"normalized": []
},
{
"id": "77706",
"type": "Participant_Sample-size",
"text": [
"eight"
],
"offsets": [
[
245,
250
]
],
"normalized": []
},
{
"id": "77707",
"type": "Participant_Condition",
"text": [
"patients in the"
],
"offsets": [
[
251,
266
]
],
"normalized": []
},
{
"id": "77708",
"type": "Participant_Age",
"text": [
"presenile"
],
"offsets": [
[
267,
276
]
],
"normalized": []
},
{
"id": "77709",
"type": "Participant_Condition",
"text": [
"age who displayed symptoms of moderate dementia ."
],
"offsets": [
[
277,
326
]
],
"normalized": []
}
] | [] | [] | [] |
77710 | 418433 | [
{
"id": "77711",
"type": "document",
"text": [
"PRL-8-53 : enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent . The effect of 3- ( 2-benzylmethylaminoethyl ) benzoic acid methyl ester hydrochloride ( PRL-8-53 ) on learning and on retention of verbal information in human subjects was investigated . Using the serial anticipation method under double-blind conditions it was found that PRL-8-53 causes slight improvement of acquisition . Retinetion of verbal information was found improved to a statistically significant degree ( most P values better than 0.01 , some better than 0.001 ) . No significant changes were found for either visual reaction time or motor control after drug when compared with placebo values ."
],
"offsets": [
[
0,
727
]
]
}
] | [
{
"id": "77712",
"type": "Intervention_Pharmacological",
"text": [
"PRL-8-53"
],
"offsets": [
[
0,
8
]
],
"normalized": []
},
{
"id": "77713",
"type": "Intervention_Pharmacological",
"text": [
"psychotropic"
],
"offsets": [
[
101,
113
]
],
"normalized": []
},
{
"id": "77714",
"type": "Intervention_Pharmacological",
"text": [
"3- ( 2-benzylmethylaminoethyl ) benzoic acid methyl ester hydrochloride ( PRL-8-53 )"
],
"offsets": [
[
136,
220
]
],
"normalized": []
},
{
"id": "77715",
"type": "Intervention_Pharmacological",
"text": [
"PRL-8-53"
],
"offsets": [
[
0,
8
]
],
"normalized": []
},
{
"id": "77716",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
711,
718
]
],
"normalized": []
},
{
"id": "77717",
"type": "Outcome_Mental",
"text": [
"learning"
],
"offsets": [
[
20,
28
]
],
"normalized": []
},
{
"id": "77718",
"type": "Outcome_Mental",
"text": [
"retention"
],
"offsets": [
[
44,
53
]
],
"normalized": []
},
{
"id": "77719",
"type": "Outcome_Mental",
"text": [
"learning"
],
"offsets": [
[
20,
28
]
],
"normalized": []
},
{
"id": "77720",
"type": "Outcome_Mental",
"text": [
"retention of verbal information"
],
"offsets": [
[
240,
271
]
],
"normalized": []
},
{
"id": "77721",
"type": "Outcome_Mental",
"text": [
"acquisition . Retinetion of verbal information"
],
"offsets": [
[
432,
478
]
],
"normalized": []
},
{
"id": "77722",
"type": "Outcome_Mental",
"text": [
"visual reaction time or motor control"
],
"offsets": [
[
643,
680
]
],
"normalized": []
}
] | [] | [] | [] |
77723 | 4187541 | [
{
"id": "77724",
"type": "document",
"text": [
"Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment : a controlled double-blind study ."
],
"offsets": [
[
0,
140
]
]
}
] | [
{
"id": "77725",
"type": "Intervention_Pharmacological",
"text": [
"1-adamantanamine hydrochloride"
],
"offsets": [
[
21,
51
]
],
"normalized": []
},
{
"id": "77726",
"type": "Outcome_Physical",
"text": [
"infections"
],
"offsets": [
[
68,
78
]
],
"normalized": []
},
{
"id": "77727",
"type": "Participant_Condition",
"text": [
"influenza A2 infections in the family environment :"
],
"offsets": [
[
55,
106
]
],
"normalized": []
}
] | [] | [] | [] |
77728 | 4198313 | [
{
"id": "77729",
"type": "document",
"text": [
"A multicenter investigation of lorazepam in anxiety neurosis ."
],
"offsets": [
[
0,
62
]
]
}
] | [
{
"id": "77730",
"type": "Intervention_Pharmacological",
"text": [
"lorazepam"
],
"offsets": [
[
31,
40
]
],
"normalized": []
},
{
"id": "77731",
"type": "Outcome_Mental",
"text": [
"anxiety neurosis"
],
"offsets": [
[
44,
60
]
],
"normalized": []
}
] | [] | [] | [] |
77732 | 4220015 | [
{
"id": "77733",
"type": "document",
"text": [
"[ Prognostic experiences in the long-term differential therapy of chronic aggressive hepatitides ] ."
],
"offsets": [
[
0,
100
]
]
}
] | [
{
"id": "77734",
"type": "Intervention_Educational",
"text": [
"Prognostic experiences"
],
"offsets": [
[
2,
24
]
],
"normalized": []
},
{
"id": "77735",
"type": "Participant_Condition",
"text": [
"chronic aggressive hepatitides"
],
"offsets": [
[
66,
96
]
],
"normalized": []
}
] | [] | [] | [] |
77736 | 43164 | [
{
"id": "77737",
"type": "document",
"text": [
"A double-blind crossover comparison of pindolol , metoprolol , atenolol and labetalol in mild to moderate hypertension . 1 This study was designed to compare in a double-blind randomized crossover trial , atenolol , labetalol , metoprolol and pindolol . Considerable differences in dose ( atenolol 138 +/- 13 mg daily ; labetalol 308 +/- 34 mg daily ; metoprolol 234 +/- 22 mg daily ; and pindolol 24 +/-2 mg daily were required to produce similar antihypertensive effects . 3 The overall incidence of side-effects was similar with atenolol , metoprolol and pindolol but was slightly less with labetalol . Sleep disturbances and abnormal dreaming patterns were most frequent with pindolol . 4 There was a significantly greater fall in pulse rate during atenolol and metoprolol treatment periods ."
],
"offsets": [
[
0,
796
]
]
}
] | [
{
"id": "77738",
"type": "Intervention_Pharmacological",
"text": [
"pindolol"
],
"offsets": [
[
39,
47
]
],
"normalized": []
},
{
"id": "77739",
"type": "Intervention_Pharmacological",
"text": [
"metoprolol"
],
"offsets": [
[
50,
60
]
],
"normalized": []
},
{
"id": "77740",
"type": "Intervention_Pharmacological",
"text": [
"atenolol"
],
"offsets": [
[
63,
71
]
],
"normalized": []
},
{
"id": "77741",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
76,
85
]
],
"normalized": []
},
{
"id": "77742",
"type": "Intervention_Pharmacological",
"text": [
"atenolol"
],
"offsets": [
[
63,
71
]
],
"normalized": []
},
{
"id": "77743",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
76,
85
]
],
"normalized": []
},
{
"id": "77744",
"type": "Intervention_Pharmacological",
"text": [
"metoprolol"
],
"offsets": [
[
50,
60
]
],
"normalized": []
},
{
"id": "77745",
"type": "Intervention_Pharmacological",
"text": [
"pindolol"
],
"offsets": [
[
39,
47
]
],
"normalized": []
},
{
"id": "77746",
"type": "Intervention_Pharmacological",
"text": [
"atenolol"
],
"offsets": [
[
63,
71
]
],
"normalized": []
},
{
"id": "77747",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
76,
85
]
],
"normalized": []
},
{
"id": "77748",
"type": "Intervention_Pharmacological",
"text": [
"metoprolol"
],
"offsets": [
[
50,
60
]
],
"normalized": []
},
{
"id": "77749",
"type": "Intervention_Pharmacological",
"text": [
"pindolol"
],
"offsets": [
[
39,
47
]
],
"normalized": []
},
{
"id": "77750",
"type": "Intervention_Pharmacological",
"text": [
"atenolol"
],
"offsets": [
[
63,
71
]
],
"normalized": []
},
{
"id": "77751",
"type": "Intervention_Pharmacological",
"text": [
"metoprolol"
],
"offsets": [
[
50,
60
]
],
"normalized": []
},
{
"id": "77752",
"type": "Intervention_Pharmacological",
"text": [
"pindolol"
],
"offsets": [
[
39,
47
]
],
"normalized": []
},
{
"id": "77753",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
76,
85
]
],
"normalized": []
},
{
"id": "77754",
"type": "Intervention_Pharmacological",
"text": [
"pindolol"
],
"offsets": [
[
39,
47
]
],
"normalized": []
},
{
"id": "77755",
"type": "Intervention_Pharmacological",
"text": [
"atenolol"
],
"offsets": [
[
63,
71
]
],
"normalized": []
},
{
"id": "77756",
"type": "Intervention_Pharmacological",
"text": [
"metoprolol"
],
"offsets": [
[
50,
60
]
],
"normalized": []
},
{
"id": "77757",
"type": "Outcome_Other",
"text": [
"dose"
],
"offsets": [
[
282,
286
]
],
"normalized": []
},
{
"id": "77758",
"type": "Outcome_Physical",
"text": [
"antihypertensive effects"
],
"offsets": [
[
448,
472
]
],
"normalized": []
},
{
"id": "77759",
"type": "Outcome_Adverse-effects",
"text": [
"side-effects"
],
"offsets": [
[
502,
514
]
],
"normalized": []
},
{
"id": "77760",
"type": "Outcome_Mental",
"text": [
"Sleep disturbances"
],
"offsets": [
[
606,
624
]
],
"normalized": []
},
{
"id": "77761",
"type": "Outcome_Mental",
"text": [
"abnormal dreaming patterns"
],
"offsets": [
[
629,
655
]
],
"normalized": []
},
{
"id": "77762",
"type": "Outcome_Physical",
"text": [
"significantly greater fall in pulse rate"
],
"offsets": [
[
705,
745
]
],
"normalized": []
},
{
"id": "77763",
"type": "Participant_Condition",
"text": [
"A double-blind crossover comparison of pindolol , metoprolol , atenolol and labetalol in mild to moderate hypertension ."
],
"offsets": [
[
0,
120
]
],
"normalized": []
}
] | [] | [] | [] |
77764 | 4346973 | [
{
"id": "77765",
"type": "document",
"text": [
"Dipyrone for treatment of post-operative pain ."
],
"offsets": [
[
0,
47
]
]
}
] | [
{
"id": "77766",
"type": "Intervention_Pharmacological",
"text": [
"Dipyrone"
],
"offsets": [
[
0,
8
]
],
"normalized": []
},
{
"id": "77767",
"type": "Outcome_Pain",
"text": [
"post-operative pain ."
],
"offsets": [
[
26,
47
]
],
"normalized": []
},
{
"id": "77768",
"type": "Participant_Condition",
"text": [
"post-operative pain"
],
"offsets": [
[
26,
45
]
],
"normalized": []
}
] | [] | [] | [] |
77769 | 4353587 | [
{
"id": "77770",
"type": "document",
"text": [
"A study of postoperative cytostatic medication in patients with operable carcinoma of the lung ."
],
"offsets": [
[
0,
96
]
]
}
] | [
{
"id": "77771",
"type": "Intervention_Pharmacological",
"text": [
"postoperative cytostatic medication"
],
"offsets": [
[
11,
46
]
],
"normalized": []
},
{
"id": "77772",
"type": "Participant_Condition",
"text": [
"postoperative cytostatic medication"
],
"offsets": [
[
11,
46
]
],
"normalized": []
},
{
"id": "77773",
"type": "Participant_Condition",
"text": [
"with operable carcinoma of the lung"
],
"offsets": [
[
59,
94
]
],
"normalized": []
}
] | [] | [] | [] |
77774 | 4404700 | [
{
"id": "77775",
"type": "document",
"text": [
"Auditory signal detection in paranoid and nonparanoid schizophrenics ."
],
"offsets": [
[
0,
70
]
]
}
] | [
{
"id": "77776",
"type": "Intervention_Physical",
"text": [
"Auditory signal detection"
],
"offsets": [
[
0,
25
]
],
"normalized": []
},
{
"id": "77777",
"type": "Outcome_Physical",
"text": [
"Auditory signal detection"
],
"offsets": [
[
0,
25
]
],
"normalized": []
},
{
"id": "77778",
"type": "Participant_Condition",
"text": [
"paranoid and nonparanoid schizophrenics"
],
"offsets": [
[
29,
68
]
],
"normalized": []
}
] | [] | [] | [] |
77779 | 4407133 | [
{
"id": "77780",
"type": "document",
"text": [
"Letter : Cephaloridine and gentamicin in prophylaxis of surgical wound infection ."
],
"offsets": [
[
0,
82
]
]
}
] | [
{
"id": "77781",
"type": "Intervention_Pharmacological",
"text": [
"Cephaloridine"
],
"offsets": [
[
9,
22
]
],
"normalized": []
},
{
"id": "77782",
"type": "Intervention_Pharmacological",
"text": [
"gentamicin"
],
"offsets": [
[
27,
37
]
],
"normalized": []
},
{
"id": "77783",
"type": "Outcome_Physical",
"text": [
"prophylaxis"
],
"offsets": [
[
41,
52
]
],
"normalized": []
},
{
"id": "77784",
"type": "Outcome_Adverse-effects",
"text": [
"surgical wound infection ."
],
"offsets": [
[
56,
82
]
],
"normalized": []
},
{
"id": "77785",
"type": "Participant_Condition",
"text": [
"prophylaxis"
],
"offsets": [
[
41,
52
]
],
"normalized": []
},
{
"id": "77786",
"type": "Participant_Condition",
"text": [
"surgical wound infection"
],
"offsets": [
[
56,
80
]
],
"normalized": []
}
] | [] | [] | [] |
77787 | 4448416 | [
{
"id": "77788",
"type": "document",
"text": [
"Coagulation factor concentrate in the treatment of the haemorrhagic diathesis of fulminant hepatic failure . To assess the value of clotting factor concentrate infusions in fulminant hepatic failure , a controlled trial was performed in which nine patients were randomly allocated to treatment with either concentrate alone or concentrate plus heparin . The five patients receiving concentrate alone all died , with major bleeding as the direct cause of death in three , whereas in the four receiving heparin as well there was only one instance of bleeding and one patient survived . Clinical evidence of intravascular coagulation appeared in two patients treated with concentrate alone and the laboratory evidence of this progressed during the period of infusions in all patients in both treatment groups , although to a lesser extent in those receiving heparin . Additional evidence for intravascular coagulation came from the changes observed in factor VIII levels which , although initially high in all patients , fell subsequently , particularly in those given concentrate alone . There was some improvement in the prothrombin ratio in both groups of patients but not complete correction , and serial assays of clotting factors showed that although factor II rose to high levels during treatment , factors IX and X showed little response . Thus , the use of concentrate of factor IX in this trial , as well as potentiating intravascular coagulation , was inadequate as replacement for the clotting factor deficiencies ."
],
"offsets": [
[
0,
1524
]
]
}
] | [
{
"id": "77789",
"type": "Intervention_Pharmacological",
"text": [
"Coagulation factor concentrate"
],
"offsets": [
[
0,
30
]
],
"normalized": []
},
{
"id": "77790",
"type": "Intervention_Pharmacological",
"text": [
"clotting factor concentrate infusions"
],
"offsets": [
[
132,
169
]
],
"normalized": []
},
{
"id": "77791",
"type": "Intervention_Pharmacological",
"text": [
"concentrate alone or concentrate plus heparin"
],
"offsets": [
[
306,
351
]
],
"normalized": []
},
{
"id": "77792",
"type": "Intervention_Pharmacological",
"text": [
"concentrate"
],
"offsets": [
[
19,
30
]
],
"normalized": []
},
{
"id": "77793",
"type": "Intervention_Pharmacological",
"text": [
"heparin"
],
"offsets": [
[
344,
351
]
],
"normalized": []
},
{
"id": "77794",
"type": "Intervention_Pharmacological",
"text": [
"concentrate alone"
],
"offsets": [
[
306,
323
]
],
"normalized": []
},
{
"id": "77795",
"type": "Intervention_Pharmacological",
"text": [
"heparin"
],
"offsets": [
[
344,
351
]
],
"normalized": []
},
{
"id": "77796",
"type": "Intervention_Pharmacological",
"text": [
"concentrate"
],
"offsets": [
[
19,
30
]
],
"normalized": []
},
{
"id": "77797",
"type": "Outcome_Physical",
"text": [
"haemorrhagic diathesis"
],
"offsets": [
[
55,
77
]
],
"normalized": []
},
{
"id": "77798",
"type": "Outcome_Physical",
"text": [
"fulminant hepatic failure ."
],
"offsets": [
[
81,
108
]
],
"normalized": []
},
{
"id": "77799",
"type": "Outcome_Physical",
"text": [
"hepatic failure"
],
"offsets": [
[
91,
106
]
],
"normalized": []
},
{
"id": "77800",
"type": "Outcome_Mortality",
"text": [
"died"
],
"offsets": [
[
404,
408
]
],
"normalized": []
},
{
"id": "77801",
"type": "Outcome_Physical",
"text": [
"major bleeding"
],
"offsets": [
[
416,
430
]
],
"normalized": []
},
{
"id": "77802",
"type": "Outcome_Physical",
"text": [
"bleeding"
],
"offsets": [
[
422,
430
]
],
"normalized": []
},
{
"id": "77803",
"type": "Outcome_Mortality",
"text": [
"survived ."
],
"offsets": [
[
573,
583
]
],
"normalized": []
},
{
"id": "77804",
"type": "Outcome_Physical",
"text": [
"intravascular coagulation"
],
"offsets": [
[
605,
630
]
],
"normalized": []
},
{
"id": "77805",
"type": "Outcome_Physical",
"text": [
"factor VIII levels"
],
"offsets": [
[
949,
967
]
],
"normalized": []
},
{
"id": "77806",
"type": "Outcome_Physical",
"text": [
"prothrombin ratio"
],
"offsets": [
[
1120,
1137
]
],
"normalized": []
},
{
"id": "77807",
"type": "Outcome_Physical",
"text": [
"factor II"
],
"offsets": [
[
1254,
1263
]
],
"normalized": []
},
{
"id": "77808",
"type": "Outcome_Physical",
"text": [
"factors IX and X"
],
"offsets": [
[
1303,
1319
]
],
"normalized": []
},
{
"id": "77809",
"type": "Outcome_Physical",
"text": [
"factor IX"
],
"offsets": [
[
1378,
1387
]
],
"normalized": []
},
{
"id": "77810",
"type": "Outcome_Physical",
"text": [
"intravascular coagulation"
],
"offsets": [
[
605,
630
]
],
"normalized": []
},
{
"id": "77811",
"type": "Participant_Condition",
"text": [
"haemorrhagic diathesis of fulminant hepatic failure"
],
"offsets": [
[
55,
106
]
],
"normalized": []
},
{
"id": "77812",
"type": "Participant_Condition",
"text": [
"fulminant hepatic failure"
],
"offsets": [
[
81,
106
]
],
"normalized": []
}
] | [] | [] | [] |
77813 | 4459905 | [
{
"id": "77814",
"type": "document",
"text": [
"[ Carticaine in the therapie of pain ( author 's transl ) ] ."
],
"offsets": [
[
0,
61
]
]
}
] | [
{
"id": "77815",
"type": "Intervention_Pharmacological",
"text": [
"Carticaine"
],
"offsets": [
[
2,
12
]
],
"normalized": []
},
{
"id": "77816",
"type": "Outcome_Pain",
"text": [
"pain"
],
"offsets": [
[
32,
36
]
],
"normalized": []
},
{
"id": "77817",
"type": "Participant_Condition",
"text": [
"pain"
],
"offsets": [
[
32,
36
]
],
"normalized": []
}
] | [] | [] | [] |
77818 | 447787 | [
{
"id": "77819",
"type": "document",
"text": [
"On the possibility of incorporating patients from non-randomising centres into a randomised clinical trial ."
],
"offsets": [
[
0,
108
]
]
}
] | [
{
"id": "77820",
"type": "Participant_Condition",
"text": [
"patients"
],
"offsets": [
[
36,
44
]
],
"normalized": []
}
] | [] | [] | [] |
77821 | 4479815 | [
{
"id": "77822",
"type": "document",
"text": [
"Comparative trial of cephacetrile versus cephaloridine in the treatment of secondary respiratory infections in childhood pertussis ."
],
"offsets": [
[
0,
132
]
]
}
] | [
{
"id": "77823",
"type": "Intervention_Pharmacological",
"text": [
"cephacetrile"
],
"offsets": [
[
21,
33
]
],
"normalized": []
},
{
"id": "77824",
"type": "Intervention_Pharmacological",
"text": [
"cephaloridine"
],
"offsets": [
[
41,
54
]
],
"normalized": []
},
{
"id": "77825",
"type": "Outcome_Physical",
"text": [
"secondary respiratory infections"
],
"offsets": [
[
75,
107
]
],
"normalized": []
},
{
"id": "77826",
"type": "Participant_Condition",
"text": [
"secondary respiratory infections"
],
"offsets": [
[
75,
107
]
],
"normalized": []
},
{
"id": "77827",
"type": "Participant_Age",
"text": [
"childhood"
],
"offsets": [
[
111,
120
]
],
"normalized": []
},
{
"id": "77828",
"type": "Participant_Condition",
"text": [
"pertussis"
],
"offsets": [
[
121,
130
]
],
"normalized": []
}
] | [] | [] | [] |
77829 | 4605864 | [
{
"id": "77830",
"type": "document",
"text": [
"[ Pivampicillin treatment of uro-genital infections in gynaecological patients . A clinical evaluation ] ."
],
"offsets": [
[
0,
106
]
]
}
] | [
{
"id": "77831",
"type": "Intervention_Pharmacological",
"text": [
"[ Pivampicillin"
],
"offsets": [
[
0,
15
]
],
"normalized": []
},
{
"id": "77832",
"type": "Outcome_Physical",
"text": [
"uro-genital infections"
],
"offsets": [
[
29,
51
]
],
"normalized": []
},
{
"id": "77833",
"type": "Participant_Condition",
"text": [
"uro-genital infections"
],
"offsets": [
[
29,
51
]
],
"normalized": []
},
{
"id": "77834",
"type": "Participant_Condition",
"text": [
"gynaecological"
],
"offsets": [
[
55,
69
]
],
"normalized": []
}
] | [] | [] | [] |
77835 | 4615718 | [
{
"id": "77836",
"type": "document",
"text": [
"[ Psychoexperimental studies on the effect of a valepotriate combination as well as the combined effects of valtratum and alcohol ] ."
],
"offsets": [
[
0,
133
]
]
}
] | [
{
"id": "77837",
"type": "Intervention_Pharmacological",
"text": [
"valepotriate combination"
],
"offsets": [
[
48,
72
]
],
"normalized": []
},
{
"id": "77838",
"type": "Intervention_Pharmacological",
"text": [
"valtratum and alcohol ]"
],
"offsets": [
[
108,
131
]
],
"normalized": []
},
{
"id": "77839",
"type": "Participant_Condition",
"text": [
"valepotriate combination as well as the combined effects of valtratum and alcohol"
],
"offsets": [
[
48,
129
]
],
"normalized": []
}
] | [] | [] | [] |
77840 | 4619431 | [
{
"id": "77841",
"type": "document",
"text": [
"[ Piribedil in arterial diseases ] ."
],
"offsets": [
[
0,
36
]
]
}
] | [
{
"id": "77842",
"type": "Intervention_Pharmacological",
"text": [
"[ Piribedil"
],
"offsets": [
[
0,
11
]
],
"normalized": []
},
{
"id": "77843",
"type": "Outcome_Physical",
"text": [
"arterial diseases ]"
],
"offsets": [
[
15,
34
]
],
"normalized": []
},
{
"id": "77844",
"type": "Participant_Condition",
"text": [
"arterial diseases"
],
"offsets": [
[
15,
32
]
],
"normalized": []
}
] | [] | [] | [] |
77845 | 4623522 | [
{
"id": "77846",
"type": "document",
"text": [
"The effect of phenytoin on the absorption of synthetic folic acid polyglutamate . The absorption of synthetic pteroyltriglutamate has been measured in nine normal students with and without the anticonvulsant drug phenytoin . It has been shown that phenytoin has no effect on the absorption of this folate polyglutamate . The reasons are discussed for the disparity between this result and those reported in the literature when folate polyglutamates derived from yeast were used ."
],
"offsets": [
[
0,
479
]
]
}
] | [
{
"id": "77847",
"type": "Intervention_Pharmacological",
"text": [
"phenytoin"
],
"offsets": [
[
14,
23
]
],
"normalized": []
},
{
"id": "77848",
"type": "Intervention_Pharmacological",
"text": [
"phenytoin"
],
"offsets": [
[
14,
23
]
],
"normalized": []
},
{
"id": "77849",
"type": "Intervention_Pharmacological",
"text": [
"phenytoin"
],
"offsets": [
[
14,
23
]
],
"normalized": []
},
{
"id": "77850",
"type": "Outcome_Physical",
"text": [
"folate polyglutamate"
],
"offsets": [
[
298,
318
]
],
"normalized": []
},
{
"id": "77851",
"type": "Participant_Condition",
"text": [
"nine normal students with and without the anticonvulsant drug phenytoin ."
],
"offsets": [
[
151,
224
]
],
"normalized": []
}
] | [] | [] | [] |
77852 | 4678681 | [
{
"id": "77853",
"type": "document",
"text": [
"Joint study of extracranial arterial occlusion . VI . Racial differences in hospitalized patients with ischemic stroke ."
],
"offsets": [
[
0,
120
]
]
}
] | [] | [] | [] | [] |
77854 | 4716523 | [
{
"id": "77855",
"type": "document",
"text": [
"Truncal vagotomy and drainage for duodenal ulcer ."
],
"offsets": [
[
0,
50
]
]
}
] | [
{
"id": "77856",
"type": "Intervention_Surgical",
"text": [
"Truncal vagotomy and drainage"
],
"offsets": [
[
0,
29
]
],
"normalized": []
},
{
"id": "77857",
"type": "Outcome_Physical",
"text": [
"Truncal vagotomy and drainage"
],
"offsets": [
[
0,
29
]
],
"normalized": []
},
{
"id": "77858",
"type": "Outcome_Physical",
"text": [
"duodenal ulcer ."
],
"offsets": [
[
34,
50
]
],
"normalized": []
},
{
"id": "77859",
"type": "Participant_Condition",
"text": [
"duodenal ulcer"
],
"offsets": [
[
34,
48
]
],
"normalized": []
}
] | [] | [] | [] |
77860 | 4752239 | [
{
"id": "77861",
"type": "document",
"text": [
"Mebendazole in enterobiasis : a placebo -- controlled trial in a paediatric community ."
],
"offsets": [
[
0,
87
]
]
}
] | [
{
"id": "77862",
"type": "Intervention_Pharmacological",
"text": [
"Mebendazole"
],
"offsets": [
[
0,
11
]
],
"normalized": []
},
{
"id": "77863",
"type": "Intervention_Control",
"text": [
"placebo -- controlled"
],
"offsets": [
[
32,
53
]
],
"normalized": []
},
{
"id": "77864",
"type": "Outcome_Physical",
"text": [
"enterobiasis"
],
"offsets": [
[
15,
27
]
],
"normalized": []
},
{
"id": "77865",
"type": "Participant_Condition",
"text": [
"enterobiasis :"
],
"offsets": [
[
15,
29
]
],
"normalized": []
},
{
"id": "77866",
"type": "Participant_Condition",
"text": [
"paediatric"
],
"offsets": [
[
65,
75
]
],
"normalized": []
}
] | [] | [] | [] |
77867 | 4772206 | [
{
"id": "77868",
"type": "document",
"text": [
"The gastric emptying and small intestinal transit after highly selective vagotomy without drainage and selective vagotomy with pyloroplasty ."
],
"offsets": [
[
0,
141
]
]
}
] | [
{
"id": "77869",
"type": "Intervention_Surgical",
"text": [
"gastric emptying"
],
"offsets": [
[
4,
20
]
],
"normalized": []
},
{
"id": "77870",
"type": "Intervention_Physical",
"text": [
"and"
],
"offsets": [
[
21,
24
]
],
"normalized": []
},
{
"id": "77871",
"type": "Intervention_Surgical",
"text": [
"small intestinal transit"
],
"offsets": [
[
25,
49
]
],
"normalized": []
},
{
"id": "77872",
"type": "Outcome_Physical",
"text": [
"gastric emptying and small intestinal transit"
],
"offsets": [
[
4,
49
]
],
"normalized": []
},
{
"id": "77873",
"type": "Participant_Condition",
"text": [
"vagotomy"
],
"offsets": [
[
73,
81
]
],
"normalized": []
},
{
"id": "77874",
"type": "Participant_Condition",
"text": [
"selective vagotomy with pyloroplasty"
],
"offsets": [
[
103,
139
]
],
"normalized": []
}
] | [] | [] | [] |
77875 | 4818631 | [
{
"id": "77876",
"type": "document",
"text": [
"[ Folic acid deficiency in pregnant women in Switzerland ] ."
],
"offsets": [
[
0,
60
]
]
}
] | [
{
"id": "77877",
"type": "Outcome_Physical",
"text": [
"Folic acid deficiency"
],
"offsets": [
[
2,
23
]
],
"normalized": []
},
{
"id": "77878",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
36,
41
]
],
"normalized": []
}
] | [] | [] | [] |
77879 | 484261 | [
{
"id": "77880",
"type": "document",
"text": [
"A controlled study of early discharge after uncomplicated myocardial infarction . Out of 383 myocardial infarction ( MI ) patients aged below 70 years , 252 ( 66 % ) were judged after the third day in hospital to have had uncomplicated infarctions . These patients were allocated at random to two groups , one of which was given treatment for 8 days and the other for 15 days . No significant differences in mortality , morbidity or incapacity for work could be detected during the three-month period of follow-up . The findings thus support previous conclusions that early discharge from hospital after uncomplicated MI is not associated with greater risk for the patient than later discharge ."
],
"offsets": [
[
0,
695
]
]
}
] | [
{
"id": "77881",
"type": "Intervention_Educational",
"text": [
"early discharge"
],
"offsets": [
[
22,
37
]
],
"normalized": []
},
{
"id": "77882",
"type": "Intervention_Educational",
"text": [
"one of which was given treatment for 8 days and the other for 15 days"
],
"offsets": [
[
306,
375
]
],
"normalized": []
},
{
"id": "77883",
"type": "Intervention_Educational",
"text": [
"early discharge"
],
"offsets": [
[
22,
37
]
],
"normalized": []
},
{
"id": "77884",
"type": "Outcome_Mortality",
"text": [
"mortality"
],
"offsets": [
[
408,
417
]
],
"normalized": []
},
{
"id": "77885",
"type": "Outcome_Other",
"text": [
"morbidity"
],
"offsets": [
[
420,
429
]
],
"normalized": []
},
{
"id": "77886",
"type": "Outcome_Mental",
"text": [
"incapacity for work"
],
"offsets": [
[
433,
452
]
],
"normalized": []
},
{
"id": "77887",
"type": "Participant_Condition",
"text": [
"myocardial infarction"
],
"offsets": [
[
58,
79
]
],
"normalized": []
},
{
"id": "77888",
"type": "Participant_Sample-size",
"text": [
"383"
],
"offsets": [
[
89,
92
]
],
"normalized": []
},
{
"id": "77889",
"type": "Participant_Condition",
"text": [
"myocardial infarction ( MI )"
],
"offsets": [
[
93,
121
]
],
"normalized": []
},
{
"id": "77890",
"type": "Participant_Age",
"text": [
"70"
],
"offsets": [
[
142,
144
]
],
"normalized": []
},
{
"id": "77891",
"type": "Participant_Sample-size",
"text": [
"252"
],
"offsets": [
[
153,
156
]
],
"normalized": []
},
{
"id": "77892",
"type": "Participant_Condition",
"text": [
"uncomplicated infarctions ."
],
"offsets": [
[
222,
249
]
],
"normalized": []
}
] | [] | [] | [] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.